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Abstract 
Schizophrenia (SCZ) and bipolar disorder (BPD) are common, highly heritability psychiatric 
disorders. Genome-wide association studies have found evidence of shared genetic 
susceptibility to both diseases. The most notable example is CACNA1C which encodes the 
1 subunit of L-type calcium channels. Several other calcium channel genes have also been 
implicated in BPD and/or SCZ and together there is support for a role for these genes in both 
diseases.  
 
The primary function of several  subunit calcium channel genes appears to be the regulation 
of AMPA receptor localisation and function. Collectively these are known as 
Transmembrane AMPA receptor Regulatory Proteins (TARPs). This thesis aimed to identify 
disease relevant genetic variation in one such TARP, CACNG5, and to study the effect of 
these variants.  
 
CACNG5 variants in the exons and promoter region were identified in 1098 BPD, 618 SCZ, 
and 1087 control individuals. Four novel non-synonymous SNPs (nsSNPs) and four nsSNPs 
were identified. Burden analysis of nsSNPs in BPD and SCZ found evidence for association 
(p=0.0022). This association was strengthened by inclusion of data from European samples 
in the 1000 Genomes project (p=0.00057). However, combined data with the UK10K and 
Swedish exome sequence studies founds a weakened association signal (p=0.0082). 
Functional analyses using co-expression of AMPAR2 and CACNG5 constructs containing 
the eight nsSNPs were used to analyse changes in the expression and/or trafficking of 5 and 
AMPA receptors.  Four of the variants were associated with decreased AMPAR2 expression 
as a consequence of altered trafficking to the cell surface. V146M (identified in 2 SCZ 
patients) overexpression increased AMPAR2 trafficking to the cell surface (p<0.005); 
conversely, T164L (identified in one SCZ patient) overexpression decreased the expression 
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of AMPAR2 and its cell surface trafficking (p<0.05).  Our results suggest a role for CACNG5 
variants in SCZ and/or BPD and that this may be mediated via dysregulation of AMPARs.  
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GWAS  Genome-wide association study 
GWASs  Genome-wide association studies 
HCl   Hydrogen chloride 
HEK293  Human embryonic kidney 293 cells  
HPLC   High-performance liquid chromatography 
HRM   High resolution melting 
HRMA  High resolution melting analysis 
HS   High sensitivity 
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HS-TK  Herpes simplex virus thymidine kinase 
ICD   International Classification of Disease 
ICD   International Classification of Disease, 10
th
 revision 
iGluRs   Ionotropic glutamate receptors 
K
+
   Potassium ion 
KA   kainite 
LB   Luria-Bertani 
LBD   Ligand binding domain 
LD   Linkage disequilibrium 
LTD   Long-term depression 
LTP   Long-term potentiation  
M4   Fourth membrane spanning segment 
MAGUKs  Membrane associated guanylate kinases 
MAOI   Monoamine oxidase inhibitors 
MAP1-LC2  Microtubule associated protein 1 light chain 2 
MCS   Multiple cloning site 
mEPSCs  miniature excitatory post-synaptic currents 
Mg
2+
   Magnesium ion 
MgCl
2
   Magnesium chloride  
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mGluRs  Metabotropic glutamate receptors 
mRNAs  Messenger ribonucleic acids 
MZ   Monozygotic 
N-   Amino- 
Na
+
   Sodium ion 
NH4
+
   Ammonium 
NARI   Noradrenaline reuptake inhibitors 
Netos   Neurophilin and Tolloid like protein 
NCS-R  National Comorbidity Survey Replication 
NHGRI  National Human Genome Research Institute 
NHS   National Health Services 
NICE   National Institute for Health and Clinical Excellence 
NIR   Near-infrared 
NMDA  N-methyl-D-aspartate  
NMDAR  N-methyl-D-aspartate receptor 
nPIST   Neuronal PDZ domain protein interacting specifically with TC10 
NTD   Amino-terminal domain 
OFC   Olanzapine-fluoxetine combination 
OPCRIT  Operational Criteria for Psychotic Illness 
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PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PGC   Psychiatric Genomics Consortium 
PSD   Postsynaptic density 
Q   Glutamine 
Q/R   Glutamine/arginine 
R/G   Arginine/glycine 
RDC   Research Diagnostic Criteria 
RFP   Red fluorescent tag protein 
RIPA   Radio-immunoprecipitation assay buffer  
RNA   Ribonucleic acid 
RS   arginine/serine 
SADS-L  Schizophrenia and Affective Disorders Schedule 
SCZ   Schizophrenia 
SDS   Sodium dodecyl sulphate 
SDS-PAGE  Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
SEP   Super-ecliptic pHluorin 
SH3   src homology 3 
SMR   Standardised mortality ratio 
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SNP   Single nucleotide polymorphism 
SNPs   Single nucleotide polymorphisms 
SNRI   Serotonin-noradrenaline reuptake inhibitors 
SNV   Single nucleotide variant 
SRP   Single recognition particle 
ssDNA  Single strand deoxyribonucleic acid 
SSRI   Selective serotonin reuptake inhibitors 
SSRs   Simple sequence repeats 
STEP-BD  Systematic Treatment Enhancement Program for Bipolar Disorder 
STRs   Short tandem repeats 
SV40   Simian virus 40 
Tm   Temperature 
TARP   Transmembrane AMPAR regulatory protein 
TARPs  Transmembrane AMPAR regulatory proteins 
TBE   Tris-borate-EDTA 
TBS   Tris-buffered saline 
TMD   Transmembrane domain 
UCL   University College London 
UK   United Kingdom 
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US   United State 
UV   Ultraviolet 
V   Volt 
VCF   Variant call format 
VCFS   Velco-cardio-facial syndrome 
VDCC   Voltage-dependent calcium channel 
VGCC   Voltage-gated calcium channel  
VGCCs  Voltage-gated calcium channels 
WHO   World Health Organisation 
WIBR   Wolfson Institute for Biomedical Research 
WTCCC  Wellcome Trust Case Control Consortium 
Zn
2+
   Zinc ion 
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1 Introduction 
1.1 Psychiatric disorders 
1.1.1 Overview 
Schizophrenia (SCZ) and bipolar disorder (BPD) are serious psychiatric disorders, which are 
characterised by impaired thinking, emotions, and behaviours over a period of time. These 
disorders can cause extensive disability leading to impairments in social and ordinary life. 
People suffering with these illnesses are common in the population (Kessler et al. 2007) and 
have significantly increased morbidity and mortality due to physical illness compared to the 
general population (Whiteford et al. 2013). The National Comorbidity and worldwide 
surveys reported a lifetime prevalence of 4.5 – 4.8% for BPD (Merikangas et al. 2007, 
Merikangas et al. 2011). The worldwide prevalence for SCZ is approximately 0.4 – 1 % 
(Shivashankar et al. 2013). The combined lifetime prevalence rates of both disorders can be 
up to 3% with heritability rates of up to 80% (Nierenberg et al. 2010). Because of their 
significant impacts on the patient, family, and society, BPD and SCZ also lead to a 
significant economic burden (Kleinman et al. 2003, Wyatt et al. 1995). Effective 
management and treatment of these illnesses depends on early and correct diagnosis.  
Over the decades, psychiatric classification and definition systems for the diagnosis of 
mental disorders have included the International Classification of Disease (ICD) produced by 
the World Health Organisation (WHO) since 1949 (World Health Organisation 1992a) and 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) produced by the American 
Psychiatric Association (APA) since 1952 (American Psychiatric Association 2013). These 
classification systems have been developed and revised in order to improve the reliability of 
clinical diagnosis to inform treatment strategies and to guide research. They define the 
characteristics of SCZ as marked by positive, negative, and disorganisation symptoms; 
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whereas BPD is marked by episodes of depression alternating with mania and/or hypomania 
positive (psychotic) symptoms. The positive features of the disorders share characteristics in 
BPD and SCZ, and they may include mood and psychotic symptoms with varying degrees of 
admixture. Both are potentially severe neuropsychiatric conditions, the aetiology of which is 
poorly understood. Genetic studies may be particularly fruitful endeavours in such conditions, 
as the underlying aetiology might be illuminated by a detailed knowledge of risk alleles. 
Furthermore, both disorders are diagnosed solely on the basis of behavioural signs and 
symptoms as neither currently has a specific, clearly defined, pathophysiological foundation 
on which to base diagnostic tests. Because genetic studies inherently examine biological 
markers, they may provide clues in the development of such tests, which may be clinically 
useful in risk prediction.  
1.1.2 History of psychiatric disorders 
Early written references from Chinese, Egyptian, Hebrew, and Greek refer to individual 
abnormal symptoms or behaviour and attribute these to a demon or god who had taken 
possession of a person. If a person’s speech or behaviour appeared to have a religious or 
mystical significance, it was thought that he or she was possessed by a good spirit or god; 
whereas, if a person became excited or overactive and engaged in behaviour contrary to 
religious teachings, it was considered to be the work of an angry god or an evil spirit, which 
represented the wrath and punishment of God. It was not until the 4
th
 century B.C, when a 
Greek physician Hippocrates denied the theory of deities and demons involved in the 
development of mental illnesses; instead he believed that the brain is the central organ of 
intellectual activity and injuries to the head could cause sensory and motor disorders. From 
clinical observation Hippocrates invented the first classification of mental disorders, dividing 
them into three general categories: mania, melancholia, and paranoia (Angst and Marneros 
2001). 
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1.1.2.1 History of the concept of bipolar disorder 
In the first or the second Century AD, another Greek physician Areteus of Cappadocia 
considered mania and melancholia as one single disorder, which was the first time that these 
two symptoms were linked together (Yutzy et al. 2012). During the seventeenth and 
eighteenth centuries, psychiatrists continued to study the association between mania and 
melancholia until the nineteenth century when the modern term of bipolar disorder was 
adopted. In 1854, a founder of German scientific psychiatrist, Wihelm Griesinger believed 
that the disorder was a circle of melancholia to mania with regular changes, and also further 
created seasonal affective disorders: melancholia usually occurs in autumn and winter, 
whereas mania occurs in spring. In the middle of the 19
th
 century, Jean-Pierre Falret finally 
drew the conclusion that bipolar disorder is an entity of its own, based on his long-term 
observations. In his published statements, he named “folie circulaire”, which is characterised 
by a continuous cycle of melancholia, mania and the interval in between as an independent 
disease on its own (Angst and Marneros 2001). Later in 1899, a German psychiatrist, Emil 
Kraepelin characterised the major endogenous psychoses into the disease concepts of 
dementia praecox, which was reformulated as schizophrenia (SCZ) in 1911, and manic-
depressive psychosis (Zivanovic and Nedic 2012), which has now been reconceived as 
bipolar disorder (BPD). These clinical definitions of Kraepelinian theory brought a 
revolution of psychotic characterisation in the 20
th
 century, where a term dichotomy of 
psychotic disorders was introduced comprising of BPD on the one end and SCZ at the other. 
The term bipolar was actually invented by Leonhard in 1957, which was described for the 
patients who experienced both depression and mania, and it was further differentiated into 
bipolar I (BP-I) and bipolar II (BP-II) disorder based on DSM-IV classification (American 
Psychiatric Association 1980). People with BP-II (often known as hypomania) have fewer 
and less severe symptoms that usually do not require hospitalisation compared to those with 
BP-I (known as mania).  
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1.1.2.2 History of the concept of schizophrenia 
In the middle of 19
th
 century, a French psychiatrist, Benedict Morel used the phrase 
“démence-précoce” to describe a characteristic of bizarre behaviour and abnormal mental 
function with an early-onset deteriorating state. He believed that mental degeneration with 
acute episodes of madness begins in the young and this essential which is now termed SCZ. 
Later, Emil Kraepelin used the term “dementia praecox” to refer the “sub-acute development 
of mental weakness occurring at the early age”. It was not until 1911 that a Swiss psychiatrist, 
Eugen Bleuler effectively renamed dementia praecox as schizophrenia, and believed that the 
condition was characterised primarily by disorganisation of thought processes, a lack of 
coherence between thought and emotion, and an inward orientation away from reality. SCZ 
was also thought to have a split within the intellect, between intellect and emotion, and 
between the intellect and external reality. Bleuler believed SCZ was not a single diagnostic 
entity; hence the two general symptom patterns or syndromes of SCZ have been 
differentiated as positive- and negative syndromes (Andreasen 1985, Andreasen 1995). 
Although the Kraepelinian dichotomy suggested that dementia praecox and manic-depressive 
psychoses had specific and separate causes; Jacob Kasanin coined the term schizoaffective 
psychosis to refer to a disorder with mixed features of schizophrenia and affective disorder in 
1933 (Kasanin 1994).  
1.1.3 Diagnosis of psychiatric disorders 
The clinical diagnosis of psychiatric disorders are based on the presenting symptoms, 
physical and mental status examinations, corroborative data obtained from interviews with 
the patient, family members, and other relevant sources of information as well as 
observations of the patient’s behaviour during hospitalisation. Laboratory or psychometric 
testing is warranted in certain circumstances. Currently, the definition and classification 
systems in use for the diagnosis of mental illness are in the tenth version of the international 
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statistical classification of disease and related health problems (ICD-10) (World Health 
Organisation 1992b) and the fifth edition of the diagnostic and statistical manual of mental 
disorders (DSM-V) (American Psychiatric Association 2013). A diagnostic summary of 
bipolar disorder and schizophrenia is described below and is also shown in Table 1-1.  
Table 1-1 A summary of the symptoms of bipolar disorder, schizophrenia or other 
relevant disorders  
Bipolar 
disorder 
An episodic recurrent pathological disturbance in mood ranging from 
extreme elation or mania to severe depression, which is usually 
accompanied by disturbances in thinking and behaviour; psychotic 
features (delusions and hallucinations) often occur.  
Bipolar I 
disorder 
A type of bipolar disorder in which severe episodes of mania (energised 
state) occur.  
Bipolar II 
disorder 
A type of bipolar disorder in which no severe episodes of mania 
(energised state) occur but in which milder episodes, known as 
hypomania, occur.  
Schizophrenia A chronic disorder in which a wide variety of clinical features can occur 
and which is usually characterised by deterioration in social functioning 
and impaired cognitive function; delusions and hallucinations are often 
prominent and, although mood disturbance is common, it is not the most 
prominent feature.  
Schizophrenia 
disorder, 
bipolar type 
An illness in which prominent features of both bipolar disorder and 
schizophrenia occur.  
Unipolar 
(major 
depression) 
A mood disorder in which only episodes of depressed mood occur; 
psychotic features can occur but are less common than for bipolar 
disorder. 
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1.1.3.1 Diagnosis of bipolar disorder 
Bipolar disorder (BPD) is classified into bipolar I disorder (BP-I) and bipolar II disorder 
(BP-II) according to DSM-V classification system; whereas there is no such distinction in the 
ICD-10 classification system. BP-I requires at least one manic episode to be diagnosed; 
whereas the BP-II requires experience only milder hypomanic episodes, as well as major 
depressive episodes (Akiskal and Benazzi 2005). In a manic episode the patient has markedly 
elevated mood, and this is often interrupted by occasional outbursts of intense irritability or 
even violence. For a diagnosis of as BPD, the duration of a manic episode must persist for at 
least one week. In addition, three or more additional symptoms must occur in the same time 
period, such as grandiosity, decreased need for sleep, pressure of speech, flight of ideas, 
distractibility, hyperactivity, increased sexual activity and impulsive behaviour. Psychotic 
symptoms, such as delusions and hallucinations, may or may not need to be present in a 
manic episode. Depressive episodes are characterised by depressed mood, loss of interest, 
decreased sexual interest, accompanied by reduced self-confidence, decreased energy and 
feelings of worthlessness, which should markedly depressed for most of every day and for 
most days for at least 2 weeks to be diagnosed. Hypomanic episodes occur when a patient 
experiences abnormally elevated, expansive, or irritable mood for at least 4 days, and also 
has at least three other symptoms of mania but to a lesser degree (American Psychiatric 
Association 2013). The ICD-10 classification system defined characteristics of BPD are that 
the individual has to experience a manic episode along with another mood disturbance 
(WHO 1993). 40% of patients who experience depression and only mild or short-lived 
hypomanic episodes that do not quite meet the threshold criteria for a diagnosis of BP-I or 
BP-II are diagnosed as having unipolar depression instead. The occurrence of these episodes 
may last from one week to several months varying across different patients. In addition a 
patient with BPD may suffer from many depressive episodes before experiencing their first 
episode of mania (Akiskal 2005). The course of illness is generally variable among 
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individuals and the frequency of depressive episodes tends to be higher than manic episodes. 
Furthermore, researchers have also reported a seasonal pattern of episodes occurring, where 
manic episodes more likely to occur in the spring or early summer and depressive ones in the 
autumn or winter (American Psychiatric Association 2013).  
 Other characteristics of BPD such as cyclothymia, mixed episodes, rapid cycling, 
schizoaffective disorder and seasonal affective disorders are defined as bipolar disorder not 
otherwise specified (BP-NOS). In DSM-V, cyclothymia is defined as a less serious version 
of full-blown BPD because it is minus certain extreme symptoms and psychotic features such 
as delusions and the marked impairment caused by full-blown manic or major depressive 
episodes. If the person is subject to cyclical mood changes that are less severe than the mood 
swings seen in BPD and persist for at least a year, he or she may receive a diagnosis of 
cyclothymic disorder. Mixed episode is characterised by symptoms of both full-blown manic 
and depressive episodes nearly every day over at least one week, whether the symptoms are 
intermixed or alternate rapidly every few days. Additionally, psychotic features may also be 
present during mixed episodes (American Psychiatric Association 2013). Schizoaffective 
disorder is a form of recurrent mood and psychotic illness in which manic episodes occur 
together with schizophrenia-like psychotic symptoms. In other words, it is a boundary of 
schizophrenia and bipolar disorder. Rapid cycling is another condition in which the patient 
experiences at least four distinct episodes of mood disturbances in a year separated by 
periods of remission. These individuals are usually resistant to many available treatments 
such as lithium therapy and are therefore, clinically challenging to treat.  
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1.1.3.2 Diagnosis of schizophrenia 
The characteristics of SCZ on the basis of DSM-V criteria includes thought echo; thought 
insertion or withdrawal; thought broadcasting; delusional perception and delusions of control, 
influence or passivity; hallucinatory voices commenting or discussing the patient in the third 
person; thought disorders; disorganised speech; grossly disorganised or catatonic behaviour 
as positive and negative symptoms (American Psychiatric Association 2013). Negative 
symptoms often refer to symptoms involving domains which are intact in unaffected 
individuals but not found in a patient with SCZ such as social impairment, lack of motivation 
(avolition), poverty of speech (alogia), affective blunting and inattention. By contrast, 
positive symptoms are those that reflect an excess or distortion in a normal repertoire of 
behaviour and experience such as delusions and hallucinations. The course of SCZ can be 
either continuous, or episodic with progressive or stable deficit, or there can be one or more 
episodes with complete or incomplete remission. In some cases, only one negative symptom 
is required if the delusions or the hallucinations consist of a voice keeping up a running 
commentary on the person’s behaviour our thought, or two or more voices conversing with 
each other. SCZ patients may also have dysfunctional work, interpersonal relations or self-
care. In many cases, severe mood symptoms up to and including manic and major depressive 
episodes are also present in SCZ patients.  
According to the classification systems, SCZ is sub-divided into five different definitions 
based on their clinical symptomology: paranoid, hebephrenic, catatonic, undifferentiated, and 
residual. The characteristic of paranoid SCZ is that it is dominated by relatively stable, often 
paranoid delusions and usually accompanied by hallucinations, particularly of the auditory 
variety and perceptual disturbances. If SCZ patients experience delusions and hallucinations 
that are fleeting and fragmentary, have behaviour that is irresponsible and unpredictable, 
have shallow and inappropriate mood, disorganised thought and have incoherent speech, he 
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or she is generally diagnosed as suffering from hebephrenic SCZ. The prognosis is usually 
poor because of the rapid development of negative symptoms, particularly flattening of affect 
and loss of volition. Hebephrenic SCZ should normally only be diagnosed in adolescents or 
young adults. Patients suffering from catatonic SCZ are required to have one or more of the 
following prominent catatonic behaviours such as stupor, excitement, posturing, negativism, 
rigidity, waxy flexibility, and command automatism for a period of at least two weeks. The 
catatonic phenomena may be combined with a dream-like (oneiroid) state with vivid scenic 
hallucinations. For diagnosis of undifferentiated SCZ there is the requirement for the general 
criteria for SCZ to be met, while there may be insufficient symptoms to meet the criteria of 
other subtypes. If the patient suffers more than four of the negative symptoms such as 
psychomotor slowing, blunting of affect, passivity, reduced speech throughout the previous 
twelve months; he or she is diagnosed as suffering from residual SCZ. This class of SCZ may 
also be present at a lower intensity than positive symptoms.  
While there are clinical distinctions between these two nosological groups, there are no 
pathogenomonic signs or symptoms. Although BPD is characterised by repeated episodes of 
both depression and mania, no such opposite poles of SCZ exist. However to some extent the 
negative symptoms of SCZ do share clinical characteristics of depression, such as social 
withdrawal and psychomotor retardation. In addition to some extent, the positive symptoms 
of SCZ share characteristics of mania, a syndrome frequently characterised by delusions and 
hallucinations.  
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1.1.4 Epidemiology similarities in BPD and SCZ 
Epidemiology is the study of the distribution and determinants of disease in human 
populations and the variations of these distributions among different groups of people. 
Prevalence is an epidemiological population measure, which refers to the proportion of 
individuals that have a disorder at a specified time or during a specified period. Lifetime 
prevalence is the proportion of those in the population who had a disorder at some time in 
their life up to their age at the time of interview. Researchers have found that BPD and SCZ 
tends to share several epidemiologic characteristics: (i) both of them have a similar lifetime 
risks of approximately 1% across the world’s populations and occur at this rate with little 
variation across continents (Meltzer 1999); (ii) both disorders also have similar gender and 
age-at-onset distributions; men and women are equally affected; they both commonly occur 
in young adulthood particularly between ages 15 and 25; and are relatively unusual in pre-
pubertal children and after the age of 40 (Castle et al. 1993, Smith A 1992); (iii) once DSM-
IV criteria for BPD or SCZ are met, the disorders tend to persists through life and become 
relatively chronic with a relapse-remit course, rarely showing full recovery, especially in 
SCZ; (iv) the two disorders are associated with high morbidity and health services use and 
are also characterised by increased risk of self-harm and suicidal behaviour (Guze and 
Robins 1970).  
1.1.4.1 Epidemiology in BPD  
According to the World Health Organisation, BPD affected an estimated 29.5 million 
individuals worldwide in 2004 (World Health Organization 2008). Recently, a study 
involving a combined sample of 61,392 community-dwelling individuals in 11 countries, 
mainly in the Americas, Europe, and Asia, found an aggregate lifetime prevalence of 2.4% in 
BPD, 0.6% in BP-I, 0.4% in BP-II (Merikangas et al. 2011). Of the 11 countries examined in 
this study, the lowest lifetime prevalence of bipolar spectrum illness was in India at 0.1%, 
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and the highest was in the United States at 4.4% (Merikangas et al. 2011). Interestingly, BPD 
prevalence decreased with increasing age and education level and was higher in 
unemployed/disabled individuals compared with employed individuals, or those with an 
income (Merikangas et al. 2011). Childhood-onset BPD prevalence showed some potentially 
substantive geographic variation (Merikangas et al. 2012, Stringaris et al. 2010). For example, 
childhood-onset BPD may be less common in Europe than in the United States (Post et al. 
2008). Indeed, among the first 1,000 participants in the US-based Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD), 27.7% had an age of onset of less 
than 13 years, this was associated with a greater number of lifetime depressive and manic 
episodes, and a greater likelihood of past suicide attempt compared with adolescent onset and 
adult onset (Perlis et al. 2004). Childhood-onset BPD thus may entail greater genetic 
vulnerability, in particular the offspring of parents with childhood-onset BPD may be at 
higher risk of developing BPD. Furthermore BPD has been consistently associated with 
significant medical and psychiatric comorbidity. For instance, 94.6% of patients with BPD 
reported in the National Comorbidity Survey Replication (NCS-R) having at least one 
comorbid disorder, with a mean of 4.6 medical and/or psychiatric comorbidities reported by 
such individuals (Gadermann et al. 2012). Moreover, in STEP-BD, 58.8% of BPD patients 
had at least one medical comorbidity and the prevalence was significantly higher in those 
with lifetime anxiety and substance use disorders (Magalhaes et al. 2012). With regard to 
medical comorbidities, cardiovascular and metabolic diseases are particularly prevalent 
among BPD patients, who have shown increased rates of hypertension, obesity, metabolic 
syndrome, and diabetes (Fiedorowicz et al. 2008, Goldstein et al. 2011, McIntyre et al. 2005, 
Vancampfort et al. 2013). For example, a large population-based cohort study in Sweden 
found that BPD patients had increased mortality rates due to cardiovascular and other 
medical illnesses. On average they died of cardiovascular disease, 10 years earlier than the 
general population (Westman et al. 2013).  
39 
 
1.1.4.2 Epidemiology in SCZ 
SCZ is devastating psychiatric disorder with a median lifetime prevalence of approximately 4 
cases per a thousand people with a morbid risk of 7.2 cases per a thousand people (McGrath 
et al. 2008). The standardised mortality ratio (SMR; ratio of observed deaths to expected 
deaths) for all-cause mortality is 2.6 for patients with SCZ and dying 12 – 15 years earlier 
compared to the general population (McGrath et al. 2008, Saha et al. 2007), with excess 
deaths mainly from suicide during the early phase of the disorder and later from 
cardiovascular complications. The age-at-onset is typically in adolescence or early adulthood 
(age group 15 – 35 years) (Messias et al. 2007), onset after the age of 50s and in childhood 
both being rare (Girard and Simard 2008, Remschmidt and Theisen 2005). Although the 
prevalence for males and females is similar  (McGrath et al. 2008), the course of SCZ is 
often more severe and with earlier onset for males  (Leung and Chue 2000, Messias et al. 
2007) whereas after the age of 40 it is women who are considered the most at risk (Aleman et 
al. 2003). The mechanism underlying the late-age-onset in women has been suggested to be 
the effects of oestrogen on reduction in dopamine receptors sensitivity in the central nervous 
system (Hafner et al. 1999). Because of this confounding information it is often accepted as a 
general view that there are no sex differences in the lifetime risk of developing SCZ.  
There is some evidence for other epidemiological risk factors affecting localised prevalence 
such as family, history, seasonal or urban birth, immigration, perinatal infection and famine. 
In a comparison study of immigrants in the Netherlands there was evidence that not only 
does immigration increase the risk of psychiatric illness but that the effect is also exacerbated 
depending on your age. A lower age at the time of migration was associated with a higher 
incidence of psychosis among the immigrants (Veling et al. 2011). The effect of immigration 
factors on prevalence of SCZ has also been replicated on numerous occasions (Bhugra et al. 
2011, Mallett et al. 2004, Saha et al. 2005).  
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Although substantial variations in the prevalence and incidence of SCZ across different 
countries and cultural groups have been reported (US Institute of Medicine 2001), these 
differences are reduced when stricter diagnostic criteria are applied (Jablensky 1997). The 
incidence of SCZ across ten countries was shown to be quite similar in a World Health 
Organisation (WHO) study (Jablensky et al. 1992). Replication of the WHO study across 
multiple countries also indicates that the clinical syndrome of SCZ is similar across a wide 
range of cultures and countries, including those developed and developing countries 
(Jablensky et al. 1992, World Health Organization 1979).  
1.1.5 Treatment  
Early pharmacological treatment are frequently used in the management of both BPD and 
SCZ, including antidepressants, mood stabilisers (lithium, valproic acid, carbamazapine), and 
benzodiazepines. Until recently, treatments of these two disorders were relatively separated. 
For example, mood stabilisers, such as lithium, anticonvulsants, and antidepressants, do not 
show substantial efficacy in SCZ. On the other hand, lithium is the most common medication 
for BPD treatment, which is particularly effective in patients with a family history of the 
disorder according to a National Health Service report (Mendlewicz 1973). In light of the 
evidence for overlap in susceptibility, perhaps it should be expected that some medications 
for one category of these disorders might be beneficial for individuals with the other category 
of illness.  
1.1.5.1 Treatment in BDP 
The pharmacological treatment of BPD is based on the course of the illness, for example 
specific drugs for manic/hypomanic, mixed or depressive episodes (Fountoulakis and Vieta 
2008). Mood stabilisers such as lithium and lamotrigine are the most significant 
pharmacological treatments and are used to ameliorate manic symptoms and sometimes for 
depression (Fountoulakis and Vieta 2008, Malhi 2009, Malhi et al. 2009). Other medications 
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such as anticonvulsants for epilepsy and antipsychotics for SCZ have also been used in BPD 
treatment. Mood episodes in BPD may relapse during continuation treatment as well as 
recurring during maintenance/prophylactic treatment; therefore long-term treatment to 
prevent mood episodes is important in the management of BPD. Since the 1960s (Abou-
Saleh and Coppen 1986), lithium has been recognised to prevent mood episodes; however, it 
only gained approval in 1970 from the US Food and Drug Administration. Since then, 
lithium has become a mainstay treatment in BPD as well as in unipolar depression (Cipriani 
et al. 2006), where it has been proposed to have a robust neuroprotective and neurotropic 
action leading to the upregulation of synaptic plasticity. Recently, a study found that a 4-
week administration of lithium magnified the long-term potentiating of CA1 pyramidal cells 
thus up-regulating the synaptic plasticity in the hippocampus (Shim et al. 2012). Conversely, 
lithium has a narrow therapeutic index and its toxicity can be fatal on some occasions. 
Alternative mood stabilisers that have been used in clinical practice are valproate, 
carbamazepine, gabapentine and lamotrigine.  
According to clinical observation, BPD patients tend to spend more time being depressed 
than being manic (Fountoulakis et al. 2012), which causes greater psychosocial impairment 
and disability. Currently, there are a number of antidepressants have been used widely, 
including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI), 
monoamine oxidase inhibitors (MAOI), noradrenaline reuptake inhibitors (NARI), serotonin-
noradrenaline reuptake inhibitors (SNRI) and atypical antidepressents (Palucha and Pilc 
2007). Among atypical antipsychotics, quetiapine, olanzapine and fluoxetine are routinely 
used in monotherapy or in combination for the management of bipolar depression. Recently, 
lithium, lamotrigine or quetiapine monotherapy have been suggested as the first-line choice 
of treatment. The use of antidepressant agents in combination with antimanic agents such as 
lithium and valproate, as well as the use of olanzapine-fluoxetine combination (OFC) to 
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avoid manic switches have also been recommended (Fountoulakis et al. 2005). A similar 
treatment strategy has also been suggested by the NICE (National Institute for Health and 
Clinical Excellence). NICE also recommend adding antipsychotic drugs such as olanzapine, 
quetiapine, or risperidone for acute bipolar mania to the combination of antidepressant and 
antimanic agents (Nivoli et al. 2012). Recently, olanzapine showed efficacy among BPD 
patients in preventing recurrences of both mania and depression (Tohen et al. 2003). 
1.1.5.2 Treatment in SCZ 
Antipsychotic medication can reduce the severity of symptoms and the susceptibility to 
relapse of these symptoms. The rate of relapse can be worsened by substance abuse. On the 
other hand, psychosocial therapy can minimise the harmful effects of stress and reduce the 
effects of stress on vulnerability, and enhance a patient’s coping skills (Mueser and McGurk 
2004). Studies of combinations of therapies have suggested that relapses were significantly 
reduced in those receiving high-dose antipsychotics and family therapy compared to 
individuals receiving neither drug treatment nor psychological intervention (Dixon et al. 
2010, Goldstein et al. 1978, Huxley et al. 2000). This result suggests that complementary 
psychosocial treatments increase the benefits of pharmacotherapy, by enhancing social 
functioning and are also being associated with fewer hospitalisations.  
Atypical antipsychotics represent the primary medication for schizophrenia because they 
improve psychotic symptoms and prevent relapse (Kane and Marder 1993). Although 
antipsychotics have dramatic effects on psychotic symptoms, they have more modest effect 
on negative symptoms and cognitive impairment (Greden and Tandon 1991).  
In the early 1950s, typical or conventional antipsychotics were made available as the primary 
pharmacological intervention for SCZ. These antipsychotics included chlorpromazine, 
thioridazine, haloperidol and fluphenazine (Agid et al. 2008). Although conventional 
antipsychotics are relatively effective at treating psychotic symptoms, they can also produce 
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problematic side-effects, including Parkinsonian/extrapryamidal symptoms and tardive 
dyskinesia (Carlini 2004, Malhotra et al. 1993). More recently several other atypical 
antipsychotics were developed that have a more favourable side-effect profile. These include 
clozapine, risperidone, olanzapine, quetiapine and sertindole (Leucht et al. 2009). The 
fundamental property of this group of antipsychotics is their ability to reduce symptoms in 
the absence of adverse extrapyramidal side effects that patients experience with conventional 
antipsychotics treatment (Kapur and Mamo 2003). Despite this benefit, they confer an 
increased risk of metabolic side effects such as diabetes, hypercholesterolemia and weight 
gain (Schultz et al. 2007). All atypical antipsychotics have a relatively low binding affinity 
for dopamine receptors. Based on their chemical structure they are classified into 
dibenzodiazepines, benzisoxazoles, and thienobenzodiazepines. In addition to their low 
affinity for dopamine receptors, they differ from their earlier counterparts in having a higher 
affinity for the serotonin (5-HT) 2, receptor upon which they have an antagonistic affect 
(Worrel et al. 2000). A meta-analysis of comparisons between the efficacy of conventional 
and atypical antipsychotics showed that atypical antipsychotic treatments are more effective 
for negative symptoms of SCZ (Arango et al. 2013). Surprisingly, only clozapine has been 
found to be truly effective in the treatment of both positive and negative symptoms as well as 
the associated co-morbidity of depression (Kane et al. 1988). However, while clozapine has 
unique potency for the treatment of persistent psychotic symptoms, negative symptoms, and 
suicidality (Meltzer et al. 2003, Wahlbeck et al. 1999), it can cause a fatal agranulocytosis in 
less than 1% of patients (Alvir et al. 1995). As a result patients treated with clozapine require 
routine monitoring of their white blood-cell count (Cohen and Monden 2013). Despite these 
side effects overall clozapine has one of the lowest mortality rates in comparison to other 
anti-psychotics, mainly due to its effect on reducing the risk of suicide.  
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1.1.6 Pathophysiology of BPD and SCZ 
The Kraepelinian dichotomy states that patients with dementia praecox (SCZ) and manic 
depression (BPD) present as two separate psychotic disorders. Accumulating evidence from 
clinical observations and antipsychotic treatments in SCZ and BPD recently argued against 
the Kraepelinian dichotomy. However there is also evidence supporting the dichotomy 
including data showing volumetric neuroimaging differences in brain regions such as the 
amygdala, hippocampus, and lateral ventricles that appear to be disorder-specific (Bellivier et 
al. 2013, Murray et al. 2004, Yu et al. 2010). In addition, reduction of grey matter volumes 
and neurocognitive neuromoter impairment occur in the early stage of SCZ, but this does not 
occur in BPD despite both diseases often having an onset during adolescence. Patients 
suffering from BPD are thought to exhibit less extensive brain morphological abnormalities 
and less severe neurocognitive deficits in comparison with patients suffering from SCZ 
(Depp et al. 2007, Ellison-Wright and Bullmore 2010, Krabbendam et al. 2005, Schretlen et 
al. 2007, Seidman et al. 2002). Recent findings of both shared and different genetic 
predispositions in BPD and SCZ do not allow firm conclusions about the nature of the 
Kraepelinian dichotomy (Demjaha et al. 2012, Fusar-Poli et al. 2012, Lewandowski et al. 
2011, Murray et al. 2004, Napal et al. 2012, O'Donnell 2007, Young et al. 2006). 
By contrast, findings in the molecular pathology of SCZ and BPD have recently challenged 
to the Kraeplinlian dichotomy. For example, the dysregulation of dopamine and serotonin 
have been implicated in both disorders, which suggest that antipsychotic drugs may be useful 
in the management of BPD as well as SCZ (Demjaha et al. 2012, Murray et al. 2004). 
Specific serotonin receptor knock-out mice studies consistently show an anxious and 
depressed phenotype and abnormal physiological responses to stress paradigms (Holmes et al. 
2003, Parks et al. 1998, Richardson-Jones et al. 2011, Weisstaub et al. 2006). Selective 
serotonin reuptake inhibitors have also been found to be effective in treating the negative 
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symptoms of SCZ (Singh et al. 2010). Furthermore, some of the psychotic experiences in 
BPD are mediated through dopamine pathways, where antipsychotics act as dopamine D2 
receptor blockers (Brugue and Vieta 2007). The depletion of monoamines does not lead to 
depression in all individuals and administration of monoamine-based antidepressants takes 
several weeks to improve core depressive symptoms, suggesting downstream neural adaption, 
as opposed to direct effects (Sanacora et al. 2012). Therefore, researchers have begun to 
focus on the hypothesis that glutamate and the N-methyl-D-aspartate receptor (NMDAR) 
may play an important role in the pathophsyiology of BPD, SCZ and related disorders. 
Postmortem studies have shown increased glutamate levels in diverse brain areas in 
individuals with mood disorders (Hashimoto et al. 2007) and a reduction of NMDARs in 
BPD patients (Hashimoto et al. 2007, Rao et al. 2012). Patients suffering from SCZ showed a 
significant reduction in glutamate levels and a hypoactive glutamate system (Coyle 1996, 
Goff and Coyle 2001, Goff and Wine 1997, Jentsch and Roth 1999, Kim et al. 1980, Meador-
Woodruff and Healy 2000, Olney and Farber 1995), an increased release of glutamate was 
shown in selected brain areas (Olney et al. 1999). Other neurotransmitter systems, such as the 
-aminobutyric acid (GABA) B subunits (GABAB) receptors, which mediate the release of a 
number of neurotransmitters including dopamine, serotonin, noradrenaline, somatostatin, 
glutamate and GABA (Nyitrai et al. 2003, Sakamaki et al. 2003, Steiniger and Kretschmer 
2003, Takahashi et al. 2010, Waldmeier et al. 2008). Postmortem and genetic studies have 
demonstrated changes in GABAB receptors that are thought to be involved in the 
pathophysiology of BPD and SCZ (Ghose et al. 2011, Ishikawa et al. 2005, Klempan et al. 
2009, Mizukami et al. 2000, Zai et al. 2005). 
With regards to neurocognitive functioning, several studies have reported poorer 
neurocognitive functioning in patients with SCZ compared to those with BPD, but there are 
also data suggesting that patients with SCZ are comparable with BPD patients in terms of 
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neurocognitive impairments (Altshuler et al. 2004, Daban et al. 2006, Depp et al. 2007, 
Glahn et al. 2006, Meesters et al. 2013, Sanchez-Morla et al. 2009, Simonsen et al. 2011, 
Varga et al. 2007). These inconsistent neurocognitive functioning findings may be due to 
differences in sample size, the specific neurocognitive deficits that are measured, the types of 
scales used, and the presence of other confounders including age and premorbid intelligence 
(Bora et al. 2008, Daban et al. 2006, Glahn et al. 2006, Simonsen et al. 2011). 
1.1.7 Heritability of BPD and SCZ 
The heritability of BPD and SCZ has been studied for almost one hundred years using twin 
and family studies. These have produced estimates of approximately 60 – 90% in SCZ and 
60 – 80% in BPD. Co-occurrence of the two disorders has also been shown in families 
(Berrettini 2000, Lichtenstein et al. 2009, McGuffin et al. 2003, Sullivan et al. 2003). The 
lifetime risk of BPD is only 0.5 – 1.5%; however, if there is a parent or other first-degree 
relative with BPD, it increases to about 5 – 10%; and also if there is a more extensive family 
history such as both parents are affected, then this risk is multiplied several-fold (Craddock 
and Jones 1999). There is a ten-fold increase in the lifetime risk of SCZ in the first-degree 
relatives of a person suffering from SCZ (Gottesman II 1982). The genetic risk increases to 
nearly 50% when both parents are affected (McGuffin et al. 1995). These results strongly 
suggest that genetic factors are playing an important role in the aetiology of BPD and SCZ.  
1.1.7.1 Twin and adoption studies 
In twin studies concordance rate differences between monozygotic (MZ, identical) twins 
point to the role of the environment, and concordance rate differences between dizygotic (DZ, 
fraternal) twins point to both hereditary and environmental factors. The concordance rate is 
the probability that a second twin will develop a disorder if the proband (first examined) twin 
has the disorder, is commonly used. The concordance rates of SCZ for MZ twins have been 
found to be about 40 – 50% (Cardno and Gottesman 2000, Sullivan et al. 2003); where the 
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concordance rate for BPD is also 65% higher among MZ twins (McGuffin et al. 2003). The 
high heritability estimates and high monozygotic concordance rates are convincing indicators 
of the importance of genetic factors affecting BPD and SCZ susceptibility.  
Adoption studies allow dissection of genetic from environmental contributions to a disorder 
in ways that twin studies cannot (Ingraham and Kety 2000). These studies have found an 
elevated risk for psychosis in such offspring, whether the affected parents had an onset of 
disease before or after adoption, and whether the rearing environment was foster parents or 
an institution (Heston 1966, Higgins 1976, Tienari 1991, Tienari et al. 1985, Tienari et al. 
1994, Wender et al. 1974). Consistent with the risk travelling with the biological rather than 
the adoptive relationship, it was also shown that the risk was similar for offspring of SCZ 
mothers, whether they were raised by the affected biological affected parent or an adoptive 
un-affected parent (Higgins 1976). The offspring of mothers without SCZ also did not have 
an increased risk when raised by adoptive parents suffering from psychosis (Wender et al. 
1974). Furthermore, adoption studies can yield some insight into gene-environment 
interactions, for example by comparing communication deviance in adoptive parents of high-
risk adoptees (Wahlberg et al. 1997). The adoptees’ family approach starts with SCZ 
adoptees and matched control adoptees, and evaluates their adoptive and biological families 
for illness. These studies have shown elevated rates of SCZ and SCZ spectrum disorders in 
biological families of SCZ adoptees compared to biological families of control adoptees, 
coupled with low and equivalent such rates in adoptive families of both types of 
adoptees (Kendler et al. 1994, Kendler et al. 1981, Kety et al. 1994). 
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1.1.7.2 Family studies 
Familial aggregation has been demonstrated repeatedly in SCZ and BPD (Lichtenstein et al. 
2009), and also in schizoaffective disorder (Cardno et al. 2002). A meta-analysis of high-risk 
family studies recently compared offspring of parents with SCZ, BPD and major depressive 
disorder (Rasic et al. 2014). The study showed that the offspring of adults with SCZ, BPD or 
major depressive disorder had a 32% probability of developing one of these disorders 
themselves by adulthood and that the risks to offspring were not limited to their parent’s 
index disorder. For example, the offspring of patients with SCZ or BPD had an increased risk 
of SCZ, BPD and major depressive disorder. However, although the relative risk of SCZ and 
BPD was also elevated in offspring of parents with depression, this finding did not reach 
statistical significance. Another meta-analysis of family studies of SCZ and BPD confirmed 
an overlap in familial risk (Van Snellenberg and de Candia 2009). However, a Swedish 
population register recently showed although the cross-disorder risk is lower than the same-
disorder risk, a that partial overlap exists in familial genetic susceptibility for BPD and SCZ 
(Lichtenstein et al. 2009). Therefore, these family studies are consistent with partial overlap 
in familial susceptibility of BPD and SCZ. 
BPD and SCZ susceptibility gene identification has been a slow and difficult process, as with 
other common complex traits such as diabetes, asthma, and hypertension. This inconsistency 
of the findings among all these studies can be attributed to the small effect sizes of BPD or 
SCZ susceptibility genes, locus heterogeneity, and phenotypic heterogeneity (Schulze and 
McMahon 2003).  
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1.2 Molecular Genetics Studies  
Advances in molecular genetic studies such as genome-wide association studies (GWASs), 
meta-analyses, mega-analyses, high-throughput DNA and RNA sequencing and gene 
expression arrays have detected susceptibility genes or variants that are likely to contribute to 
the risk diseases such as bipolar disorder (BPD) and schizophrenia (SCZ). The evidence from 
these studies has provided psychiatry with an unprecedented opportunity to identify the 
biological systems that are involved in illness and with the potential to lead to genetic 
medicine. Both BPD and SCZ have a complex aetiology pattern, thus they fall into the 
category of complex genetic disorders which may involve multiple genes either in an 
oligogenic model (the interaction of a small number of major genes) or a polygenic mode 
(minor involvement of many genes) and environmental risk factors. The clinical diagnosis of 
these two disorders is based on behavioural signs and symptoms from each individual. 
Neither disorder currently has a specific, clearly defined, pathophysiological foundation on 
which to base diagnostic tests. Examining biological markers by molecular genetic studies 
may provide clues in the development of such tests, which may be clinically useful in risk 
prediction. A review of molecular genetics findings in BPD and SCZ will be discussed in 
four different stages: linkage studies, association studies, GWAS and copy number variation 
(CNV) studies. 
The initial genetic research focused on family linkage and allelic association methods, which 
have been applied to narrow the location of genes to small regions of the genome for 
identification and characterisation of the susceptibility gene and eventually the casual variant. 
Before the introduction of GWAS, molecular genetic studies can be conceptually divided 
into positional and candidate gene approaches. Positional linkage studies are based on 
chromosomal positions identification of the susceptibility genes in a few large families 
conferring a high degree link between the families and disease risk. This method can be 
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considered as a purely genetic approach that does not require prior knowledge of disease 
pathophysiology. In contrast, the researcher requires sufficient understanding of disease 
biology for the candidate gene approach to identify genes that may be associated with 
psychiatric disorders (Craddock and Jones 1999). With increasing understanding of common 
genetic variation and advances in the technological ability to genotype more people, interest 
shifted to association studies of larger numbers of case of BPD or SCZ and healthy people to 
detect population-level associations. Traditionally, association studies were focused on 
identification of variants within specific candidate genes of interest. With advances in 
mapping of the human genome and high throughput genotyping, focus shifted to GWASs. 
GWAS studies were made possible by to advances in technology and also a reduction in 
genotyping costs. GWAS studies are able to detect common risk variants across the whole 
human genome in an unbiased way. These studies typically genotype hundreds of thousands 
of single nucleotide polymorphisms in thousands of people. This genome-wide analysis data 
can also be applied to determine rare structural chromosomal variants, also known as copy 
number variants (CNVs). To date, these analyses have provided robust and replicable 
findings in psychiatric genetics, which will be discussed in more detail later. With emerging 
technologies such as next generation sequencing that makes whole genome sequencing 
feasible in many thousands of samples. It has become possible to determine the contribution 
of rare variants with a modest effect on susceptibility genes. These various experimental 
approaches have the capacity to provide a complete picture of the genetic variation that 
affects disease risk.   
BPD and SCZ are classified as different psychiatric disorders in modern western 
classification systems and historically this distinction is often referred to as the Kraeplinian 
dichotomy (described earlier). However, several similarities have been found, such as 
lifetime risks of approximately 1% across the world’s populations, an age-at-onset in young 
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adulthood, psychotic symptoms with a relapse-remit course, shared antipsychotic 
medications, high morbidity and increased risk of self-harm and suicidal behaviour, and a 
difficult differential diagnosis with schizoaffective disorder. These similarities have 
suggested possible shared common genetic susceptibilities in BPD and SCZ. This notion is 
supported by evidence from studies implicating common linkage regions, gene expression 
patterns and molecular mechanisms in BPD and SCZ (Craddock et al. 2006, Knight et al. 
2009, Le-Niculescu et al. 2007, Shao and Vawter 2008).  Given these clinical observations 
and the shared genetic findings it was widely expected that the genetic approaches described 
above would reveal genes that increase risk for both BPD and SCZ. In fact, BPD and SCZ 
susceptibility gene identification has been a slow and difficult process, as with other common 
complex traits such as diabetes, asthma, and hypertension. The inconsistency of the findings 
among all these studies can in part be attributed to lack of statistical power due to small 
sample size, the small effect of BPD and/or SCZ susceptibility genes, locus heterogeneity 
and phenotypic heterogeneity (Schulze and McMahon 2003).  
1.2.1 Factors affecting genetic studies 
1.2.1.1 Locus heterogeneity 
The term genetic heterogeneity can be divided into two different dimensions, known as locus 
and allelic heterogeneity. Locus heterogeneity means that similar phenotypes may be caused 
by mutations at different gene loci, whereas allelic heterogeneity refers to the same 
phenotypic outcome at a specific gene locus for different alleles. Since linkage to the same 
chromosomal region is still detectable in the presence of allelic heterogeneity this does not 
represent a problem for linkage analysis; however, it is a problem for association analysis 
where tests of association generally depend on cases sharing the same allele. Conversely, the 
presence of several different genes with similar phenotypes generally is troublesome for 
linkage analysis. Although locus heterogeneity has fewer problems from association analysis, 
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it reduces the power of linkage and association analysis in identifying disease variants 
(Gershon and Goldin 1986, Risch and Botstein 1996). One of the main approaches to the 
problem of locus heterogeneity is by careful ascertainment. This may be achieved restricting 
collection of individuals or their family to geographical regions or to population isolates with 
the aim of reducing the number of different susceptibility genes.  
1.2.1.2 Phenotypic heterogeneity 
Recently, phenotype definition has become increasingly important because imprecision may 
result in variation in the validity of the diagnosis. A clear and distinct phenotype that 
captures the underlying mechanism of BPD and SCZ has yet to be defined. For instance, the 
identification of an affected phenotype for BP-I is highly accurate and reliable compared to 
the BP-II, which has a less valid and reliable diagnosis (Craddock and Jones 1999). Because 
of these difficulties endophenotypes have been used in order to discover clinical entities that 
are associated with a disease but may be closer to the underlying biology compared to the 
symptoms of the disease. This approach has increased the understanding of the clinical 
picture in SCZ (Adler et al. 1982, Gorman et al. 1990, Porjesz et al. 2002), but have not yet 
led to the same insights in BPD (Turecki et al. 2001). These findings suggest that the 
disorder spectrum phenotype for genetic analysis needs to be as broad as possible, especially 
for complex disorders such as BPD.  
1.2.1.3 Sample sizes 
The final well-known problem that has faced linkage and association studies of complex 
disorders such as BPD and SCZ is sample size.  A sample size with sufficient statistical 
power is an important factor for success in genetic studies that seek to detect causal genes for 
complex human disease. To date many weak linkage and association findings have been 
reported and these have had inconsistent replication findings. Meta-analyses of genome-wide 
53 
 
association studies and/or meta-analyses of linkage scans may overcome some of the 
limitations of small sample size (Levinson et al. 2003). 
1.2.1.4 Anticipation 
SCZ and BPD are the two major psychotic disorders with a life-time prevalence of 
approximately 1%. Both disorders have a substantial genetic contribution. Several studies 
have shown that early onset of these two major psychoses are generally characterised by an 
increased number of psychotic symptoms and episodes of mania, a higher level of 
comorbidity with drug addiction and poor clinical outcomes (Craddock and Sklar 2009, 
Thibaut et al. 1995). Anticipation is one explanation for increased disease severity or 
decreased age of onset in succeeding generation within families. This phenomenon is known 
to involve either methylation effects on susceptibility genes or the expansion of trinucleotide 
repeat DNA sequences in some genetic illnesses, such as myotonic dystrophy, fragile X 
mental retardation and Huntington disease (Holmes et al. 1999, Koob et al. 1999, Ridley et al. 
1988). Many recent studies have also found consistently positive results for genetic 
anticipation in SCZ and BPD (Vincent et al. 2000) but more studies are still required to 
confirm and elucidate the mechanism that underlies this phenomenon.  
1.2.2 Genetic Markers 
The human genome is approximately 99.5% identical and the difference between individuals 
is about 0.1 – 0.5%. This variation is caused by several types of structural sequence variants 
and polymorphisms. Genetic markers are commonly used to study the relationship between 
an inherited disease and its genetic cause in disease gene mapping studies. Genetic markers 
can be either a single nucleotide polymorphism (SNP) or comprise longer DNA sequences 
such as microsatellites. Microsatellites are also known as simple sequence repeats (SSRs) or 
short tandem repeats (STRs). They were initially introduced by Weber and May and Litt and 
Buty in 1989 (Litt and Luty 1989, Schlotterer 2000) and have traditionally been used in 
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linkage studies.  Microsatellites are short tandem repeating sequences of 2-6 base pairs of 
DNA. They are widely distributed in the genome and are highly polymorphic among 
individuals (Putman and Carbone 2014). They are widely used for fingerprinting, parentage 
identification, genetic mapping, conservation and population genetics. Conversely, SNPs are 
common single nucleotide substitutions with a population frequency of approximately 1%. 
SNP markers have been widely used for positional fine mapping and functional candidate 
genes. Recently, sets of hundreds of thousands of SNPs on a single array have been used for 
GWAS of the whole human genome.  
1.2.3 Linkage analysis 
Linkage analysis utilises genetic information from families with multiple affected individuals 
and search for regions of the genome segregating or linked with the disorder. The presence of 
genetic linkage is a violation of Mendel’s law of independent assortment in which alleles at 
two chromosomal locations assort independently and are transmitted to offspring in random 
combinations.  
1.2.3.1 Linkage findings susceptibility loci in common 
More than 20 years of linkage studies in psychiatric genetics have produced a huge amount 
of data. To date linkage regions likely to harbour SCZ susceptibility genes are spread over 21 
out of the 23 pairs of chromosomes (Crow 2007, Tandon et al. 2008). For BPD linkage loci 
have been found on every single chromosome (Serretti and Mandelli 2008). Epidemiological 
studies performed before linkage studies suggested an overlap in susceptibility across the 
boundaries between SCZ and BPD. Subsequent genetic linkage studies also demonstrated the 
existence of common linkage regions for these two disorders (Berrettini 2003, Hamshere et 
al. 2005, Shao and Vawter 2008). 
Molecular linkage studies have so far revealed promising overlapping susceptibility regions 
for the two disorders including 18p11.2, 13q32, 22q11-3, 10p14, and 8p22 (Berrettini 2003). 
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Historically, the first chromosomes reported to harbour genes for mental illness was 
chromosome 18 (Richards et al. 1970) and an affected sibling pair study in BPD reported a 
susceptibility locus on 18p11 (Berrettini 1997, Berrettini et al. 1997, Berrettini et al. 1994, 
Detera-Wadleigh et al. 1999) that has been replicated by several investigators (MacKinnon et 
al. 1998, Nothen et al. 1999, Stine et al. 1995, Turecki et al. 1999). This region has also been 
implicated harbouring putative loci for SCZ in a study of families multiply affected by this 
disorder (Schwab et al. 1998b). However, it has been argued that the SCZ families might 
have been misdiagnosed as suffering from BPD. Other SCZ susceptibility loci were also 
identified in the same study including regions on 6p and 10p14 and these results indicate that 
the diagnosis of SCZ was likely to be correct (Schwab et al. 1995, Schwab et al. 1998a, 
Schwab et al. 1998b). Another positive linkage and association finding at 18p11.2 was 
reported to be shared between the BPD, SCZ, psychosis not otherwise specified, and 
schizoaffective disorder (Mukherjee et al. 2006). Later, meta-analyses were performed to 
solve the problem of sample size in traditional linkage studies, and also to evaluate evidence 
for linkage from the combined data of multiple genome scans to determine the significance 
of finding. A rank-based meta-analysis conducted on all the published genome scans 
confirmed that 18p11 is a nominally significant locus for major psychotic disorders such as 
BPD, BP-I, BP-II, schizoaffective disorder and recurrent unipolar disorder (Schwab et al. 
1998b). 
More than 44 positive findings of susceptibility loci on chromosome 22 have been reported 
in patients with SCZ, while only a few have been reported in patients with BPD (1996, Gill 
et al. 1996, Moldin 1997, Schwab and Wildenauer 1999). However, most of the positive 
findings were weak and do not reach the levels of significance suggested by Lander and 
Kruglyak (Lander and Kruglyak 1995). Furthermore, a number of studies suggest that marker 
D22S278 on 22q12 is possibly linked to a susceptibility locus for SCZ (Schwab and 
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Wildenauer 1999). Later, a genome survey of 20 North American families (Kelsoe et al. 
2001) reported that the same marker had a maximum parametric lod score of 2.8 in 
individuals with BPD and marker D22S419 on 22q11 with a secondary lod score peak of 
2.19. The location of the marker D22S419 is close to marker D22S315, which was reported 
to have a maximum lod score of 3.5 in a genome survey of SCZ families (Myles-Worsley et 
al. 1999). Deletions in chromosome 22q11 are present in 85% of individuals with velco-
cardio-facial syndrome (VCFS) (Driscoll et al. 1992). VCFS is a rare congenital disease 
consisting of characteristic facial and palatal dysmorphology, heart disease, learning 
disabilities, and interestingly, a high prevalence of psychiatric symptoms including SCZ and 
BPD. Pulver et al. reported that nearly 80% of VCFS in their cases were given a psychiatric 
diagnosis, and 29% of those had SCZ (Pulver et al. 1994), while Murphy et al (Murphy et al. 
1999) reported that 30% of their VCFS cases also had psychotic symptoms and nearly all of 
them fulfilled criteria for SCZ. These findings suggest that a small proportion of cases of 
SCZ may result from deletions of 22q11. Several authors have reported evidence for a BPD 
susceptibility locus on chromosome 22q11-13, near the VCFS locus (Detera-Wadleigh et al. 
1999, Edenberg et al. 1997, Murphy et al. 1999). Furthermore, Papolos et al. (Papolos et al. 
1996) reported that 16% of their VCFS sample had psychotic symptoms, and that 64% met 
criteria for some form of BPD. A risk chromosomal region 22q12-13 has also been identified 
as having an overlapping in both SCZ and BPD (Badner and Gershon 2002, Lewis et al. 
2003, Liang et al. 2002, Takahashi et al. 2005).  
10p14 markers have been linked to SCZ (Faraone et al. 1998, Schwab et al. 1998b, Straub et 
al. 1998). Although the data from these studies were statistically less significant than the 
other regions, the fact that three studies coincide suggests that it is a true effect. 10p14 
linkage was also found in a sample of families with BPD, suggesting that this region is likely 
to be another locus of shared risk between BPD and SCZ (Foroud et al. 2000). Several 
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independent studies have revealed linkage of SCZ to a 13q32 locus (Blouin et al. 1998, 
Brzustowicz et al. 1999, Lin et al. 1997), while linkage of this locus to BPD was also 
reported in a family study (Detera-Wadleigh et al. 1999).  
Other meta-analyses of linkage studies based on clinical phenotypes have identified and 
replicated overlapping loci including 1q32, 10p11-15, 13q32, 18p11.2 and 22q11-13 (Badner 
and Gershon 2002, Baron 2001, Berrettini 2000, Bramon and Sham 2001, Sklar et al. 2002). 
Linkage studies of psychotic BPD showed other suggestible seven regions that evidence for 
an overlap with SCZ including 5q33, 6q21, 8q24, 15q26, 17p12, 18q21, 20q13 (Park et al. 
2004). Taken together, these studies implicate shared susceptibility loci for SCZ and BPD 
and this argues against traditional categorical diagnoses.  
1.2.3.2 Disease specific linkage findings  
Although several susceptibility loci have been identified for both SCZ and BPD, the majority 
of susceptibility loci identified to date are not actually shared between these two disorders. 
Specifically implicated in risk for SCZ are 6p22-24, 8p21-22, and 5q21 (McGuffin and 
Owen 1996, Williams et al. 1999); whereas unique loci for BPD are including 4p16, 12q23-
24, 18q22 and 21q21 (Blackwood et al. 1996, Stine et al. 1995). In addition, several large 
meta-analyses have also found evidence of numerous genetic linkage of which 6p22-24, 
1q21-22, and 13q32-43 are the best supported for SCZ (Lewis et al. 2003, Owen et al. 2004), 
and suggestive linkages have also been reported in 8p21-22, 6p22, 6q21-25, 5q21-33, and 
1q42 (Baron 2001, Berrettini 2000, Lewis et al. 2003, Owen et al. 2004, Segurado et al. 
2003). An international collaboration performed a linkage scan using 6,000 SNPs on over 
900 pedigrees that showed the most significant evidence for linkage in a region spanning 
1Mb of chromosome 8p21 (Holmans et al. 2009). This has been replicated numerous times 
and was validated by an independent case-control association study (Walss-Bass et al. 2006). 
Several other meta-analyses of BPD data sets indicated and confirmed the most promising 
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linkage regions were 4p16, 16q12, 18q22, 21q21 and 12q24 (Berrettini 2000, Liu et al. 2003, 
Segurado et al. 2003).  
1.2.4 Association studies  
Genetic association is a statistical statement about the co-occurrence of alleles or phenotypes. 
The aim of genetic association studies is to find statistically significant differences in single-
locus alleles or genotype frequencies in a patient group compared with a normal control 
group. Several molecular genetics association studies have focused on the identification of 
genetic variation based on positional and/or functional evidence, which increase the risk of 
psychotic symptoms in psychiatric disorders. The hypothesis used to find candidate genes 
involved in the aetiology of BPD were those involved in neurobiological pathways such as 
dopamine, serotonin or in the circadian rhythm. The hypothesis considered for SCZ were 
genes involved in dopamine, glutamate, or in neurodevelopment.  
1.2.4.1 Association findings shared across disorders  
Recent reports have shown that the candidate genes originally implicated in SCZ may also 
influence susceptibility to BPD. Amongst the genes that have shown evidence for association 
are those involved in component symptom dimensions, such as psychosis or mood symptoms, 
in the boundary between SCZ-BPD. Association studies of psychotic BPD and subtypes such 
as mood-incongruent psychotic BPD have revealed modest positive results for several 
candidate susceptibility genes, including dysbindin (distrobrevin-binding protein 1) on 
6p22.3, DISC1 (disrupted in schizophrenia 1) on 1q42, and NRG1 (neuregulin 1) on 8p12 
(Goes et al. 2008). For instance, Green et al. (Green et al. 2005) found the association of 
NRG1 in BPD with mood-incongruent psychotic symptoms as well as with SCZ with lifetime 
manic episodes, suggesting that NRG1 may confer susceptibility to a phenotype with 
combined features of psychosis and mania. A recent study reported additional evidence for 
association between psychotic BPD and NRG1 (Goes et al. 2009). In addition, there is 
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evidence that variation in the DISC1 gene influences susceptibility to disorders of the 
psychosis spectrum, including SCZ, schizoaffective disorder and BPD (Owen et al. 2007).  
Dysbindin has been extensively implicated in SCZ and it has also been reported to be 
associated with BPD with recurrent psychotic symptoms (Raybould et al. 2005). Several 
SNPs in the dysbindin (DTNBP1) gene have been found to be associated with psychotic 
major depression compared with non-psychotic major depression (Domschke et al. 2011). 
This finding is in accordance with the hypothesis that dysbindin crucially influences 
dopamine and glutamate neurotransmission and that this dysregulation is involved psychotic 
disorders (Papaleo and Weinberger 2011). The finding of DTNBP1 genetic association with 
psychotic depression (Domschke et al. 2011) substantiates the role of DTNBP1 genetic 
variation which had been reported to confer an increased risk of SCZ (Benson et al. 2004, 
Fanous et al. 2005, Pae et al. 2009, Schwab et al. 2003, Straub et al. 2002, van den Oord et al. 
2003, Zuo et al. 2009), psychotic symptoms in general (Kohn et al. 2004), BPD (Breen et al. 
2006, Gaysina et al. 2009, Joo et al. 2007, Pae et al. 2007, Raybould et al. 2005) and unipolar 
depression (Kim et al. 2008). These tentative results are consistent with the hypothesis that 
psychotic BPD (and psychotic unipolar depression) may represent a clinical manifestation of 
the effect of overlapping genes across SCZ and mood disorder syndromes.  
Furthermore, a study implicated genetic variation in G72 (DAOA)/G30 (D-amino acid 
oxidase activator (G72)/G30) on 13q33 in susceptibility to major mood episodes across the 
traditional SCZ and BPD categories (Williams et al. 2006) suggesting that even though this 
locus was originally described as a SCZ risk gene, it may be more strongly associated with 
mood symptoms than with psychosis with the SCZ/BPD continuum. However not all studies 
support this finding (Maheshwari et al. 2009, Shi et al. 2008a).   
A cross-disorder approach reported variation in exon 3 of the DRD4 (dopamine D4 receptor) 
gene to be associated with delusional symptoms as assessed using the OPCRIT (McGuffin et 
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al. 1991) across major depression, SCZ, delusional disorder, and psychotic disorder not 
otherwise specified (Serretti et al. 2001, Serretti et al. 1999). Association of DRD4 gene 
variation across affective and psychotic disorders has been corroborated in an independent 
sample comprising patients with SCZ, schizoaffective and unipolar affective disorders 
(Weiss et al. 1996). Additionally, the dopamine receptor 2 (DRD2) S311C variant has been 
observed to be associated with delusional symptoms across major depression, SCZ, 
delusional disorder and psychotic disorder not otherwise specified (Serretti et al. 2000). 
COMT (catechol-O-methyltransferase) on 22q11 (Funke et al. 2005), CACNA1C (Green et al. 
2010), and HTR5A (Birkett et al. 2000) have also been identified as common vulnerability 
genes for both affective disorders and SCZ (Craddock et al. 2006).  
In summary, molecular genetic studies, as well as epidemiological and family studies, have 
shown evidence that SCZ and BPD partly share a common genetic cause. These data 
challenge the current nosological dichotomy between the two types of psychosis, and are 
reflective of the need for reappraisal of these disorders as distinct diagnostic entities.  
1.2.4.2 Association studies identify disease specific risk genes 
The Wellcome Trust Consortium reported genes associated with BPD and in particular that 
there was support for genes involved in GABA neurotransmission (rs7680321 in GABRB1 
encoding a ligand-gated ion channel (GABA A receptor, beta 1)), glutamate 
neurotransmission (rs1485171 in GRM7 (glutamate receptor, metabotropic 7)) and synaptic 
function (rs11089599 in SYN3 (synapsin III)). In a Japanese sample of patients with major 
depression, the met allele of the brain derived neurotrophic factor (BDNF) val66met 
polymorphism was found to be associated with psychotic features (Iga et al. 2007). 
Examining intermediate phenotypes in BPD has been strongly advocated, although rarely 
done, as a critical element in identifying informative genetic loci (Glahn et al. 2004, Lenox et 
al. 2002, MacQueen et al. 2005). Studies of genes controlling the circadian rhythm provide a 
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compelling example of how the phenotypic approach can be used to identify genetic risk 
factors for BPD.  
Other reports suggest that CLOCK (Benedetti et al. 2007, Benedetti et al. 2003, Lamont et al. 
2007, McClung 2007, Shi et al. 2008c), BmaL1 (Mansour et al. 2006, McClung 2007, 
Nievergelt et al. 2006), TIMELESS (Mansour et al. 2006, Shi et al. 2008c), and PERIOD1-3 
(Nievergelt et al. 2006, Shi et al. 2008c) are candidate loci associated with the circadian 
rhythm in the BPD phenotype, although the majority of reports are preliminary and not all 
studies confirm these associations (Bailer et al. 2005, Nievergelt et al. 2005, Shiino et al. 
2003). In a 2007 review of the genetics of BPD (Kato 2007) additional associations with 
TRPM2 (21q22.3), GPR50 (Xq28), Citron (12q24), CHMP1.5 (18p11.2), GCHI (14q22-24), 
MLC1 (22q13), GABRA5 (15q11-q13), BCR (22q11), CUX2, FLJ32356 (12q23-q24), and 
NAPG (18p11) looked promising but it was suggested that future replication studies were 
warranted.  
Association studies have also identified several putative candidate genes for SCZ. Some of 
these are SCZ specific risk genes and they include, but are not limited to, COMT (Egan et al. 
2001, Malhotra et al. 2002, Shifman et al. 2002, Wonodi et al. 2006); BDNF (brain derived 
neurotrophic factor) (Buckley et al. 2007, Gratacos et al. 2007, Ho et al. 2007); RGS4 
(regulator of G protein signalling 4) on 1q23 (Chen et al. 2004, Chowdari et al. 2002, Morris 
et al. 2004, Williams et al. 2004); MTHFR, PPP3CC, GABRB2 and TP53 (Shi et al. 2008b); 
although the reports of successful replication of these findings vary considerably. Protective 
allele associations in DAOA, IL1B (interleukin-1 beta), and SLC6A4 genes were also reported 
in a meta-analysis (Shi et al. 2008b). By contrast, variation in the IL1B gene has been 
reported to be associated with the subtype of SCZ with high levels of depressive symptoms 
(Boks et al. 2008, Rosa et al. 2004). SCZ is a common illness with presumably multiple 
genes of small effects involved in the aetiology and many of the studies to date are 
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statistically underpowered. Geneticists suggest that tens of thousands cases and controls may 
be needed to find firm associations (please see the later section on GWAS studies (Abbott 
2008). The development of a fundamental understanding of the effect of risk genes will 
undoubtedly be complex. And even though several risk genes have been implicated, the 
associated variants are often different in different populations and it is therefore difficult to 
determine the biological effect of each risk gene. Potential interactions between risk genes 
add to the complexity of the picture. In addition, the phenomenological heterogeneity of 
psychotic disorders, as well as lack of clear boundaries and biologically based definitions in 
the existing diagnostic categories may contribute to difficulties facing genetic studies.  
1.2.5 Summary 
Despite all the efforts, no single genetic variant has reliably been established as functionally 
implicated in the pathogenesis of SCZ or BPD. The lack of reproducibility of linkage or 
association findings may depend on several study-specific issues, such as variable power, 
differences in phenotypic models, inadequate sample sizes, differences in modelling 
parameters, different markers used, insufficient variation coverage, differences in linkage 
disequilibrium (LD) between studied populations, and most likely reflects true locus and 
allelic heterogeneity between and probably also within the populations studied. Although the 
replication of findings clearly provides an indication for the credibility of a story, there is no 
clear criterion for distinguishing signal from noise in single gene association studies and also 
lack of correlation with strong biological evidence. Thus, it is difficult to fully grasp the 
importance of existing findings until the causative susceptibility variants are found and 
functionally validated. 
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1.2.6 Genome-wide association studies  
Although genetic linkage and single locus association studies have produced a range of 
evidence of association for a range of susceptibility loci and candidate genes with limited a 
priori evidence and/or with limited sample sizes, these have been difficult to replicate 
consistently. Thus, the focus has moved to large-scale genome-wide association studies 
(GWAS), which are geared to identify the effect of common genetic variants or candidate 
genes that are especially important in traits for which the biological pathway is unknown or 
complicated, such as psychiatric disorders. This is the first analysis of common variation 
across the entire human genome by genetic markers to identify positive genetic associations 
when there is a greater frequency in the presence of genetic variants in individuals with 
observable traits such as a disease or unaffected individuals. Therefore, GWAS potentially 
allows multiple susceptibility genes to be detected simultaneously when sufficiently large 
number of cases and controls are assayed (Ansorge 2009). However, a serious difficulty in 
evaluating the results of GWASs is the issue of multiple testing. For instance, a large number 
of SNPs may be tested within the same study for their association with a disease and this 
generates many nominally significant findings that are actually false positives. It is therefore 
necessary to set a stringent level for defining statistical significance, which can minimise the 
chance that a marker artificially exhibits evidence of phenotypic association, often requiring 
statistical evidence stronger than a p-value of 7.2 x 10
-8
 (Dudbridge and Gusnanto 2008). 
This level is dependent upon the number of SNPs analysed, and the threshold for currently 
available GWA chips is approximately 5 x 10
-8
 (Dudbridge and Gusnanto 2008, Hoggart et al. 
2008). In order to be able to reliably detect genomic regions that are genuinely influencing 
disease risk requires the analysis of large numbers of cases and controls for the initial study 
and for subsequent replication studies (Cantor et al. 2010). However, the design and 
execution of independent replication studies can be difficult, particularly those involving 
population groups that are genetically diverse from the original discovery population. 
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Homogenous samples that are limited to a single ancestry group such as Japanese or 
Ashkenazi Jewish represent and exception to this and result in the best associations. 
Moreover, the variants that are significantly associated in GWASs are generally at specific 
locations and do not implicate complete genes. Often GWAS had been found with variants 
that are not located close to a protein-coding gene or are within genes that were not 
previously considered to be candidate genes. GWASs only detect common variants (> 5%) in 
a population, which generally have small effect. For the successful conduct of a GWAS 
study it is important to have appropriate statistical methods that are necessary to reduce the 
risk of multiple false positive results. It is also preferable to only perform GWASs when 
statistical power is not limited by small sample size. Furthermore, in order to find possible 
casual variants, refined analysis is required to understand the biological pathway and the role 
that the gene variants may have in the disease process or in the condition.  
Several successful GWASs have been conducted for a variety of common, complex diseases 
including several psychiatry disorders, and their result can be found at Catalogue of 
Published Genome Wide Association Studies from the National Human Genome Research 
Institute (NHGRI) and the European Bioinformatics Institute (EMBL-EBI) 
(http://www.ebi.ac.uk/gwas/).  
1.2.6.1 GWASs in BPD 
To date, there are several GWAS have been conducted on patients with BPD. The initial 
GWAS BPD studies were published in 2007 by Nick Craddock from the Welcome Trust 
Case-control Consortium (WTCCC), which involved 14,000 cases of seven major diseases 
including 1,900 BPD patients versus 3,000 shared controls. They identified a genetic 
association signal at chromosome 16p12 with p = 6.3 x 10
-8
, a region that contains PALB2, 
DCTN5, and NDUFAB1 genes (Wellcome Trust Case Control Consortium 2007). Another 37 
SNPs selected genotyping study by Baum et al. 2008 from the NIMH intramural program 
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detected the strongest association signal at a marker within the first intron of DGKH 
(diacylglycerol kinase eta; p = 1.5 x 10
-8
) with an odd ratio of 1.59 (Baum et al. 2008). These 
two first genome-wide association studies of BPD showed that several genes had modest 
effect, where implicated that BPD may be a polygenic diseases. A year later Sklar et al (Sklar 
et al. 2008) published a GWAS of 1,868 BPD and 2,938 controls. The strongest association 
signals in this study were for SNPs within the voltage-dependent calcium channel, L-type, 
alpha 1C subunit (CACNA1C) gene. Later that year, combined studies of the WTCC 
(Wellcome Trust Case Control Consortium 2007) data and the Sklar et al (Sklar et al. 2008) 
BPD data including total of 4,387 patients and 6,209 controls discovered the first genome-
wide significant association signal in ANK3 gene (encoding the protein ankyrin G) 
(rs10994336, p = 9.1 x 10
-9
) and further support for the previously reported CACNA1C gene  
(rs1006737, p = 7 x 10
-8
) for BPD (Ferreira et al. 2008). Since these early success BPD 
GWAS studies, many GWAS have been conducted with various populations, including 
European American, African, American, German, Japanese, Han Chinese, Norwegian, 
Icelandic, Bulgarian, Canadian, and UK populations (Lee et al. 2011, Hattori et al. 2009, 
Djurovic et al. 2010, Cichon et al. 2011, Yosifova et al. 2011, Smith et al. 2011, Smith et al. 
2009), but many of these failed to detect genome-wide significant signals due to small 
sample size. In order to improve the power to detect BPD candidate variants with genome-
wide significant findings, the Psychiatric Genomics Consortium (PGC) analysed and 
published a combined genome-wide association study of 7,481 BPD and 9,250 controls with 
a replication study of 4,496 cases and 42,422 controls to form an analysis of a total 11,974 
BPD cases and 51,792 controls. This study confirmed genome-wide significant evidence of 
association for CACNA1C and also identified a new intronic variant in ODZ4 gene (encoding 
teneurin-4) (11q14) (Psychiatric GWAS Consortium Bipolar Disorder Working Group1 
2011). Later, Chen et al (2013) (Chen et al. 2013) conducted a GWAS meta-analysis 
including European and Asian populations with 7,773 cases and 9,883 controls and revealed 
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a significant GWAS signal near TRANK1 gene. In the same year, another genetic variation 
found in neurocan gene (NCAN) showed genome-wide significant association with BPD in 
2,411 patients and 3,613 controls (rs1064395, p = 3.02 x 10
-8
 (odd ratio, 1.31) (Cichon et al. 
2011). Last year, a large case-control study combined previously reported PGC-BPD data set 
of 7,481 cases and 9,250 controls with 2,266 cases and 5,028 controls from MooDs 
(systematic investigation of the molecular causes of major mood disorders and schizophrenia) 
consortium showed 56 SNPs reaching genome-wide significant association at five genomic 
loci including previously described risk loci, ANK3, ODZ4, and TRANK1, and one new risk 
locus ADCY2 (5p15.31), which is a key enzyme in cAMP signalling and a region between 
MIR2113 and POU3F2 (6q16.1) (Muhleisen et al. 2014).  
1.2.6.2 GWASs in SCZ 
The early GWASs in SCZ used DNA pooling in their methodology to identify candidate 
genes with higher risk effect, but none of these were reached a Genome-wide (GW) 
significant threshold. For example, Mah et al. (2006) (Mah et al. 2006) pooled together 
samples from 320 European individuals with SCZ and identified a candidate locus on 
chromosome 1q32 (p = 6.0 x 10
-3
; OR = 1.49), implicating the PLXNA2 gene in SCZ. 
Although the association did not meet GW significance threshold, the authors supported their 
finding with evidence of consistent association signals in different population groups such as 
European Americans (OR = 1.38, p = 0.035), Latin Americans (OR = 1.26) and Asian 
Americans (OR = 1.37). Later, Kirov et al (2009) (Kirov et al. 2009) also pooled their DNA 
samples from unrelated Bulgarian SCZ samples and identified SNP rs11064768 (p = 1.2 x 
10
-6
), which is within the gene CCDC60, a coiled-coiled domain gene. Their third top SNP 
was rs893703 (p = 1.6 x 10
-4
), within RBP1, which had previously been reported to be a 
candidate gene for SCZ (Farias et al. 2005, Kalkman et al. 2006). 
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Later, as GWAS sample sizes increased combined SNP data from several large genome-wide 
scans found significant association with several markers spanning the major 
histocompatibility complex (MHC) region on chromosome 6p21.3-22.1, a marker located 
upstream of the neurogranin gene (NRGN) on 11q24.2 and a marker in intron four of 
transcription factor 4 (TCD4) on 18q21.2 (Stefansson et al. 2009). The results that implicated 
the MHC region are consistent with an immune component to SCZ risk, the association with 
NRGN implicates calcium signalling because NRGN may act as a calcium sensor (Zhong et 
al. 2009), and the TCF4 finding points to perturbation of pathways involved in brain 
development, memory and cognition. Another GWAS mega-analysis of SCZ, also from the 
PGC including over 40,000 individuals, identified one of the strongest novel genetic 
associations marker rs1625579 within an intron of a putative primary transcript for MIR137 
gene (encoding mircoRNA 137) (p = 1.6 x 10
-11
) (Schizophrenia Psychiatric Genome-Wide 
Association Study (GWAS) Consortium 2011), which is a key regulator of neuronal 
development with roles in neurogenesis and maturation and highly expressed at synapses in 
the cortex and hippocampus (Smrt et al. 2010, Szulwach et al. 2010, Willemsen et al. 2011).  
Just recently, a larger multi-stage SCZ GWAS including 36,989 cases and 113, 075 controls 
identified 128 independent associations spanning 108 loci all meeting genome-wide 
significance (Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014). 
Of the 108 loci, 83 had never been previously reported in other GWAS before, and 75% 
include protein-coding genes and a further 8% are within 20 kb of a gene. Further to their 
study, associations were enriched among genes expressed in the brain and tissues that play a 
role in immunity. This second finding provides support for the previous finding that the 
MHC region of the immune system is associated with SCZ. This GWAS published last year 
highlighted approximately 35 genes that have the potential to provide entirely new insights 
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into aetiology of SCZ such as the glutamatergic neurotransmission pathway, which may hold 
the key to future target of potential therapeutic relevance to SCZ.  
1.2.6.3 Overlapping disorders finding in GWASs 
Over the past years, the BPD associated genes have also been found to be a susceptible gene 
in SCZ suggesting a possible overlap of genetic risk for SCZ, and which may constitute 
common susceptibility gene for psychosis. For instance, studies of approximately 10,000 
individuals revealed strong evidence for association with susceptibility to BPD at variants 
within two genes involved in ion channel function: ANK3 and CACNA1C (Green et al. 2010). 
The SNP found in CACNA1C showed maximum association with susceptibility to BPD 
showed similar association in UK SCZ and unipolar depression samples, indicating that 
variation at this locus influences susceptibility across the mood-psychosis spectrum.  The 
study also reported analyses of combined SCZ and BPD, with association at three loci 
reached genome-wide significance: CACNA1C (rs4765905, p = 7.0 x 10
-9
), ANK3 
(rs10994359, p = 2.5 x 10
-8
), and ITIH3-ITIH4 region (rs2239547, p = 7.8 x 10
-9
). This 
increased the levels of statistical significance in the combined analysis suggested genetic 
variants in these regions influencing risk of both disorders.  
A separate study that used a combined dataset of around 20,000 subjects an association 
signal in the ZNF804A (encoding zinc finger protein 804A) gene on chromosome 2q32 
(rs1344706, p = 1.61 x 10
-7
) with SCZ (O'Donovan et al. 2008). In order to investigate 
whether this association might involve a genetic variant that influenced risk of SCZ and BPD, 
a BPD sample was further added to the analysis. The effect size remained similar (odds ratio 
(OR) = 1.12), while the genome-wide significant association p value became notably more 
significant (p = 9.96 x 10
-9
). These findings have been further substantiated by a larger meta-
analysis consisting of 18,945 subjects with either SCZ or schizoaffective disorder, 21,274 
subjects diagnosed with SCZ plus BPD; and control samples of 38,675 and provided 
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evidence for association between rs1344706 that surpasses widely accepted benchmarks of 
significance by several orders of magnitude for both SCZ (p = 2.5 x 10
-11
; OR = 1.10) and 
SCZ and BPD combined (p = 4.1 x 10
-13
; OR = 1.11) (Williams et al. 2011). These results 
also suggested that allelic association at the ZNF804A locus to be one of the most compelling 
in SCZ and that the locus may also has an effect on illness susceptibility across the 
traditional diagnostic boundaries. 
Another combined GWAS data from five psychiatric disorders including SCZ, BPD, major 
depressive disorder, autism spectrum disorder, and attention deficit hyperactivity disorder 
(ADHD) was published by the PGC Cross-Disorder Group and revealed four regions that 
achieved genome-wide statistical significance (Lee et al. 2013). Two of the association 
signals on chromosomes 3p21 and 10q24 were in regions encompassing a number of genes. 
The other two association signals were in CACNA1C on chromosome 12 and CACNB2 on 
chromosome 10. Additional pathways analysis further supported the role of channel activity 
genes contributing all five disorders. Further, Jan et al (Jan et al. 2014) reviewed findings 
from two distinct and comprehensive meta-analyses of linkage studies for BP to identify 
significant linkage peaks (McQueen et al. 2005, Segurado et al. 2003). Among eight selected 
calcium channel genes, evidence for weak association was founds for CACNA1C 
(rs10848635), CACNA1E (rs10848635), CACNB2 (rs11013860), and CACNG2 (rs2284018) 
genes were observed, and combined analysis with independent replication samples further 
supported the association of marker rs11013860 in CACNB2 with BPD (p = 1 x 10
-6
).  
Despite the fact that powerful GWASs have revealed that common variants or genetic risk 
loci overlap between BPD and SCZ, clinical diagnostic and molecular distinctions between 
these disorders remain. An interesting BPD versus SCZ case-case comparison study carried 
out by our research group found association with a marker rs17645023 (p = 6.3 x 10
-7
) 
located between another two of the calcium channel  subunit genes, CACNG5 and CACNG4 
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(Curtis et al. 2011). As shown in the Figure 1-1, this marker lies 36kb from CACNG5 and 
79kb from CACNG4. The study revealed that the control allele frequencies for this marker 
were intermediate between those for BPD and SCZ cases. The results suggested that marker 
rs17645023 may have differential effects in the two disorders and this may help to provide an 
insight into the fundamental understanding of how these two disorders differ biologically 
possibly mediated by these two calcium channel genes. Furthermore, these comparisons of 
BPD and SCZ findings may also provide additional information that could someday be used 
in clinical diagnostics. Therefore, detailed investigation of brain calcium biology can 
possibly illustrate the underlying mechanism causing disorder conditions in SCZ and BPD.  
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 Figure 1-1Association marker rs17645023lies 36kb from CACNG5 and 79kb from CACNG4 taken from UCSC Genome Browser 
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In summary, although GWAS studies have identified genome-wide significant disease-
associated variants with some insights into the genetic basis underlying SCZ and BPD, the 
biological effect of these variants is still unclear. GWAS only inform both conditions with 
common and different genes being implicated at different levels of statistical significant; thus 
often missing detection of candidate genes that had been previously identified by other 
genetic methods. Even though the greater collaborative efforts and larger sample sizes have 
allowed better examination and detection of common alleles of small effect sizes, there is a 
need to elucidate the functional significance of the extant genetic findings to better 
understand the human brain structural changes and biological functions or pathways that 
underlie the major psychoses. A summary of GWAS findings with strong evidence for 
association (p < 5 x 10
-8
) that have small effect (odds ratio < 1.2) are shown in Table 1-2.  
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Table 1-2 Genome-Wide Association Study Findings for GWA significant genes in 
Schizophrenia and Bipolar Disorder from the PGC SCZ (Schizophrenia Working 
Group of the Psychiatric Genomics Consortium. 2014) summary data for 108 genome-
wide significant loci. Abbreviations: OR = odd ratio, SCZ = schizophrenia, BPD = bipolar 
disorder, p-values were taken from the smallest p-value in each individual studies.  
Phenotype Chromosome where 
marker is located 
Nearest gene OR 
SCZ 1 DPYD; MIR137 1.12 
 1 
2 
SDCCAG8 
CENTG2 
1.10 
0.90 
 2 PCGEM1 1.20 
 6 MHC 1.24 
 6 
6 
TRIM26 
HLA-DRB9 
1.15 
p = 9E-14 
 8 TSNARE1 p = 2E-10 
 10 CNNM2 1.10 
 10 NT5C2 1.15 
 11 NRGN 1.15 
 18 CCDC68 1.09 
 18 TCF4 1.20 
BPD 3 
5 
6 
10 
TRANK1 
ADCY2 
SYNE1 
ANK3 
1.13 
1.14 
1.15 
1.35 
 12 CACNA1C 1.14 
SCZ and BPD  2 ZNF804A 1.11 
 3 ITIH3-ITIH4 1.12 
 7 
 
10 
MAD1L1, SNX8, 
NUDT1, FTSJ2 
NT5C2, CNNM2 
0.89 
 
1.23 
 12 
18 
19 
CACNA1C 
CCDC68 
MAU2 
1.07 
1.09 
p = 3E-9 
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1.2.7 Chromosomal Rearrangements and CNV 
Chromosomal rearrangements can take the form of translocations between chromosomes that 
may be balanced or unbalanced. These translocations can lead to disruption of genes at their 
breakpoints and this has been implicated in disease. The study of copy number variations 
(CNVs) in the human genome has made substantial discoveries into the genetic aetiology of 
SCZ and to a lesser extent in BPD. CNVs are structural genomic variations of DNA that 
include micro-insertions, micro-deletions. The size range thus may vary from over one 
kilobase (kb) up to several megabases compared to a reference genome. Although SNPs in 
the genome account for the most numerous variations, CNVs have been reported to involve 
account for roughly 12% of phenotypic variation within normal individuals and in complex 
diseases, such as SCZ and BPD (Stankiewicz and Lupski 2010, Sullivan et al. 2012). In 2004, 
two landmark studies demonstrated a widespread distribution of submicroscopic variations 
(<500 kb in size) in DNA copy numbers in normal human genomes (Iafrate et al. 2004, Sebat 
et al. 2004). CNVs can be inherited or appear de novo. The rates of occurrence for de novo 
CNVs can be up to four fold greater than single nucleotide substitution rates (Lupski 2007) 
and this class of CNV are considered to be involved in the development of sporadic genomic 
disease (McCarroll 2008). In comparison to SNPs, the overall proportion of genomic 
nucleotides involved is high for CNVs leading to a larger functional impact per site 
(Malhotra and Sebat 2012). Duplication and deletion CNVs can interfere with regulatory 
regions or coding sequences of various genes leading to altered gene expression and 
biological function (Freeman et al. 2006, Hurles et al. 2008). Moreover, the effect of single 
nucleotide disease susceptibility variants can be amplified by the presence of CNVs, where 
they can cause up-regulation or down-regulation of dosage sensitive genes. The presence of 
deletion CNVs also has the potential to lead to variations in intermediate phenotypes in 
complex neuropsychiatric illnesses such as cognitive impairment or in physiological 
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measures (Friedman et al. 2008). CNVs have also been implicated in the biological basis of 
SCZ and BPD (Cook and Scherer 2008, Freeman et al. 2006, Porteous 2008).  
1.2.7.1 Chromosomal rearrangements and CNV finding in BPD and SCZ 
Examples of chromosomal rearrangements detected in patients led to the identification of the 
disrupted genes and subsequent evidence for their involvement with BPD and SCZ. 
Examples are translocation t(1; 11) (q42.1;q14.3) disrupting the DISC1 gene (Blackwood et 
al. 2001, Chubb et al. 2008, Millar et al. 2000), translocation t(1; 16) (p31.2;q21) involving 
PDE4B that regulate cAMP signalling (Millar et al. 2007, Millar et al. 2005), translocation 
t(9; 14) (q34.2;q13) disrupting the NPAS3 gene (Kamnasaran et al. 2003, Pickard et al. 2009, 
Pickard et al. 2006). Specific CNVs with potential roles have been investigated both in locus-
specific and genome-wide studies for BPD and SCZ. Locus-specific studies have 
investigated CNVs in three genes in SCZ and/or BPD including a complex CNV at 15q13-14 
containing a polymorphic inversion involving CHRNA7 and its fusion variant CHRFAM7A 
that might be implicated in BPD, SCZ, and more general psychosis (Flomen et al. 2006, 
Flomen et al. 2008, Freedman et al. 1997, Riley et al. 2000); a duplication at 3q13.3 
disrupting the functional candidate GSK3beta (glycogen synthases kinases 3 beta) and two 
other genes, was shown to occur more frequently in BPD (Lachman et al. 2007); and a rare 
deletion at 7q34-36.1 affecting the CNTNAP2 gene was detected in three unrelated patients 
with both SCZ and epilepsy (Friedman et al. 2008). The 22q11.2 deletion syndrome 
(22q11.2DS) is a common syndrome with congential and late-onset features and is caused by 
a 3Mb hemizygous microdeletion, which has also been known as a significant risk factor for 
SCZ, BPD, VCFS, and Di George syndrome (DGS) (Bassett and Chow 2008, Karayiorgou et 
al. 1995, Murphy et al. 1999). 
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1.2.7.2 CNV findings in SCZ 
To date, CNV studies have established that rare structural variations (occurring in less than 
1% of the population are a significant risk factor for SCZ (Sebat et al. 2009). The 
International SCZ Consortium (International Schizophrenia Consortium 2008) reported a 
1.1 – 1.5 fold enrichment of rare gene CNVs in cases compared to controls; in addition, other 
groups observed a 3-fold enrichment of rare CNVs in SCZ cases (Walsh et al. 2008). These 
findings have further been supported by several subsequent studies (Buizer-Voskamp et al. 
2011, Kirov et al. 2009), and confirm that rare CNVs are collectively more common in SCZ 
than in normal subjects. Recent genome-wide SCZ CNV studies have found strong evidence 
for disease association with other loci including deletions at chr1q21.1, deletions at chr3q29, 
duplications of chr16p11.2, deletions at chr15q13.3, exonic deletions at chr2p16.3 (NRXN1) 
and duplications at chr7q36.3 (VIPR2). Early on, it was apparent that rare CNVs tended to 
impact genes involved in neuronal function (Walsh et al. 2008). These included functional 
categories related to synaptic activity and neurodevelopment (Malhotra et al. 2011, Walsh et 
al. 2008). De novo CNVs were significantly enriched in specific protein complexes such as 
N-methyl-d-aspartate receptor (NMDAR) and neuronal activity-regulated cytoskeleton-
associated protein postsynaptic signalling complexes as well as other components of the 
postsynaptic density (Kirov et al. 2012). 
1.2.7.3 CNV findings in BPD 
By contrast, the literature available on CNV studies of BPD is very limited (Lachman et al. 
2007), consequently the result of case-control studies has been inconsistent. While two 
studies have reported an enrichment of rare CNVs in bipolar disorder (Priebe et al. 2012, 
Zhang et al. 2009) with greater effects in subjects with an early age-at-onset, these effects 
were not further supported by other two studies (Grozeva et al. 2010, McQuillin et al. 2011). 
Notably, de novo mutations from mood disorders were showed significantly higher 
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frequencies (4.3%) in BPD as compared with healthy individuals (0.09%). The rate of de 
novo CNVs among cases with an age at onset younger than 18 was higher still (5.6%) 
(Malhotra et al. 2011). The limited CNV findings in BPD have meant that it has not been 
possible to implicate specific genes or genomic regions in BPD; similarly pathway 
enrichment analyses have also been unable to illustrate clear patterns. Pathways enriched 
among de novo CNVs in BPD showed an enrichment of genes involved in regulation of cell 
shape, but no significant enrichment of genes involved in neuronal function or development 
(Malhotra et al. 2011). 
1.2.7.4 Summary 
Although CNV studies have found several variants that are more frequent in patients than in 
controls with odds ratios of >10 for some variations, the frequency of each individual variant 
in BPD or SCZ patients is low (<1%). Therefore future studies are required to determine the 
penetrance and mutation rate of these structural variants, as well as their phenotypic spectrum. 
Research has shown that some CNVs also occur more frequently in patients with other 
neuropsychiatric phenotypes such as autism, mental disability and epilepsy (Ben-Shachar et 
al. 2009, Helbig et al. 2009, Mefford et al. 2008, Miller et al. 2009). However, the 
mechanism underlying the phenotypic outcome still remains unclear.  
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1.3 Voltage-gated calcium channel (VGCC) 
The voltage-gated calcium channels (VGCCs) are heteromeric proteins composed of a 
principle pore-forming alpha 1 (α1) subunit and auxiliary subunits: α2δ, β, and γ (Figure 
1.2.a). The α1 subunit contains the voltage sensor that controls channel activation and gating. 
Channel activation and gating is generally regulated by second messengers, drugs, or toxins 
(Vacher et al. 2008). According to their physiological and pharmacological properties, three 
subfamilies of this subunit are known to exist: Cav1 (L-type), Cav2 (P/Q-, N- and R-type) and 
Cav3 (T-type) as also shown in Figure 1.1.b. The function of auxiliary subunits α2δ and β are 
to regulate VGCC current. For instance, when co-expressed with the α1 subunit, the 
trafficking of the channel complex to the surface membrane was increased by these auxiliary 
subunits and this resulted in increased current density (Dolphin 2003, Klugbauer et al. 2003). 
Moreover, these subunits also alter the biophysical properties by increasing activation and/or 
the opening probability of channel pore (Dolphin 2003, Klugbauer et al. 2003, Neely et al. 
1993). 
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Figure 1-2 Structure of voltage-gated calcium channel α1 subunits and its subclasses. a) 
Structure of voltage-gated calcium channel α1 subunits; b) Three subclasses of α1 
subunit according to their amino acid sequence identity (Dolphin 2012). 
In expression studies, different classes of the α1 subunit and various auxiliary subunits can 
be found in many other tissues. The exception to this widespread expression is the γ (gamma) 
subunit, which was thought to be found in skeletal muscle (Klugbauer et al. 2000). When the 
γ subunit is co-expressed with the α1 subunit of L-type calcium channels, it appears to alter 
peak current and the activation and inactivation kinetics (Eberst et al. 1997, Singer et al. 
1991, Wei et al. 1991). More recently, a second type of γ subunit was identified in mice with 
epilepsy, which was found to be due to the absence of γ subunit gene (Letts et al. 1998). The 
next section will discuss more about the γ subunit family.  
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1.3.1 Ca2+ channel γ subunits 
Current literature reviews of the cellular processes influenced by the  subunits suggest that 
they are a functionally diverse protein family. The  subunits interact not just with calcium 
(Ca
2+
) channels, but with other proteins as well. In fact, the recent evidence suggests that the 
principle cellular targets of several members of this subunit family may not be Ca
2+
 channels 
at all.  
This first  subunit described, 1, was isolated biochemically as a component of a calcium 
channel expressed in skeletal muscle and has been shown to alter calcium current properties 
in both native myocytes and in cell lines (Eberst et al. 1997, Freise et al. 2000, Held et al. 
2002, Singer et al. 1991). Later, Letts (Letts et al. 1998) described a second  subunit gene 
from stargazer mouse, Cacng2. This gene encodes a 36kD protein (stargazin/2) with 
sequence similar to the 1 subunit. Stargazer mice carry a mutant stargazin and have a 
complex neurological disorder including ataxia, inner-ear defects, and epilepsy (Noebels et al. 
1990). Eventually, additional putative  subunit genes in human, such as 2 - 5, were 
identified via conserved structural features of 1 and 2, where they were shown to share 
functional similarity with 2 (Burgess et al. 1999). Furthermore, phylogenetic analysis 
identified additional  subunit family genes, 6 - 8: 6 might be important for Ca2+ channel 
regulation; whereas the 7 and 8 share functional similarity with 2 (Burgess et al. 2001). 
Historically, the studies of co-expressed stargazin/2 showed only a modest or even no effect 
on VDCC currents in heterologous cells (Green et al. 2001, Kang et al. 2001, Klugbauer et al. 
2000, Letts et al. 1998). On the other hand, stargazin/2 was discovered to prominently 
associate with and regulate the functions of alpha- amino-3-hydroxy-5-methyl-4-
isoxazolepropinonic acid receptors (AMPARs) (Chen et al. 2000). Furthermore, three closely 
related isoforms of stargazin/2, 3, 4, and 8, had the ability to substitute for stargazin/2 in 
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regulating AMPARs in in vitro expression studies. These four proteins were used to define 
the new family of transmembrane AMPAR regulatory proteins (TARPs) (Osten and Stern-
Bach 2006, Qiao and Meng 2003). More recently, TARPs were classified into two groups on 
the basis of their homologous sequence alignment with type I TARPs comprising the 
subunits stargazin/2, 3, 4, and 8, and the type II TARPs, 5 and 7. Because of 
differences in their sequence alignment, it is thought that the two classes of TARPs 
differentially modulate channel properties and/or trafficking of AMPARs in specific 
neuronal pathway (Cho et al. 2007, Haering et al. 2014, Kato et al. 2010, Kato et al. 2007, 
Tomita et al. 2005a, Tomita et al. 2003). 
1.3.1.1 Distribution and cellular functions of  subunits 
The  subunits are sub-divided into three clusters: 1 and 6, type I TARPs, and type II 
TARPs via their sequence homology. These three clusters have been shown to have a distinct 
distribution of their subunits in tissues, and also in their cellular functions. 1 and 6 are 
predominantly expressed in skeletal muscle, while the TARPs are differently expressed in 
brain regions and throughout development (Tomita et al. 2003). For example, Stargazin/2 
has been found to mainly expressed in the cerebellum, but also occurs in the cerebral cortex 
and in both CA3 and dentate gyrus regions of hippocampus (Letts et al. 1998, Moss et al. 
2003, Sharp et al. 2001, Tomita et al. 2003). Stargazin/2 is the only TARP found in cerebral 
granule cells, explaining the selective loss of AMPAR function in these cells in stargazer 
mice. 7 is another subunit that has its highest expression level also in the cerebellum, but is 
localised in the somatodendritic regions of Purkinje cells and in glomeruli of the granule cell 
layer (Kato et al. 2007). 3 on the other hand is found mainly in the cerebral cortex; whereas 
8 is predominantly expressed in the hippocampus (Tomita et al. 2003). By contrast, 4 
shows diffuse expression throughout the brain with local enrichment in the olfactory bulb 
(Tomita et al. 2003). Interestingly, within the CNS, 4 is the only TARP found in non-
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neuronal cells, particularly in glial cells. These different expression patterns of the  subunits 
indicate possible TARP-specific characteristics, which may conform to the different 
regulatory requirements of the different brain regions.  
Although the cellular distribution is distinct between the  subunit, each subunit shares a 
common topology that consists of four transmembrane domains, with intracellular N- and C- 
(carboxyl) termini. The  subunits are also known as a tetraspanin protein superfamily 
members, which includes proteins called claudins that are important components of tight 
junctions in the epithelia (Van Itallie and Anderson 2006). These tetraspanin proteins consist 
of a highly conserved N-glycosylation site (GLW) and a pair of conserved cysteine residues 
within the first extracellular loop that may form a disulphide linkage as shown in Figure 1-3.  
 
Figure 1-3 Schematic diagrams showing predicted membrane topology and putative 
functional sites on γs and claudins (Chen et al. 2007). 
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1.3.1.1.1 1 and 6 cluster 
1 and 6 are distinct from the other TARPs in that they have short C-terminal cytoplasmic 
regions that lack functional motifs (Figure 1-3). The 6 subunit distribution is different to that 
of the 1 subunit that only expresses in skeletal muscles. It appears to be expressed not only 
in skeletal muscles but also in cardiac muscles and to a lesser extent in the brain (Burgess et 
al. 2001, Chu et al. 2001, Fukaya et al. 2005). It is also the only member of the  subunit that 
is also expressed as a short isoform that lacks the second and third transmembrane domains 
(Chu et al. 2001). 
1.3.1.1.2 Type I TARPs cluster 
Type I TARPs identified as regulators of AMPAR function are widely expressed in the brain 
and share highly conserved sequences that are different from the 1 and 6 cluster (Arikkath 
and Campbell 2003, Black 2003). Notably, that the type I TARPs have the longest C-
terminal cytoplasmic tails of the  subunit family. These cytoplasmic tails include a number 
of regulatory sites including a PDZ-binding motif  (TTPV) that controls AMPA receptor 
targeting to the synapse (Figure 1-4) (Arikkath and Campbell 2003, Black 2003). In addition, 
this binding motif (TTPV) in stargazin/2 contains a consensus threonine residue for 
phosphorylation by cAMP- and cGMP-dependent kinases, and the tails are also targets for 
binding by PDZ domain proteins (Burgess et al. 2001). This suggests phosphorylation may 
regulate the interaction between stargazin/2 and the AMPARs.  
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Figure 1-4 The protein structures of type I and type II TARPs. Panel A represents type 
I TARPs that have a larger first extracellular domain (EX1) and a canonical PDZ-
binding domain (T-T-P-V) located at their c-terminal cytoplasmic Panel B represents 
type II TARPs, which have an atypical PDZ-binding domain (S/T-S-P-C). RS domain 
represents arginine/serine-rich domain (Kato et al. 2010). 
As mentioned earlier, TARPs are differently expressed throughout development: 
stargazing/2, 3, and 8 are sparingly expressed in the brains of newborns and reach their 
highest expression levels in adult brains; by contrast, 4 presents the opposite characteristics, 
showing increased expression early in development. Furthermore, 4 are also found in 
embryonic epithelial cells lining the intestines (Tomita et al. 2003). 
1.3.1.1.3 Type II TARPs cluster 
The difference in structure between type I and type II TARPs is in their C-terminal tail, 
where type II TARPs lack a PDZ-binding motif (Chu et al. 2001, Moss et al. 2002). Further, 
these type of TARPs are encoded by five exons, whereas the other  subunits are encoded by 
four exons (Chu et al. 2001, Moss et al. 2002). 
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1.4 Glutamate receptors 
The mammalian central nervous system is comprised of an incredibly complex web of 
connectivity between billions of neurons that are highly specialised for the fast processing 
and transmission of cellular signals. Communication between neurons, each of which 
contains thousands of synapses, underlies all basic and higher-order information processing 
essential for normal brain function including learning and memory. The ability of neural 
circuits to strengthen or weaken their connectivity forms the molecular basis underlying the 
experience-dependent changes in adaptive behaviours. Glutamate is the most abundant 
excitatory neurotransmitter in the mammalian central nervous system (CNS) (Curtis et al. 
1959, McLennan et al. 1968). Once nerve impulses are triggered to release glutamate from 
the pre-synaptic terminals, it binds to post-synaptic glutamate receptors (GluRs) for post-
synaptic membranes depolarisation. These depolarisations may generate action potentials in 
the postsynaptic neuron that transmit information to subsequent neurons in the neuronal 
circuit (Meldrum 2000). The mechanisms of synaptic transmission are crucial factors for the 
proper function of neuronal communications and connections. These mechanisms are 
mediated not only by altering the concentration of glutamate in the synaptic cleft, but also by 
the number and channel properties of GluRs. Therefore, it is important to understand the 
physiological mechanisms that control the abundance of GluRs and their functional 
properties at synapses.   
GluRs can be classified into two functionally distinct categories according to their role in the 
activation of postsynaptic current elevation. Metabotropic glutamate receptors (mGluRs) 
indirectly activate ion channels on the plasma membrane through a signalling cascade of G-
protein second messenger systems, in order to modulate synaptic plasticity. Whereas 
ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that mediate fast 
excitatory neuro-transmission at synapses within the CNS. Binding of presynaptically 
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released glutamate triggers conformational changes that result in a depolarising cation 
current through the iGluR channel pore to allow ion flow. Based on their pharmacology and 
molecular characteristics, iGluRs are classified into three distinct subgroups namely: N-
methyl-D-aspartate receptors (NMDAR), α-amino-3-hydroxy-5-methylisoxazole-4-
propionate receptors (AMPAR), and kainite (KA) receptors (Hollmann and Heinemann 1994, 
Nakanishi 1992, Wisden and Seeburg 1993). In Figure 1-5, when glutamate released from 
presynaptic terminal and binds on both NMDARs and AMPARs, calcium (Ca
2+
) and sodium 
(Na
+
) ions flow into neurons. Ca
2+
-dependent enzymes are activated by the influx of Ca
2+
 at 
postsynaptic sites, and trigger downstream signal cascades that are involved in synaptic 
plasticity. The distribution of AMPARs in the postsynaptic density (PSD), as well as the 
number of synaptic AMPARs play an important role in modulating synaptic strength (Bredt 
and Nicoll 2003, Collingridge et al. 2004, Kessels and Malinow 2009, Lisman 2003, 
Malenka and Bear 2004, Newpher and Ehlers 2008, Shepherd and Huganir 2007). During 
long-term potentiation (LTP), which is a type of activity-dependent plasticity that involves 
neuronal learning, NMDARs mediate the influx of Ca
2+
 and lead to the trafficking of 
AMPARs to the plasma membrane (Bredt and Nicoll 2003, Collingridge et al. 2004, Kessels 
and Malinow 2009, Lisman 2003, Malenka and Bear 2004, Newpher and Ehlers 2008, 
Shepherd and Huganir 2007). Conversely, during long-term depression (LTD), NMDARs or 
mGluRs mediate the influx of Ca
2+
 and there is a subsequent lateral diffusion of AMPARs 
from the postsynaptic density (PSD) (Bredt and Nicoll 2003, Collingridge et al. 2004, 
Kessels and Malinow 2009, Lisman 2003, Malenka and Bear 2004, Newpher and Ehlers 
2008, Shepherd and Huganir 2007). Knowledge of the mechanisms regulating AMPARs 
trafficking allows one to form an understanding of synaptic transmission and ultimately brain 
function.  
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Figure 1-5  Synaptic transmission and AMPAR trafficking. Glutamate released from 
presynaptic terminal acts on NMDARs and AMPARs at the synapse. (A) AMPARs 
trafficking to synapse: AMPARs at intracellular vesicles are trafficked to the cell 
surface by exocytosis. Surface AMPARs laterally diffuse and are stabilised at the PSD. 
(B) AMPARs removal from synapse: AMPARs laterally diffuse from the PSD via 
intracellular vesicles endocytosis. 
1.4.1 AMPA receptors 
AMPARs are ligand-gated ion channels of the iGluRs family that mediate the majority of 
fast excitatory synaptic transmission in the brain to regulate synapse stabilisation and 
plasticity (Malinow 2003). Since the function of AMPARs is critical for synaptic plasticity, 
their dysfunction leads to various neurological and psychiatric disorders, such as Alzheimer’s 
disease, amyotrophic lateral sclerosis, X-linked mental retardation, limbic encephalitis, 
ischemic brain injury, and Rasmussen’s encephalitis (Hsia et al. 1999, Hsieh et al. 2006) 
(Kamenetz et al. 2003, Kawahara et al. 2004, Lai et al. 2009, Lynch 2006, Rogers et al. 1994, 
Shepherd and Huganir 2007, Soundarapandian et al. 2005, Talos et al. 2006a, Talos et al. 
2006b, Wu et al. 2007). Several characteristics have been suggested to influence the function 
of AMPARs, such as their subunit assembly mechanisms, conformational changes, 
modulation by auxiliary proteins, trafficking, and localisation. Therefore, the understanding 
of the cell biology and the biophysical properties of AMPARs are important to illustrate the 
mechanism of synaptic plasticity and assist in identifying therapeutic measures that may be 
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used as treatment for the diseases that are caused changes in either AMPARs or their 
auxiliary proteins.  
1.4.1.1 Primary structure of the AMPAR subunits 
AMPARs are assembled by four highly homologous subunits GluR1 to GluR4 (or GluRA-D) 
(Wenthold et al. 1996); recently renamed GluA1-A4, (Collingridge et al. 2009). Each subunit 
is comprised of four major domains, which has approximately 900 amino acids with a 
molecular weight of approximately 105 kDa (Granger et al. 1996). The predicted subunit 
topology is shown in Figure 1-6 A and B. An extracellular amino (N-) terminus forms a 
highly homologous N-terminal domain (NTD), which consist of about 370 amino acids. This 
NTD is followed by a linker sequence and connects to another extracellular domain, the 
ligand binding domain (LBD). The primary structure of the LBD domain can be subdivided 
into two separate fragments known as S1 and S2 (Armstrong et al. 1998). The LBD 
undergoes conformational changes resulting in channel gating upon glutamate binding. The 
fourth membrane spanning segment (M4) is located at the C-terminal end of the S2 fragment. 
The channel pore-forming transmembrane domain (TMD) consists of M1-M4 (Hollmann et 
al. 1994). Finally, a relatively varied C-terminal domain (CTD) extends into the cytoplasm 
ending with a PSD-95 discs large-zona occludens 1 (PDZ)-binding motif (Hollmann and 
Heinemann 1994). The PDZ-binding motif is responsible for interaction with cytosolic 
proteins that regulate receptor anchoring and trafficking (Malinow and Malenka 2002, Sheng 
and Lee 2001, Ziff 2007).  
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Figure 1-6 The structure of AMPA receptors. Panel A represents as primary structure 
of a subunit of AMPA receptor (NTD represents as N-terminal domain; CTD receptors 
as C-terminal domain); Panel B represents as domains of a subunit of AMPA receptor 
(TMD represents as transmembrane domain); Panel C represents as tetrameric 
structure of AMPA receptors; Panel D represents a negative stain single particle 
electron microscope image of an AMPA receptor. (Nakagawa 2010) 
Functional AMPARs are a tetrameric complex, which are assembled from four separate 
subunits (Robert et al. 2001, Rosenmund et al. 1998). Assembly of tetrameric AMPARs are 
generally comprised of two identical heteromeric subunits dimers. The identical subunits are 
positioned on opposite sides of the channel pore (Figure 1-6 C and D). However, an 
individual AMPAR subunit is also capable of assembly into a functional homotetrameric 
ligand-gated ion channel, when over-expressed (Swanson et al. 1997). Several studies have 
revealed that the majority of AMPARs are composed of GluR2 subunits in hippocampal 
pyramidal neurons, such as GluR1/2 and GluR2/3 (Greger et al. 2003, Isaac et al. 2007, Lu et 
al. 2009). Single cell genetic approaches have suggested that GluR1/2 is the most 
predominant subtype, in approximately 80% of synaptic AMPARs and only 16% are 
GluR2/3 (Lu et al. 2009). GluR2 knock-out mice studies showed that AMPARs were not 
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efficiently targeted to synapses and were aberrant in their stoichiometry, suggesting a critical 
role for GluR2 in regulating the assembly of AMPARs (Sans et al. 2003).  
Upon ligand binding AMPARs allow the influx of sodium ions (Na
+
), and in the absence of 
the GluR2 subunit they are also permeable to calcium ions (Ca
2+
) (see section 1.4.1.1.3). The 
subunit composition of AMPARs and their post-translational modification (see later) have 
been shown to regulate the biophysical properties of receptors including channel gating 
kinetics, synaptic plasticity (Cull-Candy et al. 2006, Hollmann and Heinemann 1994, Isaac et 
al. 2007, Jonas 2000, Seeburg 1993).  
1.4.1.1.1 Long and short splice variants 
The molecular diversity amongst AMPARs includes alternative splicing and RNA editing 
(Lomeli et al. 1994). One of the alternative splice sites is located in the C-terminal coding 
region leading to short and long forms of the protein. This region comprises of between 30 
and 50 amino acids depending on the subunit. GluR2 and GluR4 genes are the only subunits 
that can undergo alternative splicing to form either long or short CTD sequences, 
(Dingledine et al. 1999, Hollmann and Heinemann 1994, Sobolevsky et al. 2009). To date, 
GluR1 has only been found to have long C-terminal sequences, which is homologous to 
GluR4 and the alternatively spliced form of GluR2 (GluR2L); whereas the C-terminus of 
GluR3 is only found as the short form, and is homologous to GluR2 and an alternatively 
spliced form of GluR4 (GluR4S) (Figure 1-7). Expression of these alternative isoforms is 
developmentally regulated and region specific; for instance, approximately 90% of GluR2 is 
expressed as the short form in vivo (Kohler et al. 1994). GluR4S is preferentially expressed 
in cerebellar granule cells and Bergmann glial cells (Gallo et al. 1992). 
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Figure 1-7 Structure of AMPAR subunit and its direct interacting proteins. Tetrameric 
AMPARs are assembled from two dimers of different subunits, such as GluR1/2 and 
GluR2/3. The GluR1 C-terminal domain contains type I PDZ ligand and directly 
interacts with SAP97, whereas the short isoform of GluR2 C-terminal domain contains 
type II PDZ ligand and interacts directly with PICK1 and GRIP1. In addition, GluR1 
also interacts with protein 4.1N through its juxtamembrane region of the C-terminus, 
while GluR2 interacts with AP-2, NSF and BRAG-2 through it C-terminus in a non 
PDZ-dependent manner. Direct binding of AMPARs and these interacting proteins 
regulates various steps in AMPAR trafficking (Anggono and Huganir 2012). 
Moreover, the long-tailed AMPARs are important for the activity-dependent AMPAR 
trafficking to synapses during synaptic strengthening, such as LTP; whereas the short-tailed 
AMPARs appear to constitutively recycled in and out of synapses in the absence of activity, 
while internalisation of both forms of AMPARs occurs during activity-dependent synaptic 
weakening, such as LTD (Kessels and Malinow 2009).   
1.4.1.1.2 Flip/flop splice variants 
The AMPAR subunit genes undergo alternative splicing resulting in flip and flop modules 
that differ by only 9 amino acids embedded in the region encompass the S2 sub-fragment of 
the LBD and the linker between the LBD and M4 (Sommer et al. 1990). Nucleotide 
sequences of the mRNAs of AMPAR subunits are enzymatically modified by the deaminase 
ADAR2 (adenosine deaminase acting on RNA 2) (Higuchi et al. 2000, Schmidt et al. 2014) 
introducing amino acids that are not encoded by the genome. This post-transcriptional 
modification known as RNA editing, occurs in two locations in the AMPAR subunits 
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(Sommer et al. 1991). The first is the R/G site located within the LBD immediately before 
the flip/flop splice site in GluR2, 3, and 4 subunits; and the other is the Q/R site only in 
GluR2 subunit located in the transmembrane domain of M2 region (see later) (Figure 1-8) 
(Higuchi et al. 1993, Lomeli et al. 1994). 
 
Figure 1-8 A linear sequence of AMPA receptor and its formation into the cell 
membrane. Transmembrane domain M1 – M4 are boxed and inserted into the cell 
membrane. M1, M3, and M4 span through the lipid bilayer, whereas M2 enters and 
exits the membrane from the intracellular side. The alternatively spliced flip/flop (F/F) 
form in AMPAR subunits showed in a grey box, and the editing (R/G) and (Q/R) sites 
are indicated by lollipops (Seeburg 1996). 
As shown in Figure 1-8, an arginine codon (AGA) for the amino acid of the R/G site in 
AMPAR subunits is adjacent to the alternative spliced exons that encode the flip/flop module. 
These exons begin with the adenosine in an unstable position of the preceding arginine codon, 
which is split by an intron (Figure 1-9). The first adenosine of the arginine codon can be 
altered by pre-mRNA editing to a GGA (glycine) codon. All AMPAR subunit transcripts can 
exist in both arginine (R) and glycine (G) versions at this site, except GluR1 that occurs only 
in the gene-specified arginine version. In addition, the five positions of AMPARs in the 
strategic segment are targeted for an arginine, where is converted to glycine via RNA editing 
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at the R/G site of GluR2-4. The four residues along the secondary structure of helices J and 
K are altered in GluR1-4 by mutually exclusive alternative splicing (Sommer et al. 1990), the 
default flip exon is replaced by the flop exon in a developmentally regulated manner (Figure 
1-9). 
 
Figure 1-9 Arrangement and sequence of the alternative RNA editing to form flip and 
flop. The upper diagram describes the position of the R/G editing site at the 3’ end of 
the exon 13 (red arrow head), the editing complementary sequence in intron 13 (ESC; 
red rectangle), and the mutually exclusive flop (green), and flip (yellow) exons. The 
sequence of the splice donor site is shown. Editing switches the adenosine to inosine is 
also show in the red letters. The lower diagram showed sequence alignment 
encompassing the GluR2 R/G site and flip/flop segment along helices J and K. 
alternative residues are highlighted in bold, the R/G site at position 743 is indicated in 
blue (Penn and Greger 2009). 
Studies have suggested that the flip/flop modules display distinct but partially overlapping 
temporal and spatial expression patterns in the nervous system (Monyer et al. 1991, Sommer 
et al. 1990). Generally, flop variants desensitise faster, although the kinetic difference 
depends on the subunit and, for heteromeric channels, on subunit composition (Grosskreutz 
et al. 2003, Koike et al. 2000, Mosbacher et al. 1994, Sommer et al. 1990). The flip/flop 
splicing has an unprecedentedly strong effect on the maturation and cellular trafficking of 
AMPARs in several cell lines: homomeric GluR4-flop receptors accumulate in the 
endoplasmic reticulum (ER) whereas the corresponding GluR4-flip receptors are efficiently 
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transported to cell surface (Coleman et al. 2006). Different transport competence of the 
isoforms is independent of desensitisation and receptor activity. These differences are also 
manifested in secretion of the soluble ligand-binding domain, and are determined by residue 
780 outside helix J. The transport block of the flop isoform is reversible and surface 
expression of GluR4-flop is completely rescued by co-expression with stargazin (Chen et al. 
2000). These results suggest an interaction between the extracellular flip/flop region and 
isoform-specific ER luminal proteins as a novel step in the early trafficking of AMPARs 
(Coleman et al. 2006).  
1.4.1.1.3 Ca2+ impermeability of AMPAR subunits 
The presence of the GluR2 subunit has a profound impact on the biophysical property of the 
AMPARs. GluR2-containing AMPARs are impermeable to Ca
2+
 and Zn
2+
 with electrically 
linear current-voltage relationship; whereas AMPARs lacking GluR2 subunits are permeable 
to Ca
2+
 and Zn
2+
, also and have an inwardly rectifying current-voltage relationship (Figure 1-
10) (Isaac et al. 2007). GluR2-containing AMPARs generally undergo a post-transcriptional 
modification by RNA edition of a glutamine (Q) to arginine (R) substitution in the M2 region  
resulting  in Ca
2+
 
 
impermeability (Figure 1-8 & Figure 1-10a) (Sommer et al. 1991). This 
substitution occurs approximately in 99% of postnatal GluR2 (Sommer et al. 1991). 
Therefore, a modest alteration in the level of GluR2 expression has the potential expected to 
have profound implications for synaptic efficacy and neuronal survival. Collectively, the 
alternative splicing and RNA editing adds to the molecular complexity and functional variety 
of AMPARs in the brain.  
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Figure 1-10 Ca
2+
 permeability of AMPARs depends on the subunit composition. Panel 
(a) presenting GluR2-lacking AMPARs are highly permeable to Ca2+. Panel (b) 
presenting GluR2-containing AMPARs are impermeable to Ca2+. The presence of the 
GluR2 in heteromeric AMPAR channels limits Ca2+ and Zn2+ influx, owing largely to 
the presence of positively charged R instead of a Q residue at the Q/R RNA editing site 
(Liu and Zukin 2007). 
1.4.2 Trafficking of AMPARs at synapses 
The trafficking of AMPARs at synapses has been proposed as three-step model (Opazo and 
Choquet 2011): (i) exocytosis of intracellular AMPARs at perisynaptic sites to the plasma 
membrane, (ii) lateral diffusion of surface AMPARs at synaptic sites and (iii) stabilisation of 
AMPARs at synapses via scaffold interactions (Figure 1-5). Activity-dependent alteration of 
AMPAR trafficking regulates long-term changes in synaptic efficacy that underlie 
physiological phenomena. An increased exocytosis of AMPARs to the plasma membrane (at 
the PSD sites) results in the LTP of strengthening synapses; whereas endocytosis of synaptic 
AMPARs leads to LTD (Opazo and Choquet 2011). Therefore, impaired AMPAR trafficking 
could lead to cognitive dysfunction that is associated with neurological disorders such as 
Alzheimer’s disease and epilepsy (Keifer and Zheng 2010). This contribution of molecular 
pathology has stimulated attempts to investigate the auxiliary subunits of AMPAR that 
modulate its trafficking and/or channel properties. Since several molecules have been 
recognised to be auxiliary subunits of iGluR such as TARPS, the Cornichon-like proteins 
(CNIHs), and the Neurophilin and Tolloid like protein (Netos), TARPs will be the only 
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auxiliary proteins to be described in this thesis (Diaz 2010, Jackson and Nicoll 2011a, 
Tomita 2010).  
1.4.3 TARPs as auxiliary protein of AMPARs 
Transmembrane AMPA receptors regulatory proteins (TARPs) were the first AMPA 
auxiliary proteins to be identified (Coombs and Cull-Candy 2009, Nicoll et al. 2006, Sager et 
al. 2009). TARPs are encoded by certain types of calcium channel  subunit genes (described 
in section 1.3.1).  There are six TARP subunits (-2, -3, -4, -5, -7, and -8), and these are 
classified into two types: Type I and Type II. The distinction between these two types is the 
C-terminal cytoplasmic tails: Type I TARPs comprised a longer C-terminal sequence 
contains a typical PDZ-binding motif, whereas a shorter C-terminal sequence in Type II 
TARPs contains atypical PDZ-binding site (Figure 1-4). The importance of these PDZ-
binding sites at the end tail of TARPs is to interact with PSD-95 for efficiently transport of 
receptors to the postsynaptic membrane of cerebellar granule cells (Chen et al. 2000). The 
role of TARPs as auxiliary proteins of AMPARs has been firmly illustrated, where the 
channel properties of AMPARs are regulated by the stable binding of AMPARs to TARPs in 
the brain (Cho et al. 2007, Fukata et al. 2005, Kato et al. 2007, Milstein and Nicoll 2009, 
Nakagawa et al. 2005, Priel et al. 2005, Schwenk et al. 2012, Tomita et al. 2005a, 
Vandenberghe et al. 2005b). TARPs are non-pore-forming proteins (Tomita et al. 2004) that 
regulate the trafficking of AMPARs, and this is then required for synaptic AMPAR activity. 
Hence, the presence of TARPs is essential for the regulation of AMPARs at the synapses and 
lead to the regulation of synaptic plasticity.  
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1.4.3.1 TARPs regulate trafficking of AMPARs to the surface 
The idea of TARPs regulating the surface trafficking of AMPARs has been confirmed by 
several research experiments. For example, the surface expression of AMPARs was 
increased, when the heterologous combinations of TARP isoforms were overexpressed in 
stargazin mice (Kato et al. 2007, Priel et al. 2005, Tomita et al. 2005a, Turetsky et al. 2005, 
Vandenberghe et al. 2005a, Yamazaki et al. 2004). A similar result was also obtained when 
TARPs were overexpressed in neurons and this led to increased surface expression of 
AMPARs both at the soma and in dendrites (Rouach et al. 2005, Schnell et al. 2002, 
Turetsky et al. 2005). Conversely, both cerebellar granule cells and hippocampal pyramidal 
cells of mice deficient in TARP-2 and TARP-8 respectively, had reduced ionic currents 
mediated by reduction of surface AMPARs compared with wild-type mice (Chen et al. 2000, 
Fukaya et al. 2006, Rouach et al. 2005). 
1.4.3.1.1 TARPs regulate the AMPARs retention pool in the endoplasmic reticulum 
Because TARPs mediate the surface trafficking of AMPAR, they may also associate with 
AMPAR assembly in the endoplasmic reticulum (ER), and generate a facilitating receptor 
complex for exit from the ER (Figure 1-11). Successive formation of dimers and tetramers of 
many integral membrane proteins in the ER is precondition for export from the ER; hence, 
the AMPAR assembly is required for escape from the ER. Although a definitive location for 
the first interaction of TARPs and AMPARs has not been identified, FRET studies have 
indicated that TARPs and AMPRs initially meet at a short distance from the ER (Bedoukian 
et al. 2006). Furthermore, the immature glycosylation of AMPARs were retained in the ER 
when the cerebellum of stargazer mice deficient TARP-2 (Tomita et al. 2003). These results 
suggest that TARPs generate export-competent receptors to facilitate AMPAR exit from the 
ER. Even though the mechanism of AMPAR assembly in the ER is still unclear, two basic 
possible steps are thought to be involved: (i) the interaction of two monomer N-termini of 
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each of the GluR subunits form a dimer AMPAR; (ii) then the dimerisation of these dimers 
occurs through interaction by the membrane-spanning regions and extracellular loops of the 
subunits (Ayalon and Stern-Bach 2001). This brief overview indicates that TARPs maintain 
an extrasynaptic pool for surface trafficking of AMPARs.  
 
Figure 1-11 TARPs generate export-competent receptors to existing AMPAR leading to 
synaptic trafficking (a) AMPARs are assembled in the ER by successive formation of 
dimers and tetramers. TARPs associate with AMPARs in the ER and generate an ER 
export-competent receptor, possibly by facilitating assembly through association with 
subunit monomers or dimmers (not shown), displacing an ER retention factor, or by 
stabilising an ER export-competent receptor conformation. (B) After exiting the ER, 
the receptor-TARP complex traffics to the plasma membrane where it is inserted at an 
extrasynaptic site. The complex diffuses to the synapse, where interaction of the TARP 
C-terminal PDZ binding site with the synaptic scaffolding protein PSD95 anchors the 
complex at the synapse. 
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1.4.3.1.2 TARPs regulate early trafficking of AMPARs  
Before AMPAR trafficking to the plasma membrane, they are required not only to exit from 
the ER, but they also need to travel through the Golgi apparatus. Trafficking and synaptic 
targeting of AMPAR involves the extreme C-terminus of TARPs (sequence, -TTPV) binding 
to PDZ domain-containing protein as PDZ-95 (Figure 1-4 A and 1-11 b). Another protein 
microtubule associated protein 1 light chain 2 (MAP1-LC2), which does not contain a PDZ-
binding domain, also interacts upstream of the –TTPV sequence of TARPs in trafficking of 
AMPARs in cerebellar neurons before they are anchored at the synapse (Ives et al. 2004). 
Furthermore, the C-terminus –TTPV sequence of TARPs has also been found to bind to the 
protein nPIST (neuronal PDZ domain protein interacting specifically with TC10), which is 
also a PDZ domain containing protein involved in synaptic clustering of AMPARs. nPIST is 
a Golgi-enriched protein implicated in trafficking of transmembrane proteins. 
Overexpression nPIST increased synaptic clustering of AMPAR (Cuadra et al. 2004). 
Colocalisation studies suggest that both TARPs and nPIST interact and localise in the brain, 
which may help AMPAR complexes leave the Golgi and be targeted to the synapse (Cuadra 
et al. 2004). AMPARs travelling from the ER to the plasma membrane need at least three 
basic steps: exit from the ER, delivery through Golgi aperture, and anchoring at the PSD site; 
all these mechanisms require either direct or indirect interaction with various proteins, which 
include chaperones, vesicular delivery stabilisers, and anchoring proteins. A recent review of 
AMPAR interacting proteins and their function in trafficking pathways include GRIP1, 
KIF1A, KIF5, Rab8, Liprin-α, NEEP21, GRASP-1, Rab4, and Stx13 (Anggono and Huganir 
2012).  
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1.4.3.2 Isoforms-specific TARPs regulate subunit-specific AMPAR trafficking  
 Several research studies have clearly identified that TAPRs are an essential auxiliary protein 
for trafficking of AMPAR, but the underlying mechanism of TARP-mediated AMPAR 
surface expression is still not completely understood. The mechanism may differ depending 
on neuronal class, TARP isoforms or AMPAR subunits. The best example is TARP-5, 
which is a type II TARP, and does not appear to have any regulatory effect on the surface 
expression of AMPAR (Kato et al. 2007, Tomita et al. 2004). Instead, the main effect of 
TARP-5 is to regulate the function of AMPAR subunit combined with the long-isoform, 
which comprises predominantly Ca
2+
 permeable AMPARs (Soto et al. 2009). TARP-5 also 
appears only to regulate AMPARs in Bergmann glia, which generally acts as a negative 
control (Soto et al. 2009). Isoform-specific TARPs have also been suggested to regulate the 
retention of AMPARs in the ER (Coleman et al. 2006). The trafficking of homomeric flop 
isoform of GluR4 was largely blocked at the ER exit, while the flip isoform of GluR4 were 
trafficked to the plasma membrane at 10 times higher levels than the flop isoform. The 
retention of the flop isoform of GluR4 in the ER escaped when cells co-expressed either 
stargazin/2 or the flip isoform. Furthermore, although TARP-2 has constantly been found 
to be involved in an early AMPAR biosynthetic pathway in cerebellar granule cells 
(Vandenberghe et al. 2005a), the null mutant TARP-2 largely stores immature AMPARs in 
the cerebellum of stargazer mice (Tomita et al. 2003). These studies suggested that isoform-
specific TARPs mediate specific AMPAR subunit trafficking and localisation in specific 
neuronal regions or cells.   
  
101 
 
1.4.3.3 Synaptic stabilisation of AMPAR-TARP complexes 
The mechanism of AMPAR-TARP complex trafficking from the ER to the synapse has not 
been precisely identified; however, the stabilisation of these complexes by membrane-
associated guanylate kinases (MAGUKs) such as PSD-95 (postsynaptic density protein 95) is 
still unclear, but it may involve phosphorylation of the C-terminus of TARPs. The C-
terminus sequence of TARPs varies in length depending on their isoform. These are between 
100 and 200 amino acids in length and are enriched for serine and threonine resides. PSD-95 
is comprised of a multiple protein interactive structure, which includes: three PDZ domains, 
an src homology 3 (SH3) domain and a guanylate kinase-like (GK) domain. The C-terminus 
of AMPAR subunits cannot interact with PSD-95; whereas TARPs contain a canonical PDZ-
binding motif located at the C-terminus, which allows direct binding to the PDZ domains of 
PSD-95 (Figure 1-4) (Chen et al. 2000, Tomita et al. 2005b). These findings suggest that the 
PDZ domains of PSD-95 capture and stabilise AMPAR-TARP complexes at synapses via 
binding to the C-terminus of TARPs. Interestingly, overexpression of PSD-95 increased 
synaptic clustering of AMPAR at the postsynaptic density. However, overexpression of PSD-
95 did not alter the clustering of NMDARs (El-Husseini et al. 2000, Stein et al. 2003). This 
result suggested that overexpression of PSD-95 may enhance the retention of synaptic 
AMPARs by opening new slots for AMPARs at synapses and the diffusion of surface 
AMPARs away from the synapse was also decreased (Stein et al. 2003). In order to confirm 
that the C-terminus of TARPs are essential binding regions for PDS-95 to stabilise AMPARs 
at the synapses, mutated TARPs lacking C-terminal tail were designed. Hippocampal 
pyramidal cells of mutant mice harbouring TARP-8 lacking the C-terminal PDZ binding 
motif (TTPV) reduced synaptic transmission and AMPARs at a level comparable to that 
of TARP γ8-deficient mice (Sumioka et al. 2011). This result indicates that the C-terminal 
tail –TTPV sequences of TARPs stabilises AMPAR expression and regulates the abundance 
of synaptic AMPAR in the brain. Overexpression of TARP-2 lacking C-terminal sequence 
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(-TTPV) in hippocampal neurons reduces synaptic AMPARs activity in a dominant negative 
manner (Bats et al. 2007, Chen et al. 2000, Schnell et al. 2002); however, the mobility of 
surface AMPARs was increased at synapses (Bats et al. 2007). PSD-95 and other MAGUKs 
directly interact with the C-terminal PDZ binding motifs in TARPs to stabilise AMPARs at 
synapses (Chen et al. 2000, Coombs and Cull-Candy 2009, Dakoji et al. 2003, Diaz 2010, 
Jackson and Nicoll 2011a, Opazo and Choquet 2011, Tomita 2010). This interaction can also 
be an important mechanism for synaptic AMPAR function by AMPAR-mediated excitatory 
post-synaptic currents (EPSCs). This theory is observed in the reduction of the AMPAR-
mediated EPSCs from stargazer mice carrying a disrupted 2/stargazin gene (Hashimoto et al. 
1999), in 2/3 double knockout mice in Golgi cells (Menuz et al. 2008), in 8 knock-out 
mice in hippocampal pyramidal cells (Rouach et al. 2005), and in 2/7 double knock-out 
mice in Purkinje cells (Yamazaki et al. 2010). Furthermore, no AMPAR activity and no 
miniature EPSCs (mEPSCs) were observed in primary cerebellar granule cell cultures from 
stargazin mice (Chen et al. 2000, Hashimoto et al. 1999); however, when type I TARPs are 
overexpressed mEPSCs are restored (Chen et al. 2000, Tomita et al. 2003). Conversely, the 
decay kinetics of mEPSCs in neurons expressing Type I TARPs are faster than those in 
neurons expressing type II TARPs (Cho et al. 2007, Milstein et al. 2007). These results 
indicate that isoforms-specific TARPs modulate AMPR kinetics in the brain (Cho et al. 2007, 
Fukaya et al. 2005, Milstein et al. 2007, Tomita et al. 2003). Overexpression of PSD-95 in 
neurons also induces synaptic AMPAR potentiation (El-Husseini et al. 2000, Stein et al. 
2003), which suggests that PSD-95 plays a role in AMPAR stabilisation during plasticity. 
However, the presence of mutated TARP-8 lacking C-terminus (-TTVP) sequence revealed 
a normal LTP induction in the hippocampus, where the interaction between PDZ-binding 
motif and PSD-95 was absent (Sumioka et al. 2011). This suggests that AMPAR trafficking 
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during activity-dependent plasticity may require more complicated interaction than the 
association with PSD-95 and TARPs. 
Calcium-/calmodulin-dependent protein kinase II (CaMKII) is a serine/threonine-specific 
protein kinase, which is involved in many signalling cascades and is thought to be associated 
with learning and memory. There is strong evidence that activated CaMKII indirectly 
induces the trafficking of AMPARs to the plasma membrane and stabilised the receptor 
complexes at the PSD of the dendrite. In their basal state AMPARs are highly mobile at the 
neuronal surface, rapidly switching between extrasynaptic and synaptic sites, while the 
concentration of CaMKII is low in the PSD. Upon activation of NMDARs there is a Ca
2+
 
influx that activates CaMKII and induces its postsynaptic translocation. Once CaMKII 
arrives at the PSD, it phosphorylates the C-terminus of TARPs to facilitate its binding to 
PSD95 and stabilises AMPAR-TARP complexes at the synaptic sites (Figure 1-12) 
(Kristensen et al. 2011, Tomita et al. 2005b).  
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Figure 1-12 Model of AMPAR stabilisation via phosphorylation of TARPs by CaMKII. 
Left panel: At the basal state, NMDAR inactivated; Right panel: activated NMDAR 
triggers downstream cascades (Opazo et al. 2010) 
Lipid bilayers have also been shown to indirectly modulate the synaptic trafficking of 
AMPAR-TARP complexes (Sumioka et al. 2010). The C-terminus of TARPs binds to lipid 
bilayers in an electrostatic manner, this interaction further inhibits the binding of TARPs to 
PSD-95 at the PSD (Sumioka et al. 2010) (Figure 1-13). The positively charged arginine 
residue in the C-terminus of TARPs interacts with negatively charged phosphates of lipids 
and lipid bilayers and subsequently inhibits the binding of TARPs to PSD-95 (Roberts et al. 
2011, Sumioka et al. 2010). Conversely, the phosphorylation of TARPs inhibits the 
interaction with lipids, which is followed by the stabilisation of AMPAR-TARP complexes 
at the synapse (Inamura et al. 2006, Sumioka et al. 2010, Tomita et al. 2005b). These protein 
interactions suggests that phosphorylation of TARPs in activity-dependent plasticity plays an 
important role for AMPAR stabilisation and thus control synaptic function.  
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Figure 1-13 Lipid bilayers enhance translocation of AMPAR-TARP complexes to 
synapses (Sumioka et al. 2010). 
In addition to modulation of AMPAR stabilisation and trafficking, TARPs also regulate the 
channel properties of AMPARs (Coombs and Cull-Candy 2009, Diaz 2010, Jackson and 
Nicoll 2011a, Opazo and Choquet 2011, Tomita 2010). The presence of TARPs slows the 
kinetics of AMPAR deactivation (channel closure upon glutamate removal) and 
desensitisation (channel closure upon glutamate binding) (Milstein et al. 2007). Moreover, 
TARPs modulate the ion permeability of AMPARs. The presence of TARPs reduces the 
reaction of AMPARs, rendering them more calcium permeable (Cho et al. 2007, Jackson and 
Nicoll 2011b, Soto et al. 2007, Soto et al. 2009).   
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1.4.4 Trafficking of AMPARs associated with neuro-disorders 
The remarkable dynamics of synaptic neurotransmitter receptor localisation and its 
importance to mechanisms underlying brain functioning such as learning and memory, as 
well as to several disease states involving cognitive dysfunction has only recently been 
recognised. Research studies have provided evidence for AMPAR trafficking underlying 
behavioural learning responses and cognitive dysfunction associated with neuro-disorder 
conditions such as Alzheimer’s disease (AD). A reduction in GluR1, GluR2, and GluR2/3 
AMPAR subunits levels has been demonstrated in several brain areas of AD patients, such as 
CA1, the subiculum, and entorhinal cortex (Ikonomovic et al. 1997, Ikonomovic et al. 1995).  
There is convincing evidence for the requirement of TARPs to mediate AMPAR trafficking 
to synapses for a variety of brain functions. While there is strong evidence of a role for 
TARP subunits, the mechanism linking this to pathology still requires further study. 
Meanwhile, human genetic studies have recently suggested that TARPs may play a role in 
neuropsychiatric disorders.  
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2 Aims of the thesis 
The main aim of the thesis was to identify genetic susceptibility variants associated with 
bipolar disorder and schizophrenia, and characterise the contribution of these genetic variants 
to the development of dysfunctional cell surface AMPA receptor expression. The specific 
hypothesis and aims of the thesis were: 
1. Hypothesis: rare variants contribute to disorder susceptibility and that they may be 
found in the same genes that harbour common disease-associated single-nucleotide 
polymorphisms. 
Aims: To scan the CACNG5 gene for functional variants and to genotype these 
variants in order to test for association with BPD and/or SCZ. 
2. Hypothesis: The disease-associated rare functional CACNG5 variants may have an 
effect on protein interaction. 
Aims: To characterize the possible contribution of these CACNG5 genetic variants on 
the development of dysfunctional cell surface AMPA receptor expression. 
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3 MATERIALS AND METHODS 
3.1 General Materials and Methods 
3.1.1 Research participants – UCL Research sample 
The UCL research samples were recruited from London and South England and consist of 
1099 volunteers with bipolar disorder, 618 volunteers with schizophrenia and 986 volunteers 
as normal comparison subjects. The control subjects were included 614 “supernormal” – 
subjects were screened for an absence of psychiatric disorder and 480 unscreened British 
normal control subjects provided by European Collection of Animal Cell Cultures (ECACC). 
For all groups participants were included only both parents were of English, Irish, Welsh or 
Scottish descent and if three out of four grandparents were of the same descent. Furthermore, 
the participants were excluded if one grandparent was of Jewish or non-Caucasian European 
ancestry based on the EU countries before the 2004 enlargement.  
All participants required to obtain UK National Health Services (NHS) multicentre with local 
research ethics committee approvals and signed an approved consent form. All cases subjects 
with bipolar disorder or schizophrenia and supernormal control subjects were interviewed by 
a psychiatrist using the lifetime version of the Schizophrenia and Affective Disorders 
Schedule (SADS-L) (Spitzer R 1977). UCL schizophrenia subjects were diagnosed according 
to standardised criteria in the International Classification of Diseases 10
th
 edition (ICD-10). 
All cases were selected on the basis of a primary clinical diagnosis of bipolar disorder or 
schizophrenia, and then they were formally diagnosed again according to Research 
Diagnostic Criteria (RDC). The “supernormal” control subjects were strictly selected on the 
basis of not having a family history of schizophrenia, alcoholism or bipolar disorder and for 
having no past or present personal history of any RDC-defined mental disorder. 
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Genomic DNA was extracted by lab colleagues from frozen blood samples using standard 
DNA extraction techniques. DNA samples were then quantified using Qubit2.0 (Section 
3.1.2 DNA quantification). 
3.1.2 DNA Quantification 
 DNA concentration was quantified using Qubit® DNA assay (Invitrogen, UK) with the 
Qubit® 2.0 Fluorometer. This is a quantitation system relying on dyes that only fluoresce 
when bound to specific molecules, such as double-stranded DNA (dsDNA), single-stranded 
DNA (ssDNA) or RNA. The calibration of instrument was using the Qubit® dsDNA high 
sensitivity (HS) Assay (declared assay range between 0.2 – 100 ng; sample starting 
concentration between 10 pg/µl – 100 ng/µl) (Figure 3-1 A) and the Qubit® dsDNA broad 
rang (BR) Assay (declared assay range between 2 – 1000 ng; sample starting concentration 
between 100 pg/µl and 1 µg/µl) (Figure 3-1 B), according to the manufacturer’s instructions.  
 
Figure 3-1 Examples of DNA concentration calibration from the Qubit® dsDNA assay. 
The points corresponding to its DNA concentration and its corresponding fluorescence 
curves and plotted. A: Qubit® dsDNA HS assay kit; B: Qubit® dsDNA BR assay kit 
(Invitrogen, UK). 
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The Qubit® 2.0 protocol for calibrating the fluorescent intensity was followed according to 
the manufacturer’s manual. Two DNA assay kits (BR and HS) assay kits were prepared from 
the calibration standard provided by the manufacturer and fluorescence signal were measured 
using Qubit® 2.0 Fluorometer. When the DNA concentrations were higher than the 
calibration curves, the DNA samples were further diluted in order to put them within the 
range of the calibration. The dilution factor is used by Qubit 2.0 algorithm to calculate the 
actual concentration. After the calibration routine, the device simply displays the 
concentration and information about the raw fluorescence intensity is omitted. For each 50 
DNA samples, a new calibration was applied to avoid maintain calibration of measurements. 
Protocol: 
Both the Qubit® dsDNA HR and BR assay required two standards provide by the 
manufacturer. All standards and sample tubes were prepared in labelled thin-wall 500 µl 
microcentrifuge tubes. The Qubit® working solution was diluted by either the Qubit® 
dsDNA HS or BR reagent 1:200 in Qubit® dsDNA HS or BR buffer. Then, 190 µl of 
Qubit® working solution was loaded into each of the tubes used for standards, and 195 µl 
was loaded for samples. 10 µl of each Qubit® standard to the appropriate tube was added and 
5 µl was added into the samples tubes to make a final volume of 200 µl in each tubes. All 
samples and standards tubes were mixed by vortexing for 3 seconds, and incubated at room 
temperature for 2 minutes. After incubation, the standards were ready to calibrate and the 
samples were ready to be quantified.  
3.2 Variant detection and genotyping  
For identification of CACNG5 variants, a rapid mutation scanning of the gene was performed 
using high resolution melting analysis (HRMA). The exons of CACNG5 gene plus their 
neighbouring flanking introns and promoter regions were amplified in UCL BPD, SCZ, and 
control samples. The presence of potentially aetiological variants detected in cases or control 
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samples were further confirmed using traditional polymerase chain reaction (PCR) and 
followed DNA Sanger sequencing. After confirmation of validity of variants in the CACNG5 
gene, the frequency of these variants in the control and cases samples was investigated using 
the KBiosciences competitive allele specific PCR system (KASPar) (Kbiosciences, UK). The 
genotypic frequencies of the variants were then analysed for departure from Hardy-Weinberg 
equilibrium using chi-square tests. Allele counts were tested for single marker associations 
and further tested by burden analysis. The possible functional effects of variants were further 
predicted using online bioinformatics software.  
3.2.1 High Resolution Melting Curve Genotyping Assay 
HRMA is a post-PCR analysis method to identify variants in disease-related genes. The 
principle behind it is to detect changes in the dissociation behaviour of DNA under 
increasing temperature (Herrmann et al. 2006, Vossen et al. 2009, Wittwer 2009). This 
method involves PCR in the presence of saturating dsDNA-binding dyes such as LCGreen, 
EvaGreen, or SyBr Green, with increasing temperature to denature the double-stranded DNA 
into single-stranded DNA with loss of its fluorescence signal (Reed and Wittwer 2004). Then 
the profile gives a specific sequence-related pattern allowing identification of wild-type 
sequences and homozygote-heterozygote variants (Graham et al. 2005).  
3.2.1.1 Primer design for HRMA 
For CACNG5 mutational analysis, 7 pairs of primers (Table 3-1) with melting temperatures 
of around 60
o
C were designed using primer 3 software following the general guidelines for 
primer design as described below (Method section 3.2.1.1.1). The primers were purified by 
standard reverse-phase cartridge purification (Sigma, UK). The primers amplified around 100 
-350 basepair (bp) of genomic DNA. Using this approach the entire coding sequences plus 
their flanking introns and promoter regions of CACNG5 (Genebank: 27091) were amplified 
following the standard protocol.  
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Table 3-1 Primer sets used for HRMA 
Regions Primers Sequence  (5' to 3') Amplicons size (bp)
Forward-CCCTTCAATGGCAAGGATAG
Reverse-TAGGGAGAGTGGGTGAGCAG 
Forward-TGGCTCCTCATCTTCGTCTT
Reverse-CCTTACCTGCAAGGAAGCAG
Forward-TGTGATTCTTGTCTCCACAGG
Reverse-TGCCAGACTCAAGGCACTTA
Forward-ATTCCCTCTGGTCAGCCTCT
Reverse-CCAGGGTGCAAGAAAAGAAA
Forward-GCCTCTGGGCTGAGCATC
Reverse-AGGGAAGTAGAGTGGGTGGTC
Forward-ACTGAGCCGGGGAGAGTG
Reverse-GCGGTGTACCGCTTCATAA
Forward-CGGGGTGATGTCTGTGTACC
Reverse-CTCAGCAGGGTGAAGAGGAC 
EXON 5 254
EXON 3 153
EXON 4 320
Intron 4 - 5 318
Promoter Region 354
EXON 1 330
EXON 2 128
 
 
3.2.1.1.1 Primer design guideline 
The most important PCR parameter is the design of the primers. The primers must be 
designed to define an appropriate target with a goal to amplify a single DNA sequence. For 
instance, it is important to avoid repetitive DNA sequences and the following factors are 
needed to be considered as well: 
1. Optimally about 18 – 22 nucleotides long, which are specific for sequences flanking 
the target sequence;  
2. The forward primer sequence is complimentary to the reverse strand of DNA and the 
reverse primer to the leading strand. 
3. The GC content should be between 40 – 60% with an even distribution of all four 
nucleotides; 
4.  No stop codons (either TTA at the 3' end or TAG/TAA/TGA at the 5' end); 
5. The primer end with a T could possibly prone to mis-priming due to low efficiency of 
the Taq DNA polymerase 
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6. The melting temperature (Tm) of the primer is the temperature corresponding to the 
mid-point in the observed transition from double-stranded form to single-stranded 
form. The optimal Tm is between 55 - 65
o
C. Ideally, the calculated Tm values for two 
primers should be within 5
o
C of each other. The Tm calculation formula as shown 
below:  
Tm = [(2
o
C x AT) + (4
o
C x CG)] - 2 
7. No more than 3 G’s or C’s in the last 5 bases at the 3’ terminal sequence of the primer, 
this increases the strength of bonding at the 3’ terminal sequence, where helps 
promote specific allele can be amplified;  
8. No hairpins or dimerisation in primers is also essential; 
9. Avoid more than 3 bases in length of inverted repeats or any self-complementary 
sequence. 
Primer 3 software was selected to design primers (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). NetPrimer (Premier Biosoft) 
(http://www.premierbiosoft.com/servlet/com.pbi.crm.clientside.FreeToolLoginServlet#) is 
primer analysis software that to analyses the properties of primers such as Tm, GC%, 
secondary structures, 3' terminal sequence stability. This information was used to determine 
the quality of the primers.  
3.2.1.2 Optimisation of HRM assay 
The accuracy of HRM scanning depends on high quality PCR, thus optimisation is critical. 
Amplification of CACNG5 primers were optimised using several HRM assays which are 
available from various manufacturers such as SensiMix (BIOLINE), Roche HRMA master 
mix, AccuMelt HRM supermix (Quanta BIOSCIENCES), and LightScanner (BioFire) HRM 
assays.  
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PCR amplifications using SensiMix (BIOLINE) were optimised with adjusted MgCl2 
concentrations in a final volume of 5 µl containing 10 ng dried DNA and 200 nM of each 
primer (Table 3-2). 
Table 3-2 HRMA assay conditions for primer optimisation 
MgCl2 Concentration conditions 3.5 mM (µl) 4.0 mM (µl) 4.5 mM (µl) 5.0 mM (µl) 
SensiMix HRM 2.5  2.5 2.5 2.5 
50 mM MgCl2 0.05 0.1 0.15 0.2 
EvaGreen Dye 0.2 0.2 0.2 0.2 
Forward Primer (10 pmol/µl) 0.1 0.1 0.1 0.1 
Reverse Primer (10 pmol/µl) 0.1 0.1 0.1 0.1 
DNA (10 ng/µl) 1 1 1 1 
PCR water 1.05 1 0.95 0.9 
Total 5 5 5 5 
Roche HRM Mix assays were also optimised with adjusted MgCl2 concentrations in a final 
volume of 5 µl per reaction containing 10 ng dried DNA and 200 nM of each primer (Table 
3-3). 
Table 3-3 Roche HRM Mix assay conditions for primer optimisation (4 x 5 µl reactions 
were prepared) 
MgCl2 Concentration conditions 2.0 mM (µl) 2.5 mM (µl) 3 mM (µl) 
MasterMix 11.25  11.25 11.25 
25 mM MgCl2 1.8 2.25 2.7 
Forward Primer (10 pmol/µl) 0.45 0.45 0.45 
Reverse Primer (10 pmol/µl) 0.45 0.45 0.45 
DNA (10 ng/µl) 4.5 4.5 4.5 
PCR water 4.05 3.6 3.15 
Total 22.5 22.5 22.5 
PCR amplification using Quanta Supermix HRMA assays were optimised with adjusted 
primer concentrations in a final volume of 5 µl per reaction containing 10 ng dried DNA 
(Table 3-4). 
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Table 3-4 Quanta Supermix HRMA assay conditions for primer optimisation 
Primer Concentration conditions 200 nM (µl) 500 nM (µl) 
AccuMelt HRM SuperMix 2  2 
Forward Primer (10 pmol/µl) 0.1 0.25 
Reverse Primer (10 pmol/µl) 0.1 0.25 
DNA (10 ng/µl) 1 1 
PCR water 1.8 1.5 
Total 5 5 
LightScanner HRMA assay was the only one that do not required any adjustment of solution 
as shown in Table 3-5.  
Table 3-5 LightScanner HRM Mix assay conditions for primer optimisation 
Primer Concentration conditions 200 nM (µl) 
MasterMix 2  
Forward Primer (10 pmol/µl) 0.5 
Reverse Primer (10 pmol/µl) 0.5 
DNA (10 ng/µl) 1 
PCR water 1 
Total 5 
Reactions using the optimum assay conditions were performed in a 384-well plate prepared 
using an epMotion 5075 robot (Eppendorf). Reactions were mixed using a MixMate 
(Eppendorf), and briefly spun in a centrifuge for a minute. The plate was loaded into the 
LightCycler® 480 (Roche). The amplification were run according to the optimised 
conditions and the cycle was applied as shown in Table 3-6. Analysis of HRM curves was 
carried using the LightCycler® 480 Gene Scanning software v.1.5.0 (Roche) to visualise 
fluorescence data using normalisation, temperature-shifting, and difference plotting, and then 
analysed using the automated grouping functionalities. During the high-resolution melting 
step that followed amplification, the software records a large number of fluorescence data 
points per for each change in temperature. This altered fluorescence during an experiment 
can be used to measure temperature- induced DNA dissociation during High Resolution 
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Melting. The melting profile of the amplicon depends on the GC content, sequence, length 
and heterozygosity, therefore, any sequence variations will result in heteroduplexes with a 
different melt curve shape compared to the wild-type sequence.  
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Table 3-6 HRM cycling conditions 
Program 
name 
Cycles Analysis mode Temp (oC) Acquisition 
mode 
Hold Ramp rate 
(
o
C/s) 
Acquisitions 
(per 
o
C) 
Sec 
Target 
(
o
C) 
Step Size 
(
o
C) 
Step 
delay 
(cycles) 
Pre-Incubation 1 None 95 None 10 min  None 0 0 0 
Amplification 45 Quantification 95 None 10 s 4.8  0 0 0 
65 None 15 s 2.5  53 0.5 1 
72 Single 10 s 4.8  0 0 0 
High 
Resolution 
Melting 
1 Melting Curves 95 None 1 min 4.8     
40 None 1 min 2.5     
65 None 1 s 1     
95 Continuous  0.02 25    
Cooling 1 None 40 None 10 s 2.5  0 0 0 
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3.2.1.3 Gene scanning analysis 
The LightCycler® 480 Gene Scanning software (Roche) measured the decrease in 
fluorescence signal during the denaturation of double-stranded amplicons with temperature 
increased. Then the software generated plots of fluorescence signal over temperature, where 
the melting curves from the variant DNA can be distinguished from the wild type samples as 
shown in Figure 3-2, and more apparent diagram is shown in a difference plot.  
 
Figure 3-2 An example of HRMA reveals differences between wild-type (homozygous) 
and variants (heterozygous). Difference plot analysis allowed to differentiate between 
homozygous (blue) and heterozygous (red) samples. 
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3.2.2 Polymerase Chain Reaction (PCR) 
PCR is a basic molecular genetics technique, where applying the ability of DNA polymerase 
to synthesis new strand of DNA complementary to the offered template strand. DNA 
polymerase synthesis of a strand complementary requires two specific designed 
oligonucleotide primers.  
3.2.2.1 General PCR principle 
The principle of PCR requires three major steps: DNA melting, primer annealing and DNA 
polymerase elongation. During DNA melting step, the double strands of DNA are physically 
separated by disrupting the hydrogen bonds between complementary bases at a high 
temperature (usually performed at 95ºC) for about 30 seconds to 5 minutes, yielding single-
stranded DNA template. In primer annealing, temperatures are usually between 50 - 70ºC 
depending on the primer-template Tm. The optimal re-annealing temperature is about 5ºC 
lower than the primer-template allowing annealing of the primers to the single-stranded DNA 
template. Generally, the heat-stable DNA polymerase requires an efficient elongation 
temperature at about 70 - 75ºC. In the presence of heat-stable DNA polymerase and DNA 
precursors – the four deoxynucleoside triphosphates, dATP, dCTP, dGTP, and dTTP, the 
primers initiate the synthesis of new DNA strands which are complementary to the individual 
DNA strands of the target DNA segments. The primer concentration is another essential 
factor, generally the optimal concentration is between 0.1 and 0.5 µM for most PCR 
applications. Sufficient optimal primer concentrations increase possibility of mismatches and 
yielding non-specific PCR. 
The electrorepulsive forces between the DNA strands are weaken by the present of cations in 
PCR buffers, such as K
+ 
(potassium) and NH4
+
 (ammonium) that leading to a neutralisation 
on the negatively charged phosphate groups of the DNA backbone. Hence, the annealing 
process between the primer and the templates occurs, when the repulsive forces are reduced. 
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And it also maintains the high ratio of specific to nonspecific primer-template binding over a 
wide temperature range. 
Furthermore, the additional magnesium ions (Mg
2+
) to the reaction mix stabilises primer 
annealing, influences enzyme activity and increases the Tm of dsDNA. Mg
2+
 also forms 
soluble complexes with dNTPs in the reaction mix to produce the actual substrate that the 
polymerase recognises. The optimal concentration for each deoxynucleoside triphosphate 
(dNTP) to minimize polymerase error is 200 µM. Other solutions such as dimethyl sulfoxide 
(DMSO), betaine, and glycerol are also used to improve the amplification efficiency by 
melting the secondary structures and decreasing non-specific products. 
3.2.2.2 General optimisation of the PCR reaction 
The primers were optimised using four common master mix conditions with altered MgCl2 
concentration and the inclusive or exclusive of betaine as shown in Table 3-7 on MWG-HT 
Primus 96 thermocycler. 
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Table 3-7 PCR primer optimisation layout 
Component 
Volume (µl) 
2 mM 
MgCl2 + 
Betaine 
2 mM 
MgCl2 + 
No Betaine 
2.5 mM 
MgCl2 + 
Betaine 
2.5 mM 
MgCl2 + No 
Betaine 
10 X Buffer 2.5 2.5 2.5 2.5 
Betaine 5M 5 0 5 0 
50 mM MgCl2 1 1 1.25 1.25 
25 mM dNTP 0.2 0.2 0.2 0.2 
F primer (10 pmol/µl) 1 1 1 1 
R primer (10 pmol/µl) 1 1 1 1 
Taq polymerase (1 U/µl) 0.5 0.5 0.5 0.5 
DNA 25 ng/µl 2 2 2 2 
Water 11.8 16.8 11.55 16.55 
Total volume 25 25 25 25 
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For amplifying the PCR products, three standard PCR programs were applied such as 
Standard 55
o
C, Standard 60
o
C and Touchdown as shown below. In order to achieve the most 
efficient PCR amplification, it was essential to adjust the annealing temperature and the 
number of cycles in these experimental protocols.  
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The three standard cycling conditions were: 
Standard 55
o
C (STD55) Standard 60
o
C (STD60) Touch Down (MHTD) 
Lid heated to 105
 o
C Lid heated to 105
 o
C Lid heated to 105
 o
C 
Products denatured at 94
 o
C 
for 5 minutes 
Products denatured at 94
 o
C 
for 5 minutes 
Products denatured at 94
 o
C 
for 5 minutes 
35 cycles of 35 cycles of 3 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 94
o
C - 30 seconds 
55
o
C - 30 seconds 60
o
C - 30 seconds 63
o
C - 30 seconds 
72
o
C - 30 seconds 72
o
C - 30 seconds 72
o
C - 30 seconds 
  3 cycles of 
Hold at 72
o
C - 10 minutes Hold at 72
o
C - 10 minutes 94
o
C - 30 seconds 
Store at 4
o
C Store at 4
o
C 60
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  57
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  54
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  51
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  48
o
C - 30 seconds 
  72
o
C - 30 seconds 
   
  Hold at 72
o
C - 10 minutes 
  Store at 4
o
C 
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3.2.3 Agarose gel electrophoresis  
Agarose gel electrophoresis is the most effective technique to analysis the composition and 
quality of a nucleic acid sample. It is also used to determine the size of DNA fragments such 
as PCR products from 100 bases pairs (bp) to 25 kilo-bases pairs (kb) (Sambrook 2001). For 
this purpose, it is essential to run a standard marker containing fragments of known sizes, 
such as Hyperladder markers (Bioline).  The principle of agarose gel electrophoresis is where 
the DNA is loaded into pre-cast wells in the gel and a current applied. The phosphate 
backbone of the DNA is negatively charged, therefore when placed in an electric field, DNA 
fragments will migrate to the positively charged anode. Because DNA has a uniform 
mass/charge ratio, DNA molecules are migrated by size within an agarose gel in a pattern 
such that the moving distance is inversely proportional to the logarithm of its molecular 
weight (Helling et al. 1974). The rate of DNA migration through a gel is determined by the 
following: 1) size of DNA; 2) concentration of agarose; 3) DNA conformation (Aaij and 
Borst 1972); 4) voltage applied; 5) presence of dye; 6) type of agarose and 7) electrophoresis 
buffer. Dyes such as ethidium bromide are commonly used for both detecting and 
quantitating DNA, where its flat ring structure has ability to stack in between the bases in 
nucleic acids. After migration, the DNA stained with ethidium bromide can then be detected 
by its fluorescence when exposed to UV (ultraviolet) light  
3.2.3.1 The principle protocol of agarose gel electrophoresis 
Buffer and solutions required: 
 1X TBE running buffer: 45 mM Tris-borate, 1 mM EDTA.  
 Gel staining dye: Ethidium bromide 
 Loading dye: Biotaq red DNA polymerase 
 Molecular size marker: Hyperladder IV or Hyperladder I (Bioline, UK) 
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First, an appropriate mass of agarose was weighted into a conical flask in order to prepare a 
w/v (weight/volume) percentage (%) solution. The concentration of agarose in a gel depends 
on the sizes of the DNA fragments need to be separated. Mostly 1% w/v of agarose was 
prepared with 1X TBE buffer in a conical flask. The mixture was then heated in a microwave 
oven for one or one and half minutes to allow the agarose to completely dissolve, and then 
cooled down to around 50 - 60ºC. For gel staining, 10 mg/ml stock solution of ethidium 
bromide was added to make a final concentration of 0.5 μg/ml in the gel. After that, the gel 
was poured into a casting tray with appropriate combs, and the agarose was allowed to set for 
about 20 – 30 minutes at room temperature. Once set the combs were removed and the gel 
was placed into the electrophoresis gel tank with enough 1X TBE in the buffer tanks to cover 
the gel. The DNA samples were then added with a loading dye, Biotaq red DNA polymerase, 
it helps to track how far the DNA sample has migrated, and also allows the sample to sink 
into wells of the gel. 5 µl of the DNA samples and molecular size marker were loaded into 
separate gel wells. Then, the electrophoresis apparatus was connected to the power supply 
and run at 120 V (volt) for 30 minutes. When the electrophoresis was completed, the gel was 
removed from the gel tank and visualised under a UV transilluminator (UVP Gel-doc-it 
Imaging systems, UK), and then an image was captured using the camera attached to the gel 
doc system. 
3.2.4 PCR purification  
The quickest, cheapest and most flexible PCR purification is microCLEAN, which is a DNA 
clean-up reagent. These reagents purify dsDNA from reaction buffers, enzymes, primers, 
primer dimers or dNTPs that can interfere during sequencing reactions. 
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3.2.4.1 The protocol of microCLEAN 
Buffers and solutions required:  
 MicroCLEAN (Microzone Limited, UK): 0.5 M NaCl, 1 mM Tris HCl pH 8.0, 0.1 
mM EDTA, 20 % w/v PEG8000, 1.75 mM MgCl2; All the above contents were 
mixed with 50 ml of PCR water (Sigma, UK) and the solution was heated gently so 
that it completely dissolved. The solution was then filter sterilised using a 0.45 µM 
filter. 
 An equal volume of MicroCLEAN reagent was added to the DNA sample. The 
solution was mixed using a vortex for tubes or a Mixmate (Eppendorf, Germany) for 
plates and incubated at room temperature for 5 minutes.  
MicroCLEAN protocol for tubes: 
The mixture of DNA and microCLEAN solution in tubes was spun in a microcentrifuge at 
13,000 rpm for 7 minutes. The supernatant was removed and the tubes were briefly spun 
again to remove all the liquid.  
MicroCLEAN protocol for 96 well plates: 
The mixture of DNA and microCLEAN solution in plates was spun in a centrifuge at 4,000 
rpm for 40 minutes. The plate was placed upside down on a tissue in the centrifuge holder to 
remove the supernatant and spun at 1,000 rpm for 30 seconds.  
The both pellet from tubes or plates was resuspended in 5 µl PCR water and then rehydrated 
at room temperature for 5 minutes. The purified DNA was ready for further processing. 
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3.2.5 DNA sequencing 
DNA cycle sequencing is a fluorescence-based cycle sequencing, which requires a DNA 
template, a sequencing primer, a thermal stable DNA polymerase, nucleotides 
deoxynucleotides (dNTPs) and dideoxynucleotides (ddNTPs), and buffer. The principle of 
this method is that fluorescent dyes are attached to the extension product of reactions that are 
involve successive rounds of DNA denaturation, primer annealing, and elongation in a 
thermal cycler to amplify linear extension products. These amplified linear extension 
products are terminated by one of the four fluorescent ddNTPs as shown in Figure 3-3. The 
optimised ratio of deoxynucleotides to dideoxynucleotides amplifies a balanced population 
of long and short extension products. 
 
Figure 3-3 DNA sequencing cycle (Taken from Big Dye Sequencing kit 3.1 manual, 
Applied Biosystems, UK) 
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3.2.5.1 BigDye terminator sequencing reaction 
BigDye terminator sequencing is a reaction using fluorescent fragments that generated by 
dye-labelled ddNTPs (dideoxynucleotide) complexes such as terminator of extension product. 
Because each four ddNTP - ddATP, ddCTP, ddGTP, or ddTTP terminators carries a unique 
fluorescent dye. The 3’ terminal dideoxynucleotide (A, C, G or T) of the extension product is 
identified by the fluorescent dye that it carries (Figure 3-4). 
 
Figure 3-4 Schematic showed a cycle procedure of BigDye terminator cycle sequencing 
(Taken from Big Dye Sequencing kit 3.1 manual, Applied Biosystems, UK) 
PCR products were sequenced by BigDye Terminator v3.1 sequencing kit (Applied 
Biosystems, Warrington, UK) according to their manufacturer's instructions. Each sample 
was performed with two reactions, one using designed forward primer and the other one with 
the reverse primer, using the following reaction mixture and the cycling conditions as shown 
below (Table 3-8).   
Table 3-8 Reaction mix used for Big Dye sequencing reaction 
Reagent Final concentration Volume (µl) 
Terminator ready reaction mix 1X 1 
BigDye Sequencing buffer 5X 1X 1.5 
10 µM M13 primer F or R  0.32 pmol 0.32 
Template (0.5 - 1 kbp PCR product) (5 - 20 ng) 1 
Water As required 6.18 
Total volume 10 µl 10 
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Cycling conditions: 
 Heat the lid to 105oC 
 Initial denaturation:  
94
o
C for 5 minutes 
 25 Cycles of- 
96
o
C - 10 seconds 
50
o
C - 5 seconds 
60
o
C - 4 minutes 
 Store the reactions at 4oC 
3.2.5.2 DNA sequencing purification 
DNA sequencing purification is an important step to completely remove the excess dye 
terminators and salts from previous BigDye terminator sequencing reaction before 
electrophoresis analysis for generating clean sequencing data. Ethanol/EDTA precipitation 
method was applied for DNA sequencing purification in 96-well plates. For a 10 µl 
precipitation reaction in 96-well plates, 2.5µl of 125 mM EDTA and 30 µl of absolute 
ethanol was added directly to each sample. The reaction plate was mixed using a MixMate 
for 15 seconds, and then left at room temperature for at least 10 minutes to precipitate the 
extension products. The reaction plates were then spun in a centrifuge at 4,000 rpm for 60 
minutes. In order to discarded supernatant, the reaction plate was inverted onto a paper towel 
and spun at 1,000 rpm for a minute. Afterwards, 30 µl of 70% ethanol was added to the 
reaction plates and mixed with a MixMate for 15 second. The plate was then centrifuged at 
4,000 rpm for 10 minutes. The supernatant was discarded again as described above by 
inverting the reaction plates and brief centrifugation. The reaction plate was left at room 
temperature for 15 minutes to evaporate any residual ethanol. The dried pellets were 
resuspended with 15 µl of Hi-Di
TM
 formamide (Applied Biosystems, UK) per well, a DNA 
denaturing reagent and sent off for sequencing at the Centre of Comparative Genomics, 
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Department of Biology, UCL and GOSH, York Way, London. The samples were then run on 
the 3730xl DNA Analyzer (Applied Biosystems, UK) (Figure 3-5). 
 
Figure 3-5 Diagram of the Applied Biosystems 3730xl DNA Analyzer run cycle steps 
(Manual guide of ABI Sequencing) 
3.2.5.3 DNA sequencing data analysis 
Finch TV software was used to visualise of DNA sequence traces, the display an entire 
trance, linked to BLAST searching of the databases, and also has the ability to reverse 
complement sequences and traces. For analysis of DNA sequencing data, the Staden Package 
was performed with an assembly program consists of Gap4 and Pregap4. Gap4 performs 
assembly, contig joining, and assembly checking, repeat searching, experiment suggestion, 
read pair analysis and contig editing. Pregap4 provides a graphical user interface to set up the 
processing required to prepare trace data for assembly or analysis. 
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3.2.6  KASPar Genotyping Assay 
The KBiosciences Competitive Allele-Specific PCR SNP genotyping system (KASPar) is the 
simplest and most cost effective and flexible way to determine SNP genotypes. This system 
relies on the discrimination power of a novel form of competitive allele specific PCR to 
determine the alleles at a specific locus within genomic DNA based on fluorescent resonance 
energy transfer (FRET). The system is comprised of two components: 
1. The KASP assay mix contains three non-labelled oligonucleotides (Figure 3-6): two 
allele-specific forward primers (one for each allele of the SNP) and one common 
reverse primer. The allele-specific forward primers are labelled with a unique tail 
sequence at the 5' end that corresponds with a universal FRET cassette; one labelled 
with FAM
TM
 dye and the other with CAL
TM 
Fluor Orange 560, both with quenchers 
bound at the 3' ends. 
2. The KASP Master Mix contains Taq polymerase enzyme and the universal FRET 
cassettes passive reference dye 5-carboxy-X-rhodamine, succinimidyl ester (ROX), 
and MgCl2 in an optimised buffer solution. The composition of reaction mix is 
described as below 
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Table 3-9 Reaction mix for KASPar assay 
Component Concentration in 
Assay Mix (µM) 
Volume in 
Assay Mix (µL) 
Allele specific primer F1 
(100 µM) 
12 12 
Allele specific primer F2 
(100 µM) 
12 12 
Common reverse primer R 
(100 µM) 
30 30 
Water  46 
Total  100 
 
Principle:  
During thermal cycling of PCR, the allele-specific forward primer binds to the template and 
elongates, thus attaching the tail 5’ sequence to the newly synthesised strand. The 
complement of the allele-specific tail 5’ sequence with fluor-labelled is then generated during 
subsequent rounds of PCR, enabling the FRET cassette to bind to the DNA. The FRET 
cassette is no longer quenched and emits fluorescence. Bi-allelic discrimination is achieved 
through the competitive binding of the two allele-specific forward primers. For instance, the 
genotype at a given homozygous SNP only one of the two possible fluorescent signals 
generates, whereas the heterozygous genotyping SNP generates a mixed fluorescent signal 
(Figure 3-6). 
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Figure 3-6 Diagrammatic representation of KASPar reaction process (Taken from 
Genotyping chemistry – KASP, KBioscience LGC) 
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3.2.6.1 Primer design for KASPar assay 
The primers for SNPs were designed using the Primer Picker software provided by 
KBiosciences. Approximately 25 bases on each side of SNP sequence was cut and pasted 
into the sequence input window and analysed using the provided software. The results 
consisted of two forward primers for the alternative alleles of the SNP and two reverse 
primers. These two reverse primers were optimised to find the best reverse primer for the 
reaction. A total of 16 sets of KASPar primers were designed and followed the standard 
protocol for analysis (Table 3-10).  
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Table 3-10 Primer sets used for Kaspar genotyping.
AS1-GAAGGTGACCAAGTTCATGCTCCCAGAGAGGACAAGGGG
AS2-GAAGGTCGGAGTCAACGGATTACTCCCAGAGAGGACAAGGGA
CP1-CAGCAATTCAGAGCGTTCTTGGCAT
CP2-GCGTTCTTGGCATGCCACTGCAA
AS1-GAAGGTGACCAAGTTCATGCTTGGCATGCCACTGCAAGGAC
AS2-GAAGGTCGGAGTCAACGGATTCTTGGCATGCCACTGCAAGGAA
CP1-ATGAATGAATGGCAGTACCCAGCAA
CP2-AGGGGACTCCCAGAGAGGACAA
AS1-GAAGGTGACCAAGTTCATGCTTGCAGTGGCATGCCAAGAAC
AS2-GAAGGTCGGAGTCAACGGATTCCTTGCAGTGGCATGCCAAGAAT
CP1-GAGGTGCCACCCTCCCCCTA
CP2-TCCCCCTAACCCCGCAGCAATT
AS1-GAAGGTGACCAAGTTCATGCTGATGAGTGCCTGCGGGAGG
AS2-GAAGGTCGGAGTCAACGGATTAAGATGAGTGCCTGCGGGAGA
CP1-GGCCCAAGCCACAGACAGCAAA
CP2-GCTCAGCAGGGTCAGGGCCTT
AS1-GAAGGTGACCAAGTTCATGCTGAGCAGTGTCTTTGCTGTCTGT
AS2-GAAGGTCGGAGTCAACGGATTGAGCAGTGTCTTTGCTGTCTGC
CP1-CGCGATACCCAGGAGGCCCAA
CP2-GTAGTCGGTGCTGACCGCGATA
AS1-GAAGGTGACCAAGTTCATGCTGCCAGTAGTCGGTGCTGACC
AS2-GAAGGTCGGAGTCAACGGATTAGCCAGTAGTCGGTGCTGACT
CP1-CAGTGTCTTTGCTGTCTGTGGCTT
CP2-TGGCTTGGGCCTCCTGGGTAT
AS1-GAAGGTGACCAAGTTCATGCTAATCACACCCTCCTCCAGGTAC
AS2-GAAGGTCGGAGTCAACGGATTCAATCACACCCTCCTCCAGGTAT
CP1-TGGCTTGGGCCTCCTGGGTAT
CP2-GTATCGCGGTCAGCACCGACTA
AS1-GAAGGTGACCAAGTTCATGCTGGTGAAGCAACGCCCCCG
AS2-GAAGGTCGGAGTCAACGGATTATGGTGAAGCAACGCCCCCA
CP1-GTTCAAGAGGGACCTGGAAATGTGAT
CP2-TGATTCTTGTCTCCACAGGTGAGGA
AS1-GAAGGTGACCAAGTTCATGCTGGTGAGGAGCGGGGGCG
AS2-GAAGGTCGGAGTCAACGGATTAGGTGAGGAGCGGGGGCA
CP1-CTGGGTGTTCATGGGCATCACATAT
CP2-GGCATCACATATTCTATGGTGAAGCAA
AS1-GAAGGTGACCAAGTTCATGCTGACACATCCGTCCCCACCG
AS2-GAAGGTCGGAGTCAACGGATTGGACACATCCGTCCCCACCA
CP1-AGAGGATAAAGAAGATGCCAGAGACAAA
CP2-AGATGCCAGAGACAAAGGCCAGTAT
AS1-GAAGGTGACCAAGTTCATGCTCCAGAGACAAAGGCCAGTATCG
AS2-GAAGGTCGGAGTCAACGGATTGCCAGAGACAAAGGCCAGTATCA
CP1-ACATCGGACACATCCGTCCCCA
CP2-GTTTATCCTGAACAACATCGGACACAT
AS1-GAAGGTGACCAAGTTCATGCTAGAGCACCAGGCCCACCAC
AS2-GAAGGTCGGAGTCAACGGATTGTAGAGCACCAGGCCCACCAT
CP1-CTGCTGCCCAACCAGGCCTCT
CP2-CCCTCTCCCCTGCTGCCCAA
AS1-GAAGGTGACCAAGTTCATGCTCCTGTTGAGCATCTCATCGTTGAT
AS2-GAAGGTCGGAGTCAACGGATTCCTGTTGAGCATCTCATCGTTGAA
CP1-AACCAGGCCTCTCTCTCGTGGT
CP2-TGGTGGGCCTGGTGCTCTACAT
rs181400884 N/A
Name
Amino acid 
change
Primer sets sequence (5' to 3')
rs3760263 N/A
rs75486725 N/A
17_64873468 Arg6Arg
rs146874664 Cys19Cys
rs71379998 Ala27Ala
rs11652480 Leu34Leu
17_64875098 Arg69Trp
17_64875105 Arg71His
rs142916987 Arg127Gln
rs149159754 Thr128Met
17_64880644 Val146Met
17_64880674 Ile156Phe
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AS1-GAAGGTGACCAAGTTCATGCTGAAGTAGGTCTCTGCATCCTTGG
AS2-GAAGGTCGGAGTCAACGGATTGAAGTAGGTCTCTGCATCCTTGA
CP1-GCTCTACATCTCCAGCATCAACGAT
CP2-CCAGCATCAACGATGAGATGCTCAA
AS1-GAAGGTGACCAAGTTCATGCTGTTAAAAGGAAGGAGATGGCGGC
AS2-GAAGGTCGGAGTCAACGGATTGTTAAAAGGAAGGAGATGGCGGA
CP1-AACTACAAGTATGGGTGGTC
CP2-ACAAGTATGGGTGGTCGTTTGCCTT
AS1-GAAGGTGACCAAGTTCATGCTGACCCAGGCGTCTGGGTG
AS2-GAAGGTCGGAGTCAACGGATTCTGACCCAGGCGTCTGGGTA
CP1-CGGCTGAGCAACTGCTCCGATT
CP2-TCCGATTACTCAGGCCAGTTCCTA
rs41280112 His233Tyr
Name
Amino acid 
change
Primer sets sequence (5' to 3')
17_64880699 Thr164Leu
rs187075595 Ala182Ser
 
3.2.6.2 Optimisation of KASPar genotyping assay 
The KASPar genotyping reactions of each primer sets were optimised as described in Table 
3-11. The optimum conditions then carried out the PCR reaction for cases and controls on 
384-well plates containing dried 10 ng of DNA. For each genotyping SNP, the master mix 
assay was prepared in bulk and dispensed in the 384-well plates using Eppendorf eoMotion 
5075. The reactions were mixed using a Mixmate and spun in a centrifuge briefly before 
loading into an LC480 (Roche). The PCR cycling conditions for KASPar genotyping were 
used as showed in Table 3-12. 
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Table 3-11 Kaspar Optimisation layout 
Component Volume (µl) 
1.8 mM 
MgCl2 
2.2 mM 
MgCl2 
2.5 mM 
MgCl2 
2.8 mM 
MgCl2 
1.8 mM 
MgCl2 + 5% 
DMSO 
1.8 mM 
MgCl2 + 
10% 
DMSO 
DNA (10 ng/µl) 1 1 1 1 1 1 
KASP Reaction 
mix (2x) 
2 2 2 2 2 2 
Assay mix 0.055 0.055 0.055 0.055 0.055 0.055 
MgCl2 0 0.032 0.56 0.8 0 0 
H2O 0.945 0.913 0.385 0.145 0.745 0.545 
DMSO 0 0 0 0 0.2 0.4 
Total reaction 
volume 
4 4 4 4 4 4 
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Table 3-12 Kaspar cycling conditions: Dual colour hydrolysis probe/UPL probe program on LC480 
Program 
name 
Cycles Analysis 
mode 
Temp 
(
o
C) 
Acquisition 
mode 
Hold Ramp rate 
(
o
C/s) 
Acquisitions 
(per 
o
C) 
Sec 
Target 
(
o
C) 
Step Size (
o
C) Step delay 
(cycles) 
Hot start 
activation 
1 None 94 None 15 min      
1st 
amplification 
20 Quantification 94 None 10 s 2.5  0 0 0 
57 Single 5 s 2.5  0 0 0 
72 None 10 s 4.8  0 0 0 
2nd 
amplification 
18 Quantification 94 None 10 s 2.5  0 0 0 
57 Single 20 s 2.5  0 0 0 
72 None 40 s 4.8  0 0 0 
Reading 1 Melting 
Curves 
40 None 1 s 2.5     
41 Continuous  0.06 5    
3rd 
amplification 
3 Quantification 94 None 10 s 2.5     
57 Single 20 s 2.5     
72 None 40 s 4.8     
Reading 1 1 Melting 
Curves 
40 None 1 s 2.5     
41 Continuous  0.06 5    
4th 
amplification 
3 Quantification 94 None 10 s 2.5     
57 Single 20 s 2.5     
72 None 40 s 4.8     
Reading 2 1 Melting 
Curves 
40 None 1 s 2.5     
41 Continuous  0.06 5    
Cooling 1 None 40 None 10 s 2.5  0 0 0 
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3.2.6.3 Endpoint genotyping analysis 
The KASP assays were run on a Light Cycler LC480 (Roche) and analysed using the 
Endpoint genotyping LC480 software (Figure 3-7). 
 
Figure 3-7 An example of the endpoint analysis of rs41280112 performed after KASPar 
PCR reaction. Genotyping results are clustered into four different colour dots: blue and 
green triangles indicate homozygous individuals for the SNP (AA/aa), red triangles 
indicate heterozygous (Aa) individuals, grey circles indicate negative samples. 
3.2.6.4 Analysis of replication data  
The diseases association of CACNG5 were further refined with additional data from the 
European ancestry subjects in the 1,000 genome project, UK10K and Swedish whole exome 
sequencing data.  
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3.2.6.5 1000 Genomes Projects  
The 1,000 Genomes Projects (http://www.1000genomes.org) was the first sequencing project 
involving a large number of people to provide a comprehensive resource on human genetic 
variation. The subjects were recruited worldwide, where included 286 participants with East 
Asian ancestry, 246 participants with African ancestry, 379 participants with European 
ancestry, and 181 Americas ancestry. Those subjects have no associated medical or 
phenotype data; hence the genetic variation data was used as control samples to refine the 
gene association study in this project with SCZ or BPD. Data for SNPs in the region 
surrounding and including the gene was extracted from the European ancestry samples in 
1,000 genomes database located at FTP directory /vol1/ftp/release/20110521 at 
ftp.1000genomes.ebi.ac.uk using a windows version of tabix. Tabix indexes a TAB-delimited 
genome position file in.tab.bgz from a position sorted and compressed input data file. Tabix 
was run with the following commands that were modified according to the gene: 
tabix -h 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/ALL.chr.phase1_release_v3.2010
1123.snps_indels_svs.genotypes.vcf.gz chr:position from-to file name.tabix 
The extracted data was then opened in Microsoft Excel and all the letters, symbols and 
numbers were removed by command replacing. The genotypes were then re-coded with 
alleles of the SNP. The data was transposed to create a ped and a map file, and those files 
were merged with the SNP data from all other resources for the gene. 
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3.2.6.6 UK10K exome sequencing data 
UK10K (http://www.uk10k.org/) is a large-scale sequencing project, which was a 
collaborative project between investigators at the Wellcome Trust Sanger Institute and 
clinical experts in genetic diseases. 5,500 participants were diagnosed with a variety of 
disease phenotypes, including SCZ as well as other disorders such as obesity, autism disorder, 
familial hypercholesterolemia, thyroid disorder, learning disabilities, ciliopathies, congenital 
heart disease, coloboma, neuromuscular disorders, and rare disorders including severe insulin 
resistance. Within the disease arm of the project, there are 1,392 British samples with a SCZ 
diagnosis. Those individuals were whole-exome sequenced to 72x depth; hence, the 
generated data were sufficient to discover novel rare and low-frequency variants associated 
with the diseases investigated in UK10K. Similarly, 4,000 participants phenotyped as control 
subjects were supplied from the TwinsUK (http://www.twinsuk.ac.uk/) registry and the 
ALSPAC study (Avon Longitudinal Study of Parents and Children, Bristol University) 
(http://www.bristol.ac.uk/alspac/). This data is available via controlled access approved by 
the specified Data Access Committee (DAC) via the European Genome-Phenotype Archive 
(EGA) (Study ID EGAS00001000123). The SNP of the gene from sequencing data was 
extracted and performed using GeneSAOcs, which is custom software designed to extract 
information from Variant Call Format (VCF) files. Moreover, GeneSAOcs was slightly 
different to PLINK/SEQ, which using appropriate filter methods to correct data by only 
included 98% success rate in the sequencing. For instance, if the genotype calls were not 
made in more than 100 samples at a location, the SNP was excluded from the analysis. 
Secondly, the conditional genotype quality (GQ) encoded as a phred quality- the threshold 
was held at 30 as well as a lower limit on read depth at each location for each sample.  
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3.2.6.7 Swedish schizophrenia and control exome sequencing data 
The Swedish schizophrenia (Purcell et al 2014) cohort comprises 2,536 control subjects and 
2,543 SCZ patients from Sweden for whom whole exome sequence data was available 
through controlled access via dbGap (Study ID phs00473.v1.p1). The SCZ participants were 
identified through the Swedish Hospital Discharge Register (Schizophrenia Psychiatric 
Genome-Wide Association Study (GWAS) Consortium 2011). The criteria were included 
two or more hospitalisations with a discharge diagnosis of SCZ, both parents were required to 
be Scandinavian descent, and age at 18 or above. By contrast, exclusive participants’ criteria 
were included hospital register diagnosis of any disorder justifying a validity diagnosis of 
SCZ. The normal control participants were randomly selected from Swedish population 
registers with none hospitalised for SCZ or bipolar disorder, Scandinavian descent of both 
parents, age at 18 or above. The data was extracted and analysis performed using GeneSAOcs 
software as described above.  
3.2.7 Association study – burden analysis 
Genotype and allele counts and minor allele frequencies were calculated for each individual 
SNVs found in the UCL case/control samples. Chi square (X
2
) test of association applied on 
individual variants was performed. However, since several SNVs were found as rare variants 
(minor allele frequency (MAF) > 0.05), where the Pearson X
2
 tests of each individual rare 
variants have low statistical power to detect association.  Pooled burden analysis was applied 
in the UCL case/control sample, where group the rare variants together as assuming a 
dominant model to improve power over a 2 degree freedom test.  For example, all nsSNVs 
that found in cases were grouped as a dominant model, where assumed phenotypes are 
affected by multiple variants in CACNG5. Table 3-13 showed the counts of nsSNVs found in 
CACNG5 in UCL cases, where sum up each nsSNVs heterozygotes and/or mutated 
homozygotes into one big variant (total).  
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Table 3-13 Example of ns SNV alleles counts for pooled burden analysis 
0|0 1|0 0|0 1|0 0|0 1|0
R69W 1071 0 599 1 937 0
R71H 1067 1 595 0 941 0
R127Q 1071 2 596 0 916 0
T128M 1069 3 599 0 926 2
V146M 1070 0 601 2 907 0
I156F 1072 1 601 0 938 0
T164L 1071 0 598 1 940 0
H233Y 1019 55 562 38 910 30
Total 1011 62 561 42 909 32
BP n = 1073 SCZ n = 603 Control n = 941
 
Separate analyses were performed for different classes of variant such as non-synonymous, 
synonymous variants, and variants that found in promoter regions. The advantage of this 
approach is that is achieves a dimension reduction through aggregation of multiple variants 
into single units of analysis. Test of association were then performed on these aggregated 
variants (as shown in total in Table 3-13) using X
2
 test with merged genotypes from UCL 
genotyping result, the 1,000 Genome Project data, UK10K exome data, and the Swedish 
exome data. For these analyses a p-value less than 0.05 was regarded as significant. 
3.2.8 Bioinformatical analysis 
A variant was designated as “novel” if it was not listed on the SNP track from UCSC 
Genome Browser (assembly Febrary 2009; http://genome.ucsc.edu/cgi-bin/hgGateway) or in 
the 1000 Genome Project (http://www.1000genomes.org/). Nucleotide positions correspond 
to genomic sequence positions (NCBI build 36) in CACNG5 cDNA (924 bases; 
chr17:64,831,235 – 64,881,603). All rare variants were investigated for possible functional 
consequences using the following tools: (i) prediction of alteration of transcription factor 
binding – TESS (http://www.cbil.upenn.edu/cgi-bin/tess/tess); (ii) prediction of functional 
effects of amino acid substitutions, i.e. benign/possibly damaging/probably damaging – 
PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) and possibly have a deleterious effect on 
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the  protein – SIFT (http://sift.jcvi.org/) and Mutation Taster (http://www.mutationtaster.org/); 
(iii) localisation in protein domains – Ensembl (http://www.ensembl.org/index.html) and 
Uniprot (http://www.uniprot.org/); (iv) comparison of amino acid sequence conservation 
through different species and subunits – HomoloGene 
(http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=homologene&dopt=MultipleA
lignment&list_uids=15424). 
3.3 Preparation of CACNG5 and AMPAR2 Constructs 
To achieve functional studies of those variants that were genotyped in the UCL cases/control 
samples it was essential to have cloned copies of the CACNG5 and AMPA receptor GluR2 
subunit gene (GRIA2). Gene cloning is a fundamental part of molecular biology, where a 
gene of interest is transferred from one organism to a self-replicating genetic element such as 
a bacterial plasmid. Bacterial plasmids are self-replicating extra-chromosomal circular DNA 
molecules, and are often used to generate multiple copies of the same gene (Figure 3-8). 
There are two main ways to achieve cloning: the polymerase chain reaction (PCR) and the 
more traditional use of restriction enzymes and modifying enzymes to “cut and paste” the 
desired gene into cloning vectors, which can then be replicated using live cells, most 
commonly E. coli. Investigation of the effect of introducing variants into these genes then 
allows analysis of the possibility that they may affect their protein function and expression in 
animal cultured cells.  
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Figure 3-8 Basic procedure for DNA (gene) cloning in a plasmid vector. (Taken from 
Health Science Academy - 
http://academygenbioii.pbworks.com/w/page/37767821/Chapter%2020%20Blog%3A%
20Genetic%20Technology%20 (Larissa)) 
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3.3.1 Plasmid vectors 
Plasmid vectors replicate independently in host bacterial cells and facilitate the manipulation 
of a newly created recombinant DNA. Other properties of vectors include that they contain a 
multiple cloning site that contains a number of unique restriction endonuclease cleavage sites 
and carrying a selectable marker to distinguish the host cells carrying the vectors from the 
host cells that do not contain a vector.  
pCR4-TOPO cloning vector:  
The pCR4-TOPO cloning vector (Figure 3-9) was provided to carry fully sequenced Homo 
sapiens CACNG5 complementary DNA (cDNA) cloned (IMAGE: 8069139; Source 
BioScience, UK). For plasmid expression in mammalian cells, the plasmid vectors requires 
an enhancer promoter region from either the human cytomegalovirus (CMV), the simian 
virus 40 (SV40), or the herpes simplex virus thymidine kinase (HS-TK) to drive transcription. 
The CMV promoter induces high-level constitutive expression in a variety of mammalian cell 
lines. In fact, pCR-TOPO vector does not contain any of these high level constitutive 
expression promoter regions; hence, the further sub-cloning of Homo sapiens CACNG5 
cDNA into a pCMV-Tag 4 vector was required. According to manufacturer’s vector 
description, the cDNA of CACNG5 was reversely inserted into TOPO cloning site, where 
contains several restriction enzyme sites such as Pst1, EcoR1 and Not1, whereas pCMV-Tag 
4 vector has a multiple cloning site region contains Pst1 and Not1 restriction enzyme sites. 
The process of traditional restriction enzyme sub-cloning for Homo sapiens CACNG5 cDNA 
is described more detailed below 3.3.2 section.  
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Figure 3-9 Circular map of the pCR4-TOPO vector (Taken from Invitrogen, UK) 
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pCMV-Tag 4 vector: 
pCMV-Tag 4 vectors is an epitope tagging mammalian expression vectors with a C-terminal 
FLAG tagging (Invitrogen) (Figure 3-10). In addition to the features of this vector, the 
cytomegalovirus (CMV) promoter allows constitutive expression of the cloned DNA in a 
wide variety of mammalian cell lines. The neomycin-resistance gene is under control of both 
the prokaryotic b-lactamase promoter to provide kanamycin resistance in bacteria and the 
SV40 early promoter to provide G418 resistance in mammalian cells. The multiple cloning 
site (MCS) of the pCMV-Tag vectors allow for a variety of cloning strategies, resulting in C-
terminal functions with FLAG. The relative location of the feathers for this vector is also 
shown in Table 3-13. Because of these features, the Homo sapiens CACNG5 cDNA from 
pCR4-TOPO vector was then sub-cloned into pCMV-Tag4 via their Pst1 and Not1 restriction 
enzyme cut and paste (as described more detail in section 3.3.2).  
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Figure 3-10 Circular map of the pCMV-Tag4 vector (Taken from Invitrogen, UK) 
Table 3-14 A table corresponed to pCMV-Tag4 vector features and its postion lists
 
  
150 
 
pCMV-Sport6 cloning vector: 
The cloned Homo sapiens glutamate receptor, AMPA receptor subunit 2 (GRIA2) into 
mammalian expression vector pCMV-Sport6 was also provided (IMAGE: 4215347; Source 
BioScience, UK). pCMV-Sport6 vector contained GRIA2 was ready to express in mammalian 
cells, as it contains CMV and SV40 regions (Figure 3-11).  
 
Figure 3-11 Circular map of the pCMV-Sport6 vector (Taken from Invitrogen, UK) 
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pCI-SEP-GluR2 (R) cloning vector: 
The cloned Rattus norvegicus glutamate receptor, AMPA receptor subunit 2 (Gria2) into 
mammalian expression vector pCI containing super-ecliptic pHluorin (SEP) coding sequence 
was provided from Addgene (Plasmid 24002). The SEP coding sequence was inserted three 
amino acids downstream of the predicted signal peptide cleavage site of the corresponding 
AMPAR subunit 2. The resultant product was then inserted into the pCI (Promega, Madison, 
WI) to generate pCI-SEP-GluR2 as shown in Figure 3-12. 
 
Figure 3-12 Circular map of the pCI vector (Taken from Promega, Madison, WI) 
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Signal peptide in Gria2 was added to ensure that peptide sequences destined for either 
secretion or membrane integration cannot fold or misfold in the cytosol. Generally, cell 
surface membrane or secretory proteins such as AMPA receptors are directed to the 
endoplasmic reticulum (ER) following their translation (Higy et al. 2004). Hence, the 
presence of a signal peptide for targeting proteins to the ER is required, which is a small 
hydrophobic region of between 7 – 25 amino acids located at the N-terminus of that protein 
(Dev and Ray 1990). Initially, the signal peptide is translated by the ribosome, where it binds 
to a signal recognition particle (SRP). The binding of SRP transiently arrests translation and 
migrate the ribosome-SRP complex to the ER membrane via binding of SRP receptor 
(Gilmore et al. 1982, Walter and Blobel 1982). Once the complex arrived in the ER 
membrane, the signal peptide is cleaved, and the protein translation resumes (Connolly and 
Gilmore 1989). In this case, a predicted signal peptide sequence of 21 amino acids was 
located at the extreme N-terminal end of Gria2 (Everts et al. 1997) 
SEP is an enhanced version of ecliptic pHluorin (EP), which is a pH-sensitive variant of 
green fluorescence protein (GFP). Generally, the excitation profile of native GFP possesses 
with a major peak at 395 nm and a minor peak at 475 nm measured with an emission 
maximum at 509 nm. In contrast, EP is almost invisible at pH values less than 6.0 (acidic 
conditions), but the fluorescence intensity increases with pH up to a maximum of 8.5 (Ashby 
et al. 2004, Miesenbock et al. 1998). For instance, targeted expression of EP to acidic 
secretory vesicles allows the real-time analysis of the exocytotic fusion of these vesicles to 
the plasma membrane where the pH becomes neutral, resulting in a corresponding increase in 
fluorescence. SEP tagging is generally applied for visualising AMPARs on the surface of 
neurons (Sankaranarayanan et al. 2000). The enhanced version of pH-sensitive GFP variant 
exhibits much brighter fluorescence compared to the EP. Thus, a chimera of SEP fused to the 
N-terminus of Gria2 (SEP-Gria2) acts as a marker for surface-expressed receptor.  
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pTagRFP-C cloning vector: 
pTagRFP-C is a mammalian expression vector encoding red (orange) fluorescent protein 
TagRFP. The vector allows generation of fusions to the TagRFP C-terminus and expression 
of TagRFP fusion protein in mammalian cells (Figure 3-13). TagRFP codon usage is 
optimised for high expression in mammalian cells: Kozak consensus translation initiation site 
is generated upstream of the TagRFP coding sequence to increase mRNA translation 
efficiency. A multiple cloning site is located between TagRFP coding sequence and SV40 
polyadenylation signal (SV40 polyA). Finally, the CMV promoter region provides strong, 
constitutive expression of TagRFP.   
The vector backbone contains immediate early promoter of cytomegalovirus (pCMV-IE) for 
protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-
antigen, pUC origin of replication for propagation in E.coli, and f1 origin for single stranded 
DNA production. SV40 polyadenylation signals (SV40 poly A) direct proper processing of 
the 3’-end of the reporter mRNA. SV40 early promoter (pSV40) provides neomycin 
resistance gene (Neo) expression to select stably transfected eukaryotic cells using G418. 
Bacterial promoter (P) provides kanamycin resistance gene expression (Kan) in E. coli.  
Homo sapience CACNG5 cDNA was also sub-cloned into MCS of this vector. It was 
expressed as a fusion to the TagRFP C-terminus when inserted in the same reading frame as 
tagRFP and no in-frame stop codons were present (more detail is described in section 3.3.2).  
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Figure 3-13 Circular map of the pTagRFP-C vector (Taken from Evrogen, UK) 
3.3.2 Sub-cloning of CACNG5 inserts into pCMV-Tag4 vectors via traditional 
restriction sites 
Upon sequence verification of the pCR4-TOPO clones containing 926 bp of CACNG5 cDNA, 
this inert was subcloned into pCMV-Tag4 as destination vector resulting in a wild-type of 
CACNG5 construct. pCMV-Tag4 vector was chosen, because of their basal transcriptional 
level difference between these two vectors. pCR4-TOPO vector lacks a constitutive promoter 
sequence result in low transcriptional level; by contrast, pCMV-Tag4 presents an SV-40 
derived promoter and cytomegalovirus CMV promoter sequence to increase its 
transcriptional level. Two double digestion reactions using restriction enzymes (Pst1 and 
Not1) common to the pCR4-TOPO and pCMV-Tag4 vector of interest were performed. This 
process was to cut out the insert from the pCR4-TOPO vector and also cleave the pCMV-
Tag4 vector. The restriction enzyme digest was performed in a volume of 20 µl consisting of 
2 µl of 10X restriction enzyme buffer, 0.2 µl of acetylated BSA (10 µg/µl), 1 µl of plasmid 
DNA (1 µg/µl) and 14.8 µl of sterile deionised water, and finally a 1 µl of each restriction 
enzyme (10 U/ µl).  
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Figure 3-14 Restriction digestion of both pCMV-Tag4 and pCR4-TOPO for subcloning 
The mixture in the tube was mixed gently by pipetting and spun briefly and incubated at 37ºC 
for 4 hours. In the double restriction enzyme digestion, the most optimal buffer for the 
activity of both enzymes was applied according to Promega Relative activity of Restriction 
Enzyme Buffer Guideline. The additional acetylated BSA in the digestion reaction was to 
stabilise the enzymes by protecting them from proteases, non-specific adsorption and harmful 
environmental factors such as heat, surface tension and interfering substances. After 4 hours 
incubation, the digested reaction mix was analysed by 1% agarose gel electrophoresis (see 
above) to confirm complete cleavage of the plasmid DNA and excision of the insert from the 
vector. Successful digestion of the pCR4-TOPO vector showed two bands of appropriate 
sizes for the vector and the insert on the gel (Figure 3-14 upper panel) and one clear band for 
the cleaved pCMV-Tag4 vector (Figure 3-14 bottom panel). The principle of DNA fragments 
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migration in agarose gel confirmed the supercoiled plasmids as uncut pCMV-Tag4 migrated 
more rapidly than linear plasmids as cleaved pCMV-Tag (Figure 3-14 bottom panel).  
After gel confirmation, the 926 bp insert and 4,319 bp cleaved pCMV-Tag4 vector were then 
extracted directly from the gel using QIAquick Gel Extraction Kit (Qiagen, UK) according to 
their manufacturer’s instructions. The extracted DNA was then quantified using NanoDrop® 
ND-1000 Spectrophotometer (Thermo-Scientific, UK), and ligated using T4 DNA ligase 
(Promega, UK).  
3.3.2.1 Ligation reaction of insert into pCMV-Tag4 vector 
Initially the sticky ends 926 bp CACNG5 digestion product was cloned into the pCMV-Tag4 
sticky cloning vector following the protocol described below. A 3:1 molar ratio of 
insert:vector DNA was applied, and the amount of insert and vector was calculated using the 
formula showed as below: 
 
The ligation reactions were performed at 4ºC overnight with a 10 µl volume of ligation mix 
consisting of 200 ng of pCMV-Tag4 vector, 35.33 ng of CACNG5 insert, 1 µl of ligase buffer, 
1 µl of T4 DNA ligase (3 u/µl), and deionised water. After the ligation reaction, the ligation 
mix was then used to transform 50 µl of maximum efficiency DH5α/XL-10 Gold competent 
cells according to the standard protocol described below in section 3.3.2.2. 
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3.3.2.2  Transformation 
50 µl of Max efficiency DH5α E. coli competent cells (Invitrogen) was briefly thawed on ice 
and transformed with 3 µl of the ligation mixture and incubated on ice for 30 minutes. After 
the incubation, a 42ºC heat-shock was performed in a water bath for 45 seconds. The cells 
were immediately placed back on ice for 2 minutes. Then the cells were added to 450 µl of 
room temperature S.O.C medium and placed in a shaking incubator at 37ºC for one hour at 
225 rpm. Once the incubation time had elapsed, aliquots of 50 µl, 100 µl, and 200 µl of cells 
were spread on LB agar plates (LB media containing 1.5% agar under sterile conditions) 
containing 100 µg/ml kanamycin. Additional aliquots of 100 µl of competent cells were 
transformed in parallel with 50 pg of control DNA (pUC19) to determine the transformation 
efficiency. The plates were then inverted and incubated overnight at 37ºC. Successfully 
transformed colonies survived on LB-amp agar plates due to the selection with kanamycin. 
Colony PCR of the transformed colonies was then used screen for the presence of the cloned 
insert.  
3.3.2.3 Colony PCR for confirmation of the presence of the cloned insert 
The simplest and most time efficient method for screening plasmid inserts directly from 
bacterial colonies is colony PCR. The transformed colony on the plate was picked up using a 
sterile 10 µl pipette tip and dipped in a 96-well plate containing 5 µl of PCR water. And the 
tip was then used to inoculate into a fresh 15 ml falcon tube containing 3 ml of LB (Luria-
Bertani) medium broth with kanamycin. For amplification of the 926 bp product, the PCR 
master mix was prepared as described in Table 3-7, and added to a 96-well plate containing 
colony cells. The optimum cycling conditions were applied based on the insert of interest. 
After the PCR amplification, the fragments were run on 1% agarose gel to determine their 
specificity (Figure 3-15).  
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Figure 3-15 Identification of pCMV-Tag4 clones containing 926 bp CACNG5 cDNA by 
colony PCR. Lanes 1 and 18 representing Hyperladder I; Lanes 2-17, randomly selected 
pCMV-Tag4 clones for screening 
3.3.2.4 Sequence verification of plasmid DNA 
The inoculated falcon tubes containing single transformed colonies carrying with the vector 
along with the insert were grown overnight in a shaker with 225 rpm at 37ºC. On the next day, 
the plasmid was isolated from the cultures using QIAprep Spin Miniprep Kit (Qiagen, UK) 
based on the manufacturer’s protocol. The quantification of plasmid DNA was then applied 
using a NanoDrop® ND-1000 or NanoDrop 2000 Spectrophotometer (Thermo-Scientific, 
UK), and then sequenced at the Scientific Support Services at the Wolfson Institute for 
Biomedical Research (WIBR), UCL using CACNG5 exon 3 forward and reverse primers.  
3.3.3 Sub-cloning of CACNG5 inserts into pTagRFP-C vector via PCR amplification 
The advantages of applying additional red fluorescent tag protein (RFP) sequence at the N-
terminus of CACNG5 sequence is to allow the visualization of CACNG5 proteins using both 
fixed and live cell images of fluorescent microscopy. Hence, the PCR forward primer was 
designed to include an ATG codon for an open reading frame site between REP sequence and 
CACNG5 starting coding region. In this way, the transfection efficiency of CACNG5 can be 
detected via fluorescence-activated cell sorting (section 3.5.2), and the appropriate antibodies 
can also target to RFP for western blot (section 3.5.5).  
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3.3.3.1 Amplification of a 894 bp CACNG5 with Xhol1 and EcoR1 restriction sites 
A 894 bp CACNG5 without non-coding region PCR product with Xhol1 and EcoR1 
restriction sites were amplified using the primers showed below (Sigma-Aldrich, UK) 
Forward Primer = 5’- TCAGATCTCGAGGAATGAGTGCC – 3’ 
Reverse Primer = 5’ – ACTGCAGAATTCTCAGCAGGGTGAAGA – 3’ 
The master mix for PCR amplification consisting of 7.5 µl of 10X Pfx amplification buffer, 
7.5 µl of 10X enhancer buffer, 0.5 µl of 50 mM MgSo4, 0.3 µl of 25 mM dNTPs, 1 µl each of 
10 pmol/µl forward and reverse primers, 0.4 µl of Platinum® Pfx DNA polymerase 
(Invitrogen, UK) and PCR water so added to a final volume of 23 µl and then dispensed into 
a 96-well plate containing 2 µl of 10 ng CACNG5 insert. Platinum® Pfx DNA polymerase is 
a highly processive polymerase that possesses proofreading 3’ to 5’ exonuclease activity with 
fast chain extension capability. Polymerase activity was restored after a PCR denaturation 
step, where providing an automatic “hot start” for increased specificity, sensitivity, and yield 
of the PCR product. Both the vector and insert were denatured at 94ºC for 5 minutes initially, 
and the PCR amplification was performed with 30 cycles of three steps cycling involving: 
denaturation at 95ºC for 15 seconds, annealing at 55ºC for 30 seconds, and extension at 68ºC 
for 5 minute and 30 second. The last extension was at 72ºC for 2 minutes and 30 second, and 
then maintained the reaction at 4ºC. The size of the amplified fragment was further confirmed 
by running a 1% agarose gel with ethidium bromide and hyperladder I as the size marker 
(Figure 3-16).  
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Figure 3-16 Verification of amplified fragment containing 894 bp CACNG5 insert. Lane 
1 Hyperladder I; Lanes 2-7 represent amplified CACNG5 insert with different master 
mix conditions 
Upon verification, the amplified fragment band was extracted from the gel using Qiagen 
MinElute Gel Extraction Kit (Qiagen, UK) according to the manufacture’s instruction. The 
purified amplified fragment was rehydrated with PCR water, and quantified using a 
NanoDrop 2000 Spectrophotometer (Thermo-Scientific, UK). And the sequence verification 
was performed at the WIBR, UCL using CACNG5 exon 2 reverse and exon 4 forward 
primers.  
3.3.3.2 Sub-cloning of the CACNG5 inserts into pTagRFP-C vectors 
Before sub-cloning the amplified CACNG5 inserts, pTagRFP-C vectors were cleaved via 
traditional restriction enzyme digestion as described in section 3.3.2. Double restriction 
enzyme digestion was performed using both Xhol1 and EcoR1 enzyme for vectors cleavage. 
After gel and sequence verification of both inserts and vector, ligation reactions were carried 
out using T4 DNA ligase as described in section 3.3.2.1. The plasmids were propagated in 
DH5α /XL-10 Gold competent cells according to the protocol described in section 3.3.2.2 and 
isolated using Qiagen miniprep kits. The plasmid DNA was then verified by sequencing at 
WIBR, UCL 
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3.3.4 Mutating the CACNG5 gene with each variant individually 
To investigate the effect of CACNG5 variants found in UCL case/control samples, each 
single base of non-synonymous mutation was introduced in into both wild-type CACNG5 
constructs via site-directed mutagenesis using the QuikChange II XL mutagenesis kit 
Strategene, UK) according to the manufacturer’s instructions. The primer for mutating 
CACNG5 constructs were designed using QuikChange Primer Design Program website 
available online at www.agilent.com/genomics/qcpd and briefly described in section 3.3.4.1.  
3.3.4.1 Primer designed for mutating CACNG5 constructs 
Each pair of primers contained a non-overlapping sequence at the 3’-terminus and a primer-
primer complementary (overlapping) sequence at the 5’-terminus. The non-overlapping 
sequence was significantly larger than the overlapping to make the melting temperature of the 
former higher than that of the latter. The primers that were used for mutagenesis are listed in 
Table 3-14. These primers targeted residues R69W, R71H, R127H, T128M, V146M, T164L, 
and H233Y.  
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Table 3-15 Primer sets for CACNG5 constructs site-directed mutagenesis 
cacaggtgaggagtgggggcgttgctt
antisense -aagcaacgcccccactcctcacctgtg
gaggagcgggggcattgcttcaccatag
antisense -ctatggtgaagcaatgcccccgctcctc
atccgtccccaccagacgatactggcc
antisense -ggccagtatcgtctggtggggacggat
ccgtccccaccggatgatactggcctttg
antisense -caaaggccagtatcatccggtggggacgg
ggcctctctctcatggtgggcctgg
antisense -ccaggcccaccatgagagagaggcc
tgctctacatctccagcttcaacgatgagatgctc
antisense -gagcatctcatcgttgaagctggagatgtagagca
gagatgctcaacaggatcaaggatgcagagacc
antisense -ggtctctgcatccttgatcctgttgagcatctc
attactcaggccagttcctatacccagacgcc
antisense -ggcgtctgggtataggaactggcctgagtaat
Ile156Phe c.526 A>T
Thr164Leu c.551 C>T
His233Tyr c.757 C>T
Arg127Gln c.440 G>A
Thr128Met c.443 C>T
Val146Met c.496 A>G
Amino Acid 
Change
Nucleotide 
Change
Primer Sequence (5' to 3')
Arg69Trp c.265 C>T
Arg71His c.272 G>A
 
3.3.4.2 Site-directed mutagenesis 
Site-directed mutagenesis primers were purchased from Sigma (UK) with addition high-
performance liquid chromatography (HPLC) purification. The primers were reconstituted 
with PCR water. The synthesis reaction of mutant strand was performed by reaction mix 
consisting of 5 µl of 10X reaction buffer, 10 ng of wild type CACNG5 plasmid DNA, 125 ng 
of forward and reverse primers, 1 µl of dNTP mix, 3 µl of QuickSolution and PCR water to a 
final volume of 50 µl in a 96-well PCR plate. At the end, 1 µl of Pfu Ultra HF DNA 
polumerase (2.5U/µl) was added to the reaction mix and mixed gently. The samples were 
then placed in a PCR machine using the cycling conditions described in Table 3-15.  
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Table 3-16 The PCR cycling conditions for CACNG5 constructs site-directed 
mutagenesis 
Cycles Temperature Time
1 95°C 1 minute
18 95°C 50 seconds
60°C 50 seconds
68°C 5 minute and 30 seconds
1 68°C 7 minutes  
After the site-directed mutagenesis, the mutated plasmid DNA was transformed into E.coli as 
described above. The presence of the mutation was verified by DNA sequence analysis as 
described above.  
3.3.5 Large-scale preparation of plasmid DNA 
For transfection experiments, large-scale plasmid DNA preparations were performed using 
25 ml LB medium containing appropriate antibiotic cultures inoculated with 50 µl of starting 
culture (the colonies growth culture) and grown overnight. The plasmid DNA was then 
extracted using QIAfilter Plasmid Midi Kit (Qiagen, UK) according to the manufacturer’s 
instructions.  
3.3.6 Preparation of bacterial glycerol stocks for long-term storage of clones 
After a single colony was inoculated in 3 ml of LB medium with appropriate antibiotic for 
overnight at 37C, 500 µl of the growth culture was added to equal volume of 80% sterile 
glycerol in a sterile screw cap tube. The glycerol stock was then mixed well with vortex and 
then stored at -80C. Meanwhile, the plasmid DNA was also isolated from 1 ml of the same 
growth culture using Qiagen miniprep kit, and then verified by sequence for confirmation.  
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3.4 Functional characterisation of CACNG5 non-synonymous variants 
3.4.1 Animal cell-culture 
3.4.1.1 Cell-line 
Human embryonic kidney 293 cells HEK293 cells were used in this study. HEK293 cells 
were provided from Queen Mary University of Cancer research department. HEK293 cells 
were originally from the transformation of human embryonic kidney cells with sheared 
fragments of human adenovirus type 5 (Ad5) DNA in 1977 by Graham, Smiley, Russell, and 
Nairn (Graham et al. 1977). The SH-SY5Y cell line was used in the preliminary experiments. 
The SH-SY5Y cell line was originally isolated from a bone marrow biopsy of a 
neuroblastoma patient, called SK-N-SH. However, because of their low transfection 
efficiency, it was not used to our main functional experiments.   
3.4.1.2 Sub-culturing mammalian cells 
Solutions required: 
 Growth medium composition: Fetal Bovine Serum (FBS; Gibco-Invitrogen, UK), 
10%; 5,000 units/ml penicillin and 5,000 g/ml streptomycin (Pen/Strep; Gibco-
Invitrogen, UK), 1%; all added directly to a 500 ml bottle of high glucose (with 4,500 
mg/L glucose) Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich, Poole, 
UK), which was then mixed by carefully pipetting up and down several times. 
 Trypsin-EDTA solution (Sigma-Aldrich, UK) 
 1 X Phosphate buffered saline (PBS) (Sigma-Aldrich, UK) 
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Subculturing protocol: 
Cultured cells were viewed using an inverted low power microscope to assess the degree of 
confluency and confirm the absence of bacterial and fungal contaminants. When cells 
reached to 75 – 95% confluent, the cells were split or sub-cultured using the procedure shown 
below: 
1. Culture media from the tissue culture flask was aspirated and the cell monolayer was 
then washed with PBS containing additional MgCl2 and CaCl2 to remove all serum.  
2. 2 ml of 1X trypsin-EDTA solution was added to the cell culture and left for no more 
than 2 minutes to disaggregate cells. Additional tapping the side of the flask could 
help disaggregation.  
3. After trypsin-EDTA treatment for 2 minutes, 10 ml of fresh culture medium was 
added to the flask to stop its reaction.  
4. The suspended cells were aspirated into a new 15 ml falcon tube, and spun in a 
centrifuge at 1,500 rpm for 5 minutes. 
5. The cell pellet was then re-suspended in 10 ml fresh culture medium. 
6. 1 ml of the cell suspension was added into a 9 ml of fresh culture medium in a 75 cm2 
flask for cell seeding.  
7. The flask was then gently swirled to mix and incubated at 37C/ 5% CO2 for 
approximately 3 – 4 days until cells were 75% - 95% confluent. 
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3.4.1.3 Mammalian cell quantification  
Materials required: 
 0.4% Trypan blue solution (Sigma): Trypan blue is a vital stain that used to 
differentiate cell viability. The intact cell membranes of live cells are very selective in 
the compounds that pass through the membrane; hence, a viable cell is not absorbed 
cell trypan blue. By contrast, when the cell membrane is damaged, dead cells are 
appeared as a distinctive blue colour.  
 Neubauer hemocytometer 
 Microscope 
Background: 
A haemocytometer is used to estimate the number of viable cells under a microscope, which 
originally is designed for counting of blood cells. The improved Neubauer haemocytometer is 
a thick glass microscope side with two rectangular indentations that creates two counting 
chambers, and the main divisions separate each chamber into nine large squares (Figure 3-17). 
The gridded area of the haemocytometer consists of several 1 mm
2
 surface area and 0.1 mm 
depth. With the coverslip in place, each square of the haemocytometer represents a total 
volume of 0.1 mm
3
 or 10
-4
 cm
3 
(1 cm
3
 = 1 ml). For cell counting, the cell suspension is 
diluted in order to avoid clumps of cells. The cells are then mixed thoroughly to ensure a 
uniform distribution. The concentration of cell per ml was determined using the following 
equation:  
Cells per ml = the average count of cells per square x the dilution factor x 10
4 
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Figure 3-17 A diagram of the improved Neubauer haemocytometer. Panel A left 
represents as top view of haemocytometer; Panel A right represents as side view of 
haemocytometer; Panel B represents as haemocytometer grid, each one of blue square 
has a 1.0 mm
2
 surface area and a 0.1 mm
3
 volume. 
Cell counting protocol: 
Before cell counting, both the haemocytometer and the coverslip was cleaned using 70% 
ethanol. The coverslip was moistened by exhaled breath on the surface, and then it was slide 
over the chamber back and forth using gentle downward pressure. The cell suspension was 
prepared using the subculturing protocol described above, and a 100 µl of cell suspension 
was then dispensed into a sterile microcentrifuge tube. An equal volume of Trypan Blue 
solution (dilution factor = 2) was added to the cell suspension in the microcentrifuge tube and 
mixed gently by pipetting. Both sides of the chamber were filled with mixed aliquot (10 - 20 
µl) of cell suspension containing Trypan Blue solution via capillary diffusion. Finally, the 
haemocytometer was viewed under the light microscope using x20 magnification. 
Analytically, both viable and non-viable cells in the four corner squares were counted 
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excluding the cells lying on the outer perimeter. The concentration of viable and non-viable 
cells and the percentage of viable cells were calculated using the equations as shown below: 
Viable Cell count = Average live cell count x dilution factor x 10
4
 
Non-viable cell count = Average dead cell count x dilution factor x 10
4
 
Percentage Viability = Viable cell count / Total cell count x 100 
3.4.1.4 Preservation of mammalian cell-line 
Preservation of cell cultures was used to maintain supplies of cell and to provide a backup 
supply of cells, in case of contamination or to have a stock of cells with a lower passage 
number. The preservation cells are when they are at their maximum growth rate to help in 
good recovery during the thawing of cells. Two ways of preservation were used in this thesis: 
cryogenic preservation and Bambanker
TM
 cryopreservation. 
3.4.1.4.1 Cryogenic preservation of cell-line 
Solution required:  
 Freeze medium consisting of 20% FBS, 10% DMSO and 1% PenStrep in DMEM 
growth medium 
Crypgenic preservation protocol: 
The freezing medium containing DMSO (Sigma, UK) is a cryoprotective reagent that reduces 
the freezing point of the culture medium, and also allows a slower cooling rate to reduce the 
risk of damaging cells from ice crystal formation. The cells were harvested using the standard 
subculturing protocol described above, and suspended in 2.5 ml of DMEM supplemented 
with 20% FBS and 1% Penstrep. After that, a 20% DMSO was added to another fresh falcon 
tube containing 2.5 ml of DMEM supplemented with 20% FBS and 1% Penstrep. This 
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medium was then slowly added to the tube containing cells drop by drop, and gently mixed. 1 
ml aliquots of this cell suspension was transferred into 1.5 ml cryogenic vials (Nunc, UK) 
that was labelled with the cell line name, passage number, cell concentration and date.  The 
cells containing cryogenic vials were stored in a freezer container, Nalgene®, Mr.Frosty 
(Sigma-Aldrich, UK) at -80C. This freezer container is made of polycarbonate, which has a 
blue high-density polyethylene closure and a white high-density polyethylene via holder and 
foam insert to provide a critical, repeatable, 1C/min cooling rate. This specific cooling rate 
is required for successful cryogenic preservation of cells. Additionally, a day before 
preservation procedure, the cryogenic container was filled with isopropyl alcohol overnight at 
-20C.  This preservation protocol can store cell-line at -80C up to 6 months.  
3.4.1.4.2 BambankerTM cryopreservation of cell lines 
The freezing medium Bambanker
TM
 was originally developed by the Japanese company 
Lymphotec, where they required a suitable medium for long-term storage of highly sensitive 
cell lines, such as lymphocytes. To date, cell freezing medium Bambanker
TM
 has been 
demonstrated in many different published articles, to allow the preservation of a high number 
of intact cells after thawing. The recovery rate of even sensitive cells is much higher 
compared to traditional media.  
Solution required:  
 BambankerTM freezing medium (NIPPON Genetics EUROPE GmbH, Germany) 
Bambanker
TM
 cryopreservation protocol: 
The freezing medium Bambanker
TM
 is a serum-free medium for long-term storage of cells at 
-80C. The cells were harvested using the standard subculturing protocol described above, 
but suspended in 1 ml of Bambnker
TM
 and placed the cells in cryo tubes that suitable for 
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freezing and preservation. Then, the cells are ready to freeze and preserve in -80C without 
preliminary freezing.  
3.4.1.5 Resuscitation of frozen cell lines 
The frozen stock cells is required a quickly thawing procedure to maximise the recovery of 
cells and minimise the loss of cells from the presence of DMSO in the freezing medium. 
Cryogenic vials were taken from -80C freezers and immediately warmed up in a 37C water 
bath for less than a minute. 
Frozen cells persevered in medium containing DMSO: 
The 1 ml of stock cells in cryogenic vial were transferred into a fresh 15 ml falcon tube 
containing 5 ml pre-warmed growth medium and mixed gently by pipetting. 
Frozen cells preserved in Bambanker
TM
 medium: 
The 1 ml of stock cells in Bambanker freezing medium were suspended into a fresh 15 ml 
falcon tube containing 10 ml pre-warmed growth medium, and mixed gently.   
The cells were then centrifuged at 1500 rpm for 3 minutes and the supernatant discarded.  
The cell pellet was resuspended in 1 ml of growth medium and then transferred into a 75 ml 
tissue culture T-flask containing 9 ml of complete growth medium. Cells were viewed under 
the microscope to check for their presence and then incubated in a humidified atmosphere of 
5% CO2 at 37C until 75 – 95% confluency was reached. 
3.4.2 Transfection  
Transfection is the most common method for introducing new functional DNA sequences 
into cultured animal cells either transiently or stably. The transfected cells can then gain the 
ability to express one or more proteins. Transfection involves the use of chemical or physical 
tricks to persuade cells to take up DNA from the culture medium, the DNA eventually 
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finding its way to the nucleus. There are numerous different transfection methods including: 
chemical transfection, liposome-mediated transfection, lipofection, electroporation, and 
receptor-mediated endocytosis. Nowadays, different types of transfection are commercially 
available, and more details of transfection are described in Appendix I.   
3.4.2.1 Lipofectamine® 2000 transfection  
Reagents required:  
 Lipofectamine® 2000 (Invitrogen Life technologies, UK) 
 DMEM supplemented with 10% FBS and with or without 1% Penstrep 
 Opti-MEM® I Reduced Serum Medium as serum-free culture medium for complex 
formation 
Background: 
Lipofectamine® 2000 is the most common transfection reagent used mainly in molecular and 
cellular biology, which is provided by Invitrogen. It is a cationic liposome based reagent that 
provides high transfection efficiency and high levels of transgene expression in a range of 
mammalian cell types. Optimum transfection efficiency and subsequent cell viability depend 
on a number of experimental variables such as cell density, liposome and DNA 
concentrations, liposome-DNA complexing time, and the presence or absence of media 
components such as antibiotics and serum. The important of these factors in Lipofectamine® 
2000 mediated transfection is discussed in Appendix I.   
Transfection protocol: 
A day before transfection, HEK293 cells were seeded 2 x 10
5
 cells per well in 2 ml of 
antibiotic-free culture medium (DMEM + 10% FBS) in 6 wells plates. The plates were then 
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incubated at 37ºC with 5% CO2, and were attained 90 – 95% confluence at the time of 
transfection.  
On the transfection day, the transfection complexes (DNA-lipofectamine® 2000 complexes) 
were prepared for each transfection sample. First, plasmid DNA was diluted in 500 µl of 
Opti-MEM®I Reduced Serum Medium, and placed in a 1.5 ml of microcentrifuge tube. The 
stock of lipofectamine® 2000 was gently mixed before it was diluted in another 500 µl of 
Opti-MEM®I Medium and then incubated for 5 minutes at room temperature. After 
incubation, the diluted DNA was combined with diluted Lipofectamine®2000, and then 
mixed gently and incubated for another 20 minutes at room temperature to allow the DNA-
Lipofectamine® 2000 lipoplexes to form. 1000 µl of transfection complexes were then added 
to each well containing cells and medium, and this was mixed gently by rocking the plate 
back and forth. The cells were incubated at 37ºC in a humidified incubator with 5% CO2. The 
medium was changed after 6 hours of incubation with complete growth medium (DMEM + 
10% FBS + 1% Penstrep) and the cell were incubated for further 24 hours until they were 
ready for expression analysis.  
3.4.2.2 FuGENE® 6 transfection 
Solution required: 
 FuGENE® 6 Transfection reagent (Promega, UK) 
 DMEM supplemented with 10% FBS and with or without 1% Penstrep 
 Opti-MEM® I Reduced Serum Medium 
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Background: 
FuGENE® 6 transfection is also the most common reagent to be used for cellular transfection. 
It is a nonliposomal reagent transfects DNA into a wide variety of cell lines with high 
efficiency and low toxicity (more details are shown in Appendix 1) 
Transfection protocol: 
A day before transfection, HEK293 cells were seeded 1 x 10
5
 cells per well in 500 µl of 
antibiotic-free culture medium (DMEM + 10% FBS) in 24 wells plates. The plates were then 
incubated at 37ºC with 5% CO2, and were 90 – 95% confluent at the time of transfection. 
On the transfection day, the vial of FuGENE® 6 Transfection reagent was warmed up to the 
room temperature and mixed by inverting the vial briefly. And the transfection optimisation 
was prepared using 10 µg of DNA per well at various ratios of FuGENE® 6 Transfection 
reagent to DNA (Table 3-17).  
Table 3-17 Optimisation protocol using varying ratios of FuGENE® 6 Transfection 
reagent to DNA 
6:1 4:1 3:1 1.5:1
A final volume of medium in a well 500 µl 500 µl 500 µl 500 µl
DNA amount 10 µg 10 µg 10 µg 10 µg
Volume of FuGENE 6 Transfection Reagent 60 µl 40 µl 30 µl 15 µl
Ratio of FuGENE Transfection Reagent to DNA
 
The varying amount of FuGENE® 6 transfection reagent was added into the 1.5 ml of 
microcentrifuge tube containing 500 µl of Opti-MEM medium (Table 3-17). This FuGENE® 
6 transfection reagent/medium mixture was mixed gently by pipetting, and incubated at room 
temperature for 5 minutes. After this incubation, 10 µg of plasmid DNA was added to the 
mixture of FuGENE® 6 transfection reagent/medium, and mixed immediately and incubated 
again for 15 minutes at room temperature. After 15 minutes incubation, 25 µl of the 
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FuGENE® 6 transfection reagent/DNA mixture was added to each well of a 24-well plate 
containing 500 µl of cells in growth medium. The cells containing 24-well plate was mixed 
gently and returned to the 37ºC humidified incubator with 5% CO
2
 for 24 hours until they 
were ready to be analysed.  
Live cell images of co-transfected HEK293 cells were then taken by a Zeiss AXIO Observer 
microscope equipped with a temperature-controlled stage at 37C.  
3.4.3 Protein isolation 
Protein extraction or isolation involved an initial step of cell lysis, where the cell membrane 
was disrupted and the cellular contents were extracted. Historically, physical lysis was the 
common method for protein extraction; however, it often requires expensive, cumbersome 
equipment, and is not conducive for high throughput analysis. In recently years, detergent-
based lysis methods have become the best choice. Different detergent-based solutions 
composed of particular types and concentrations of detergents, buffers, salts and reducing 
agents have been developed to provide the best possible protein yielding for particular types 
of cells and proteins. For instance, non-ionic detergent such as Triton X-100 has uncharged 
and hydrophilic headgroups, which are considered mild surfactants as they break protein-lipid, 
lipid-lipid interactions, and most of them do not denature proteins. Therefore, non-ionic 
detergent was preferred for the isolation of membrane proteins, such as TARP and AMPA 
receptor proteins.  
3.4.3.1 Cell lysis  
Buffers and solutions required: 
 2 M Tris-HCl buffer: Trizma® hydrochloride (Sigma, UK) 
 0.5 M NaCl buffer: sodium chloride (Sigma, UK) 
 0.5 M EDTA: ethylene diamine tetraacetic acid (Sigma, UK) 
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 Radio-immunoprecipitation assay buffer (RIPA): 50 mM Tris-HCl (pH7.6), 150 mM 
NaCl, 1 mM EDTA (pH 8)  
 Complete protease inhibitor mixture tablet (Roche, UK) 
 PhosSTOP inhibitor tablet (Roche, UK) 
 Triton X-100 (Sigma, UK) 
 1X PBS 
Efficient solubilisation of most receptor proteins is achieved when cells are lysed in standard 
RIPA buffer containing both protease and phosphatise inhibitors. Before cell lysis, the 
standard RIPA buffer were prepared as a stock, which was filter sterilised using 0.2 µm 
membrane filter and stored at 4C. After 24 hours transfection, the HEK293 cells were 
observed under live cell fluorescent microscopy to confirm the presence of AMPAR and 
TARP proteins. Then, the growth medium was removed and the cells were washed with cold 
1X PBS for twice. 100 µl of RIPA lysis buffer containing 0.1% Triton X-100 and pluses both 
1X protease and phosphatise inhibitors was added to each well containing transfected cells. 
The cells were harvested into pre-chilled 1.5 ml eppendorf tubes using cell scrapers (Nunc, 
UK). The lysates were then left to solubilise at 4C with continuous agitation for 30 minutes. 
After solubilisation, cell and nuclear debris were removed by centrifugation at 13,000 rpm for 
20 minutes. The clarified supernatant (protein extract) was then transferred to a new 1.5 ml 
microcentrifuge tube. Protein concentrations were determined using a Bradford reagent assay 
and Qubit® 2.0 protein assay as described in section 3.4.4.2.  
3.4.3.2 Determination of protein concentration 
Two ways of protein concentration determination, Bradford assay and Qubit® 2.0 protein 
assay, were applied in this thesis, and are described in next section.  
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3.4.3.2.1 Bradford assay 
The principle of Bradford reagent assay is based on the formation of a complex between the 
day, Brilliant Blue G, and proteins in solution. This protein-dye complex causes a shift in the 
absorption maximum of the dye from 465 to 595 nm. The amount of absorption is 
proportional to the protein present. The linear concentration range is 0.1 – 1.4 mg/ml of 
protein, using BSA (bovin serum albumin) as the standard protein.  
Equipment and Solution required: 
 Spectrophotometer capable of measuring absorbance in the 595 nm region 
 3 ml Disposable Plastic Cuvettes 
 Bradford reagent (Sigma, UK) consists of Brilliant Blue G in phosphoric acid and 
methanol 
 2 mg/ml Protein standard (BSA) salutation (Sigma, UK) 
Standard protein assay protocol: 
The Bradford reagent was gently mixed in the bottle and warmed up to the room temperature. 
The protein standards were created by serially diluting the 2 mg/ml BSA protein (Table 3-18).  
Table 3-18 An example of the standard protein concentration 
1 50 0 1.5
2 50 0.2 1.5
3 50 0.4 1.5
4 50 0.6 1.5
5 50 0.8 1.5
6 50 1 1.5
Tube No. 
Sample 
(µl)
BSA protein 
standard (mg/ml)
Bradford 
Reagent (ml)
 
Each standard protein samples was diluted with the cell lysis buffer; hence, any possible 
interference from the buffer components was compensated for in the protein standards. The 
unknown protein samples were also diluted in 1:10 ratio with the cell lysis. After the dilution 
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of protein samples, 1.5 ml of Bradford reagent was added to each cuvette containing standard 
protein samples, and mixed gently by pipetting. The samples were then incubated at room 
temperature for 25 minutes. The absorbance of each protein samples were measured at 595 
nm and recorded. The unknown protein concentration was then determined by comparison of 
the unknown samples to the standard curve prepared using the protein standards (Table 3-19 
and Figure 3-18).  
Table 3-19 An example of the absorbance of the BSA protein standard 
1 0 0.004
2 0.2 0.412
3 0.4 0.675
4 0.6 0.983
5 0.8 1.126
6 1 1.325
Tube No. 
BSA 
protein A595
 
 
Figure 3-18 An example of the standard curve produced from the protein assay data 
The total concentration of protein present in the original unknown protein solution was 
calculated as follows: 
 (The absorbance of protein samples – 0.1074) / 1.2936 = the concentration of protein 
sample in the cuvette. 
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 The concentration of protein sample in cuvette x 10 = the actual protein concentration 
in the sample.  
3.4.3.2.2 Qubit® 2.0 protein assay 
The Qubit® protein assay kit is designed specifically for use with the Qubit® 2.0 
Fluorometer, but it may also be used with any fluorometer or fluorescence plate reader. The 
principle of the Qubit® 2.0 Fluorometer is using fluorescent dyes to determine the 
concentration of nucleic acids or proteins in sample, which is different to the traditional UV 
(Ultraviolet)-absorbance method. Each dye provided from the manufacture is specific for one 
type of molecule, such as DNA, RNA or protein. The dye has an extremely low fluorescence 
until it binds to its targets (protein). Upon binding, it becomes intensely fluorescent.  
Equipment and Solution required: 
 Qubit® 2.0 Fluorometer (Invitrogen, UK) 
 Qubit® Protein assay kits (Invitrogen, UK) provided concentrated assay reagent, 
dilution buffer, and pre-diluted BSA standards.  
Qubit® protein assay protocol: 
The Qubit® working solution was preprared by diluting the Qubit® protein reagent 1:200 in 
Qubit® protein buffer, and mixed by vortexing. 190 µl of Qubit® working solution was 
loaded into each of the thin wall microcentrifuge tubes used for standards. Then, 10 µl of 
each Qubit® standard was added to the appropriate tube, and mixed by vortexing 2 – 3 
seconds. After that, 195 µl of Qubit® working solution was loaded into individual assay 
tubes and then 5 µl of each sample protein was added to make a final volume 200 µl in each 
sample tubes, and mixed by vortexing 2 – 3 seconds. All the tubes containing protein samples 
and standards were incubated at room temperature for 15 minutes. Meanwhile, the Qubit® 
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2.0 Fluorometer was set to the standards protein assay screen. Before determining the protein 
samples concentration, a standards calibration was required to set. Therefore, each of the 
protein standards was read in the programme according to manufacturer’s instructions. After 
the measurement was completed, a calibration curve was generated by the programme as 
shown in Figure 3-19.  
 
Figure 3-19 An example of the Qubit® 2.0 Fluorometer calculates standard curve and 
sample concentrations 
Since the standard calibration curve was set, the sample proteins were ready to test. The 
concentration of sample proteins was calculated by equation shown below: 
Concentration of unknown protein sample = QF value x (200/X) 
Where QF value = the value given by the Qubit® 2.0 Fluorometer 
X = the number of µl of sample was added to the assay tube 
After the sample measurement was completed, the actual sample protein concentration was 
calculated by selected the dilution factor into the programme.  
Once the concentration of each sample protein was determined, it was either stored at -80C 
for later use or prepared for protein detection by western blot.  
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3.4.3.3 Preparation of sample protein for loading into SDS-PAGE 
Protein detection requires a sensitive antibody to recognise the protein of interest (described 
in more detail in section 3.5). Generally, antibodies only recognise a small portion of the 
protein of interest (often referred to as the epitope), and this domain may reside within the 3-
dimentional (3D) conformation of the protein. To enable access of the antibody to the 
specific epitope, it is necessary to unfold the protein by denaturation. For protein denaturation, 
a loading buffer is required with an anionic denaturing detergent, such as sodium dodecyl 
sulphate (SDS). The sample is then fully denatured by heat. In the presence of SDS, all of the 
proteins become negatively charged by their attachment to the SDS anions. The proteins were 
then denatured by SDS wrapping around its polypeptide backbone leading to a negative 
charge of polypeptide in proportion to its length.  
Solution required: 
 Standard Laemmli 2X buffer (pH 6.8): consisting of 4% SDS, 10% β-
mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-HCl 
Protein denaturation protocol: 
The sample proteins were diluted 1:1 ratio with 2X loading buffer contained the anionic 
denaturing detergent SDS, the disulphide bridge reducer β-mercaptoethanol, glycerol to 
increase the density of the sample to be loaded into the gel, and finally a small anionic dye 
such as bromophenol blue for visualisation (Laemmli 1970). The samples were then mixed 
by vortexing before boiling at 95C for 10 minutes. After denaturing, the protein samples 
were mixed again by vortexing and stored at -20ºC for SDS-PAGE protein separation the 
following day. 
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3.5 Functional characterisation of CACNG5 variants on surface expression of 
AMPAR  
3.5.1 The use of fluorescent proteins 
For over a decade fluorescent proteins (FP) have been widely use as tags to monitor the 
spatial and temporal localisation of a variety of other proteins. The advantage of introducing 
a FP tag protein is to visualise the interested protein under any kind of fluorescent technique, 
such as fluorescence microscopy, confocal, fluorescence cell cytometry. The FP tag protein 
can also be recognised by antibodies. The principal of using FP tag protein is that the 
nucleotide coding sequence is generally fused to the cDNA of the protein of interest, usually 
at its C- or N-terminus (Section 3.3). Then, this fusion protein is expressed in the cell of 
interest for further detection and investigation. 
3.5.2 Fluorescence-activated cell sorting (FACS) 
Fluorescence-activated cell sorting known as FACS is a specialised type of flow cytometry. It 
has been widely used for the analysis of cell identity and fluorescent intensity in large 
numbers of cells. The principle of FACS is to sort a mixture of biological cells into two or 
more distinct groups based upon the specific light scattering and fluorescent characteristics of 
the cells. It is a fast, objective and quantitative of fluorescent signals from individual cells of 
particular interest.  
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Equipment and solution required: 
 BD FACSAriaII (BD Biosciences, UK) 
 FACS buffer: 0.5% FBS, 2 mM EDTA, 0.1% sodium azide (Sigma, UK) in 1X PBS 
solution 
Cell sorting protocol: 
Cells were harvested by trypsinisation, washed and resuspended in FACS buffer to avoid the 
contamination of phenol red for cytometric analysis. Cell sorting for fluorescence protein was 
performed using a FACSArialII flow cytometer equipped with a water-cooled argon laser 
emitting at 488nm. First, a control sample was analysed with a low forward scatter threshold 
to detect transfected cells while ensuring that debris and electronic noise were not captured as 
legitimate events. Then, 10,000 events were collected for each sample by list-mode data that 
consisted of side scatter, forward scatter, and fluorescence scatter. Analysis was performed 
using Kaluza software; Green fluorescence was (FL1) measured using a 530 + 30 nm band 
pass filter and red fluorescence (FL3) was determined with a 630 + 22 band pass filter. Gates 
were set to exclude necrotic cells and cellular debris, and compensation was used to exclude 
overlap between the two signals, where the fluorescence intensity of events within the gated 
regions was quantified. Two distinct populations of cells were visible on the flow histograms; 
therefore, determination of the percentage of transfected cells was based on the inclusion of 
only cells exhibiting high levels of fluorescence and exclusion of cells adjacent to 
autofluorescent, non-fluorescent protein expressed cells.  
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3.5.3 Cell surface biotinylation 
Cell surface biotinylation assays are one of the most valuable techniques to identify cell 
surface proteins. The technique uses a covalent modification of cell surface receptors by the 
addition of biotin. The biotinylated proteins can then be isolated and identified through a 
process of affinity purification followed by SDS-PAGE and Western blotting.  
Biotin is a water-soluble vitamin that covalently bonds to lysine groups at a low temperature 
to inhibit protein endocytosis. Current commercial biotin derivatives, which react with 
primary amines, have been developed to comprise linker regions, in order to minimise steric 
interference and also allow cleavage of the biotinylated molecule. Derivatives of the egg-
white protein avidin that has a high affinity for biotin can be used to efficiently purify 
biotinylated proteins from cellular lysates. The avidin derivatives may be conjugated to silica 
beads to facilitated isolation of the biotinylated proteins. The addition of denaturing agents 
such as SDS enhances the robustness of the binding and permits purification of biotinylated 
proteins from complex protein solutions. An example of a biotin derivative is sulfo-NHS-
biotin (N-hydroxysulfosuc-cinimidobiotin), which is commonly used in neuronal receptor 
trafficking experiments. The advantage of applying sulfo-NHS-biotin is that contains a 
negatively charged sulphate group with confers membrane impermeability, and it also has a 
low cytotoxicity. Biotinylation can also use to study the trafficking of multiple different 
receptors/membrane proteins within the same experiment. Since the proteins of interest have 
different molecular weights, the proteins can be separated on the same Western blot 
membrane and probed with antibodies that recognise their specific proteins of interest.  
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Material and solution required: 
 1X PBS 
 1X Tris-buffered saline (TBS) (Sigma, UK) 
 Sulfo-NHS-Biotinylation kit (Pierce, UK) 
Biotinylation protocol: 
6-wells plates of culture cells were removed from the incubator and cooled on ice throughout 
all steps and using solutions at 4ºC to prevent receptor endocytosis and membrane trafficking 
during the biotin labelling step. Culture medium was removed and cells were rinsed twice 
with 1 ml of ice-cold PBS. Sulfor-NHS-SS-Biotin was dissolved in 48 ml of ice-cold PBS 
contained 0.5 mM MgCl2 and 1 mM CaCl2. 2 ml of the dissolved biotin solution was added 
to a final concentration of 1 mg/ml and the reaction was carried out for 30 minutes at 4ºC 
with continuous gentle agitation to ensure even coverage of all cells. After biotinylation, it 
was important to removing all unreacted biotin. This was achieved by adding 300 µl of 
Quenching solution and the plates were gently tipped back and forth to ensure even coverage. 
After quenching, cells were scraped into solution and transferred into a 1.5 ml microcentfruge 
tube. The plates were rinsed with 1 ml of TBS and this was added to the transferred cells. The 
transferred cells were spun at 700 rpm for 3 minutes and the supernatant discarded. The 
remaining cell pellet was rinsed again with 1 ml of TBS, and the cells were twice gently 
pipetted up and down with a serological pipette, and then spun for 2 minutes at 700 rpm. The 
resulting supernatant was discarded. At this point, the cells were ready for cell lysis to 
identify the surface receptor pool. Quantitative western blots were then performed on both 
total and biotinylated (surface) proteins using antibodies again GFP and RFP (described more 
details in section 3.5.4).  
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3.5.4 Western Blotting 
Western blotting is a common technique for separating proteins according to their molecular 
weight, where involves electrophoresis through a polyacrylamide gel in the presence of SDS 
(SDS polyacrylamide gel electrophoresis, or SDS-PAGE). The principle of western blotting 
is to detect a specific protein, and analysis of its expression level using specific antibodies in 
combination with SDS-PAGE. Following SDS-PAGE separation, the proteins are transferred 
to a membrane by running a perpendicular current through the gel into the membrane, and a 
specific protein detected using antibodies. These antibodies are either labelled themselves, or 
commonly detected by a second labelled antibody. This technique allows identification not 
only of the presence or absence of a protein reacted with the antigen, but also its size and an 
estimate of relative expression level. Hence, each transfection of wild-type and/or mutated 
proteins expression levels were estimated for comparison.  
3.5.4.1 Polyacrylamide gel  
Polyacrylamide gels are composed of long linear polyacrylamide chains cross-linked with N, 
N-methylenebis-acrylamide (Bis) to create a network of pores interspersed between bundles 
of polymer. Gel polymerisation requires the addition of ammonium persulphate along with 
TEMED. The structural features of a gel is neural, hydrophilic, three-dimensional networks 
of a long hydrocarbons cross-linked by methylene groups, made up of random distributions 
of solid material and pores. Thus, the movement of proteins within a gel is determined on 
their size and structure, relative to the pores of the gel. Large proteins migrate slower than 
small ones, creating distinct separation proteins within the gel.  
Furthermore, polyacrylamide gels are characterised by two factors: %T, which is the weight 
percentage of total monomer including cross-linker and %C is the cross-linker ratio of the 
monomer solution. The %T indicates the relative pore size of the gel, such as increasing %T 
decreases the pore size. In general, the smallest pore size is composed with 5%C, any 
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increase or decrease in %C increases the pore size. The calculation of %T and %C are shown 
as the following equation.  
 
 
The polyacrylamide %T is not only made as a single percentage throughout the gel, it can 
also be cast as a gradient of %T throughout the gel. The single percentage gels compositions 
are commonly from 7.5% up to 20%, or range from 4-15% to 10-20% for gradients gels   
3.5.4.2 SDS-PAGE  
Assembling glass plate for gel casting: 
Firstly the shorter glass plate was placed on top of the longer glass plate with two spacers of 
equal thickness along the short edges of the rectangular plate. The glass plate sandwich was 
then placed into the casting frames along the shorter plate facing out, and then the four 
screws of the casting frames were tightened. The casting frames were placed into the casting 
stand so that the shorter glass faced out (Figure 3.20). Then, the sandwiches were tested for 
absence of leakage by pouring some water into the gap. 
%T = 
Grams acrylamide  + Grams cross-linker
Total volume (ml)
X 100 
%C = 
Grams cross-linker
Grams acrylamide + Grams cross-linker
X 100 
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Figure 3-20 Glass plate assemble for gel casting 
Stock gel solution required: 
 Acrylamide/bis 40% (Sigma, UK) 
  1.5 M Tris-HCl, pH 8.8 
 0.5 M Tris-HCl, pH 6.8 
 10% SDS 
 5X electrode (running) buffer, pH 8.3 – Tris-glycine buffer 
Gel casting: 
SDS-PAGE gel in a single electrophoresis run is generally divided into stacking gel (5% 
acrylamide) and separating gel. The acrylamide percentage in SDS-PAGE separating gel 
depends on the size of the target protein in the samples. For Mini-PROTEAN® II 
electrophoresis cell (Bio-Rad, UK), 10 ml of separating solution was prepared for two gels. 
The composition of separation solution is shown in Table 3.20.  
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Table 3-20 The composition of separation solution 
% Gel 10% 
Deionised water 4.845 ml 
1.5 M Tris-HCl, pH 8.8 2.5 ml 
10% SDS 100 µl 
Arylamide/bis (40%) 2.5 ml 
10% ammonium persulphate 50 µl 
TEMED 5 µl 
Total 10 ml 
 
After the preparation of separation solution, it was pour into the sandwiches gap without air 
bubble formation, and left at least 2 cm for stacking gel solution.  Immediately, the monomer 
solution was then covered with 2-butanol (Sigma, UK), where to prevent the solution drying 
out by the air. Then the gel was polymerised at the room temperature for 30 minutes. While 
gel was polymerised, a 5 ml of stacking gel monomer solution was prepared (Table 3.21).  
Table 3-21 The composition of 5% stacking solution 
% Gel 4% 
Deionised water 3.12 ml 
0.5 M Tris-HCl, pH 6.8 1.25 ml 
10% SDS 100 µl 
Arylamide/bis (40%) 0.5 ml 
10% ammonium persulphate 25 µl 
TEMED 5 µl 
Total 5 ml 
 
After separation solution polymerisation, 2-butanol layer was poured out and rinse off using 
deionised water. Before pouring the stacking gel, the area above the separation gel was dried 
using filter paper (Whatman). Once the stacking gel had been poured a comb was placed in 
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the gel sandwich to make sample loading wells. The stacking gel was then left at the room 
temperature for 30 minutes to allow polymerisation. After that, the gel sandwiches and gel 
comb were removed, and the gel was placed into Mini-PROTEAN® II electrophoresis cell 
with 1X running buffer. The gel was ready for sample loading and running step. 
Before loading a protein sample, protein samples were boiled at 95ºC for 10 minutes to 
denature protein structure. 20 µg of each protein sample was then loaded into each well using 
special gel loading tips. A full-range rainbow molecular weight marker (12 kDa – 225 kDa) 
(Amersham) was used to determine the size of the protein of interest and also to monitor the 
progress of electrophoresis. 5 µl of molecular weight marker was loaded in a separate well.  
The gel was then run at 180 V for 75 minutes, until the dye molecule reached to the bottom of 
the gel. After electrophoresis was completed, the gel was removed from the casting frames 
and was ready for western blotting. 
3.5.4.3 Protein blotting  
Protein blotting is the transfer of proteins to solid-phase membrane supports for visualisation 
and identification. The initial step is the transfer of proteins from a gel and immobilisation of 
those proteins on a solid membrane support. Immobilisation of proteins on a membrane 
makes the proteins accessible to probes for specific antibodies and enables quantitative 
detection. Here, wet electrophoretic transfer of proteins from a gel to a membrane was 
performed.  The advantage of performing electrophoretic transfer of proteins is fast, efficient, 
and preserves the high-resolution separation of proteins by PAGE. The method of wet 
electrophoresis protein transfer is described below. 
The principle of electrophoretic transfer: 
In an electrophoretic transfer, the membrane and protein-containing gel are placed together 
with filter paper between two electrodes. Proteins migrate to the membrane following a 
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current (I) that is generated by applying a voltage (V) across the electrodes, following Ohm’s 
law:  
 V = I x R 
Where R is the resistance generated by the materials placed between the electrodes, such as 
the transfer buffer, gel, membrane, and filter papers.  
The electric field strength (V/cm) that is generated between the electrodes is the driving force 
for electrophoretic transfer. Though a number of other factors, including the size, shape, and 
charge of the protein and the pH, viscosity, and ionic strength of the transfer buffer and gel 
%T may influence, the elution of particular proteins from gels, both the applied voltage and 
the distance between the electrodes play a major role in governing the rate of elution of the 
proteins from the gel. There are practical limits on field strength, however, due to the 
production of heat during transfer.  
The heat generated during a transfer (Joule heating) is proportional to the power consumed by 
the electrical elements (P), which is equal to the product of the current (I) and voltage (V).  
 P = I x V = I
2
 x R 
Joule heating increases temperature and decreases resistance of the transfer buffer. Such 
changes in resistance may lead to inconsistent field strength and transfer, or may cause the 
transfer buffer to lose its buffering capacity. In addition, excessive heat may cause the gel to 
deteriorate and stick to the membrane. The major limitation of any electrophoretic transfer 
method is the ability of the chamber to dissipate heat.  
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Nitrocellulose membrane: 
Nitrocellulose was one of the first membranes used for western blotting and is still a popular 
membrane for this procedure. Protein binding to nitrocellulose is instantaneous, nearly 
irreversible, and quantitative up to 80 to 100 ug/cm
2
. Nitrocellulose is easily wetted in water 
or transfer buffer and is compatible with a wide range of protein detection systems. 
Membranes are commonly available in two pore sizes: the 0.45 um pore size membranes are 
recommended for most analytical blotting experiments, while the 0.2 um pore size 
membranes are most suitable for transfer of low molecular weight (< 15 kDa) proteins that 
might move through larger membrane pores.  
Assembling the gel and membrane sandwich: 
Each gel sandwich contained the gel and membrane sandwiched between pieces of blot 
absorbent filter paper. For each gel, one piece of membrane and two pieces of filter paper 
were cut to the dimensions of the gel. The gels were briefly rinse in deionised water and 
equilibrated in transfer buffer to remove contaminating electrophoresis buffer salt. The 
presence of salt will increase the conductivity of the transfer buffer and the amount of heat 
generated during the transfer. Also, the gel will shrink or swell to various degrees in the 
transfer buffer depending on the acrylamide percentage and the buffer composition. For 
example, low percentage gels (< 12%) will shrink in methanol buffers. Equilibration allows 
the gel to adjust to its final size prior to electrophoretic transfer. The membranes, filter papers, 
and fibre pads were also need to soak in the transfer buffer for 5 minutes before assembly in 
the transfer apparatus. A gel sandwich was prepared by placing one pre-wetted fibre pad on 
top of the black side of the cassette, then placed the pre-wetted filter paper on the top of fibre 
pad, followed the equilibrated gel and then placed the pre-wetted membrane on the top of gel. 
The gel sandwich was completed by adding a piece of filter paper on the membrane and 
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gently used a glass tube to roll air bubbles out (Figure 3-21). Finally, the last fibre pad was 
added and the cassette closed firmly. 
  
Figure 3-21 Transfer assembly for a tank transfer system (Trans-Blot cell) 
  
193 
 
Transfer buffer 
The size of SFP-AMPAR2 is 120 kDa as large protein; it tends to precipitate in the gel, 
hindering transfer. Thus, the suitable transfer buffer was Tris-glycine transfer buffer 
consisting of 48 mM base (pH 9.2), 39 mM glycine, 10% methanol and 0.1% SDS. Adding 
additional SDS to a final concentration of 0.1% in the transfer buffer leads to increased 
protein transfer from the gel, but can decrease binding of the protein to the nitrocellulose 
membrane. While the additional methanol tends to remove SDS from protein, so reducing the 
methanol percentage to 10% guard against precipitation. Lowering methanol in the transfer 
buffer also promotes swelling of the gel, allowing large proteins to transfer more easily. 
Hence, the balance of SDS and methanol in the transfer buffer, protein size, and gel 
percentage can affect transfer efficiency. 
Electrophoresis of transfer 
Once the cassette was closed and locked, inserted it into the tank with the latch side up, the 
black cassette plate needed to faces the black electrode plate. The transfer buffer was added 
to the tank until the buffer level reaches the fill line. To maintain even buffer temperature and 
ion distribution in the tank, magnetic stirrer bar were added to the tank and the entire tank 
assemble was placed on the top of a magnetic stirrer plate. The addition of an ice pack was 
required for the high-intensity field transfers; due to heat generation. Finally, the lid was 
placed on top of the cells, making sure that the colour-coded cables on the lid were attached 
to the electrode cards of the same colour. The cables were plugged into the power supply, and 
the transfer was performed at 60 volt for 90 minutes. 
3.5.4.4 Coomassie gel staining 
Coomassie gel staining is useful to determine if proteins have migrated uniformly and evenly. 
And also it can use on gels post-transfer to check the efficiency of the transfer.   
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Gel staining protocol: 
After SDS-PAGE is finished, the gel were treated with a 40% distilled water, 10% acetic acid, 
and 50% methanol solution to allow all proteins to precipitate and prevent diffusion. In order 
to visualise the fixed proteins placed the gel in the same mixture of water/acetic 
acid/methanol with the addition of 0.25% by weight Coomassie Brilliant Blue R-250 
(National Diagnostics, USA). The incubation of coomassie blue was performed for 4 hours at 
room temperature on a shaker. After staining, the gel had to be destained with a buffer of 
67.5% distilled water, 7.5% acetic acid, and 25% methanol on a shaker. And then fresh 
destain buffer was required until the excess dye had been removed completely. The stain does 
not bind to the acrylamide, and only proteins in the gel remain stained.  
3.5.4.5 Ponceau S staining 
Ponceau S membrane staining is a method to visualise the proteins in a membrane and to 
check for successful of transfer.  
Staining protocol: 
After protein transfer, the membrane was washed in TBS buffer plus 0.1% Tween20 (TBST), 
which consist of Tris-HCl, NaCl, and Tween20 with pH 7.6. Then, the membrane was 
transferred into 1X Ponceau Red on a shaker for 5 minute. The 10X Ponceau Red was made 
of 2% Ponceau S in 30% trichloroacetic acid and 30% sulfosalicylic acid. After the staining, 
the membrane was then washed extensively in water until the protein bands were well-
defined.  
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3.5.4.6 Membrane blocking 
Membrane blocking is the method to prevent non-specific background binding of the primary 
and secondary antibodies to the membrane. Non-fat milk blocking reagent is a traditional 
blocking buffer, which normally consisting of 5% milk in TBST.  
Membrane blocking protocol: 
Upon completion of the transfer, the blotting sandwiches were dissembled and the membrane 
was ready for blocking. Initially, the membranes were wetted in PBS for several minutes, and 
then blocked with 5% dried skimmed mike blocking buffer: 2.5g of dry fat milk powder in 50 
ml of TBST. While the membrane was blocked with 5% milk blocking buffer for an hour at 
room temperature, the primary antibodies were diluted in 1% milk buffer. The primary 
antibodies were incubated with the membrane at 4ºC overnight, with gentle shaking. 
On the next day, the pre-probed primary antibody membranes were washed three times for 10 
minutes each at room temperature in 1x TBST with gentle shaking, using a generous amount 
of buffer. During the washing step, the fluorescently-labelled secondary antibodies were 
diluted in 1% milk buffer in 1x TBST. Prolonged exposure of the antibodies vial to light must 
be avoided. The membranes then were probed for 45 minutes at room temperature with 
gentle shaking and protected from light. Washes were repeated after secondary labelling, 
washing three times for 10 minutes in 1x TBST, then placed in normal PBS.  
3.5.5 Antibodies 
Antibody probing is the most important step in protein detection. The sensitivity of the 
antibodies determines the accuracy of the result. The selection of primary antibody depends 
on the antigen to be detected and their sensitivity to the target antigen. Here, three primary 
antibodies were used to target interested protein; anti-tRFP, anti-tGFP, and β-actin, described 
in more detail below. Primary antibodies are generally not directly detectable in western 
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blotting. Therefore, secondary antibody is usually required to detect the target antigen. The 
choice of secondary antibody depends upon the species of animal in which the primary 
antibody was raised and the detection method being used. Here, two secondary antibodies 
were used; goat anti-mouse antibody for targeting β-actin and goat anti-rabbit antibody for 
targeting GFP and RFP. Both secondary antibodies were made with fluorescence based for 
fluorescent detection.    
3.5.5.1 Primary antibodies 
 Anti-GFP (Santa Cruz, UK) 
Anti-GFP was purchased from Santa Cruz, is a rabbit polyclonal antibody raised against 
amino acids 1 – 238 representing full length GFP of Aequorea victoria origin. The full length 
antibody has ability to also recognise GFP mutant fusion protein such as SEP. For detection 
of SEP-AMPAR protein expression, the antibody was used at 1:500 dilutions.  
 Anti-tRFP (Evrogen, UK) 
Full length anti-tRFP, a rabbit polyclonal antibody and specifically to recognise both 
denatured and native TagRFP was obtained from Evrogen. For detection of RFP-CACNG5 
protein expression, the antibody was used at 1:1000 dilutions. 
 Anti-β-actin (LI-COR Biosciences, UK) 
Anti-β-actin was provided from LI-COR Biosciences, is a mouse monoclonal antibody to 
detect endogenous levels of β-actin protein. For measurement of protein expression, a 
positive control protein was required to check each lane was evenly loaded with samples, 
such as β-actin. It was also useful to check for even transfer from the gel to the membrane 
across the whole gel. Although the even loading or transfer had not occurred, β-actin bands 
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could also be used to quantify the protein amounts in each lane. For endogenous levels of β-
actin detection, the antibody was used at 1:1500 dilution.  
3.5.5.2 Secondary antibodies labelled with near-infrared fluorescence dyes 
Traditional western blot detection uses a primary antibody directed again a protein of interest 
and a secondary antibody conjugated with an enzyme reporter, such as horseradish 
peroxidase or alkaline phosphatase. Then, chemiluminescent or colorimetric detection of the 
enzyme conjugate confirms the presence of the protein of interest. Fluorescent western blot 
detection allows quantification of the target. For example, secondary antibodies labelled with 
a near-infrared (NIR) fluorescent dye such as IRDye 800 CW and IRDye 680 RD provided 
from LI-COR Biosciences, allow direct non-enzymatic detection. The advantage of using 
NIR is that cells, animal tissue, plasticware, blotting membranes, and chemical compound 
libraries all possess intrinsic autofluorescence that can interfere with detection; whereas in the 
NIR spectral region 700 – 900 nm, autofluorescent background is dramatically reduced. Since 
the protein of interest is recognised by its primary antibody and is conjugated by the 
secondary antibody labelled NIR, blot is then documented with an NIR imager such as the 
Odyssey® Imager from LI-COR Biosciences. With this approach, fluorescent signal is 
directly proportional to the amount of protein of interest present.  
 Goat anti-rabbit IR-Dye 680RD (LI-COR Biosciences, UK) 
The IR-Dye 680 RD has a maximum excitation wavelength at 690 nm and emission 
wavelength at 694 nm, where the detection channel wavelength in Odyssey® is 700 nm. This 
wavelength can be detected in a combination with IR-Dye 800CW secondary antibody, 
known as two-colour detection.  Goat anti-rabbit IR-Dye 680RD is a goat antibody to detect a 
rabbit primary antibody that is raised against to SEP-GluR2 and RFP-CACNG5 in our 
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experiment. For Odyssey® Imager detection, the antibody was optimised at 1:10,000 
dilutions. 
 Goat anti-mouse IR-Dye 800CW (LI-COR Biosciences, UK) 
The IR-Dye 800CW has a maximum excitation wavelength at 778 nm and emission 
wavelength at 794 nm, where the detection channel wavelength in Odyssey® is 800 nm. Goat 
anti-mouse IR-Dye 800CW is a goat antibody to detect a mouse primary antibody that is 
raised against to endogenous levels of β-actin protein in our experiment. The optimised 
dilution of this antibody was used at 1:10,000 dilutions.  
3.5.6 Odyssey® Imager and analytical software 
Al blots were imaged using a LICOR Odyssey® scanner and imager software to analysis and 
quantify the interest of protein in the cells. The IR imager in both 700 nm and 800 nm 
channels was set at 169 µm resolutions for all blots. Quantification of the interest of proteins 
was performed using Odyssey 3.0 analytical software (LI-COR Biosciences). Boxes were 
manually placed around each band of interest and the NIR fluorescent values of raw intensity 
with intra-line background subtracted was obtained. The given NIR fluorescent values were 
then analysed using R.  
3.5.7 Data analysis 
3.5.7.1 Quantification analysis of cells expressing AMPAR proteins 
The data was collected from FACS where the quantification of cells expression AMPAR 
proteins was measured. Then, the data was further analysed using Kaluza software and 
presented as the mean ± SEM. The statistical analysis was performed using a two-tailed 
unpaired Student’s t-test in Excel. The differences were considered significant with a P-value 
< 0.05. 
199 
 
3.5.7.2 Quantification analysis of surface receptor proteins 
The objective of the statistical analyses was to identify protein expression changes on AMPA 
receptor and CACNG5 between the total and surface expression. Then further analysis 
compared both expression between wild-type and variants. The protein expression values 
were given from the NIR fluorescence value for each protein of interest. Linear mixed 
models were used to analyse the data with the biological replicates as random effects. 
Statistical analysis was performed using a linear mixed model in R (R Core Team 2013). 
Differences of P < 0.05 were considered significant.  
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4 Identification of CACNG5 variants in cases of bipolar disorder and 
schizophrenia 
4.1 Introduction 
Bipolar disorder (BPD) and schizophrenia (SCZ) are common, severe and highly heritable 
psychiatric disorders. For instance, the heritability of BPD is estimated to be approximately 
70 – 90%, whereas the heritability for SCZ is 80 – 85% (Cannon et al. 1998, Cardno and 
Gottesman 2000, Kieseppa et al. 2004). This high degree of heritability indicates that genetics 
has an important role in pathogenesis. Although these disorders are classified into two 
distinct categories, both clinical and genetic studies have shown overlapping aetiology 
(Berrettini 2003, Hamshere et al. 2005, Moskvina et al. 2009, Shao and Vawter 2008). 
Perhaps the best example of a susceptibility gene for mental illness is the CACNA1C gene 
which encodes the 1 subunit of the L-type voltage-gated calcium channel (VGCC). 
CACNA1C has been implicated in genome-wide association studies (GWASs) of BPD, SCZ, 
and major depressive disorder (Ferreira et al. 2008, Green et al. 2010, Psychiatric GWAS 
Consortium Bipolar Diosrder Working Group 2011, Schizophrenia Psychiatric Genome-
Wide Association Study (GWAS) Consortium 2011). Recently, the Psychiatric Genomic 
Consortium extended previous association findings at CACNA1C, CACNB2 and CACNA1I, 
which encode VGCC subunits, which implicate the family members of VGCC in SCZ and 
other psychiatric disorders (Schizophrenia working Groups of the Psychiatric Genomic 
Consortium 2014). As described earlier in the GWAS section of the introduction, our 
research group previously found association with a marker rs17645023 (p = 6.3 x 10
-7
) that  
lies 36kb from CACNG5 and 79kb from CACNG4 (both genes encode  subunits of calcium 
channel genes) from a BPD versus SCZ case-case comparison study (Curtis et al. 2011) 
(Figure 1-1). The allele frequencies of this variant were 18% in SCZ, 28% in BPD, and 23% 
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in control, where showed that the control allele frequencies were intermediate between those 
of BPD and SCZ. This result implied that marker rs17645023 has significant differential 
effects in the two disorders and that this finding me may be used to demonstrate how these 
two disorders differ biologically. Although this study finding brought out new insights into 
these two disorders, the linkage disequilibrium (LD) block analysis revealed weak linkage 
disequilibrium between the marker and these two genes (Figure 4-1). Both LD analysis of 
UCL BPD and controls and 1000 Genomes Project data revealed an LD signal shift towards 
CACNG4 gene region.  Furthermore, the regional association plot of the Psychiatric 
Genomics Consortium (PGC) BPD GWAS found no associated variants in both CACNG5 
and CACNG4 genes (Figure 4-2). However, the regional association of PGC SCZ shows a 
nominally associated variant (rs185202153, p = 4.5 x 10
-4
) in the intronic region of CACNG4 
(Figure 4-3). Even though both PGC GWAS data and LD analysis did not strengthen the 
finding of disease susceptibility variants in both genes, an interesting 17q24.2 microdeletion 
study suggested that deletion of CACNG5 and CACNG4 regions might be responsible for 
speech delay and intellectual disability observed in four patients and mood swings, 
hallucinations and seizures in two patients (Vergult et al. 2012). These findings suggest that 
GWAS may not detect all genetic susceptibility genes or variants and therefore if studies only 
rely on GWAS findings or LD score analyses they may fail to detect hidden casual variants or 
genes. The finding of a nominal association with the CACNG4 SNP rs185202153 in the PGC 
SCZ data, may suggest that CACNG4 is involved more in SCZ than in BPD. However, none 
of PGC GWASs had found any association variants in CACNG5. This begs an interesting 
question as to whether CACNG5 is a gene with overlapping or distinct susceptibilities for 
these two conditions. Since the genetic evidence implicates the importance of calcium 
channel signalling in the path-physiology of psychiatric disorders.  Therefore, the genetic 
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sequence and genotyping of CACNG5 may illustrate the distinct biological patterns or 
mechanisms that underlie SCZ and/or BPD.  
Figure 4-1 LD plot of the marker rs17645023 between CACNG5 and CACNG4 genes 
obtained from the USCS Genome Brower website. The analysis was applied by using 
the UCL and 1000 Genome Project data by PLINK.  
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Figure 4-2 regional association of PGC BPD GWAS plot for the marker rs17645023 
analysed at CACNG5 and CACNG4.  
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Figure 4-3 regional association of PGC SCZ GWAS plot for the marker rs17645023 
analysed at CACNG5 and CACNG4. 
 
Here, we explored the hypothesis that genetic causes of BPD and SCZ may be found by 
identifying genetic variants that overlap in both disorders, as well as by variants that 
distinguish between these disorders. Previous observations have indicated that CACNG5 may 
be a candidate gene for these disorders with an involvement of calcium channel signalling in 
both BPD and SCZ (Curtis et al. 2011). In fact, according to literature reviews CACNG5 
encodes TARPs (transmembrane AMPA receptor regulatory proteins), a protein intimately 
involved in the trafficking of glutamatergic AMPA (-amino-3-hydroxy-5-methyl-4-
isoxazolepropinonic acid) receptors (Burgess et al. 1999, Burgess et al. 2001). Moreover, the 
subunit (CACNG5) was also shown to contribute to the regulation of calcium permeability 
via AMPA receptor assembly (Soto et al. 2009). The regulation of intracellular calcium ions 
and AMPA receptor trafficking and gating are important mechanisms that mediate the 
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excitatory synaptic transmission at the postsynaptic density. Thus dysfunctional control 
mechanisms may lead to disorders, such as BPD and SCZ (Du et al. 2004a, Du et al. 2004b). 
Despite these results, the role of CACNG5 polymorphisms in these disorders has still not 
been completely investigated. This is likely to reflect the limitation of GWAs studies, which 
are only designed to identify common variants,  possibly of small effect, and may therefore 
fail to detect associations with rare susceptibility variants (Maher 2008). We therefore 
focused our attention on identifying CACNG5 polymorphisms in subjects with either BPD or 
SCZ. 
To assess the presence of functional variants within CACNG5, we initially screened 1,099 
patients with BPD, 618 patients with SCZ and 986 control samples (this included 614 
supernormal controls). The screened regions included the entire coding regions of the gene 
(exon 1 to exon 5) plus their neighbouring flanking introns and promoter regions. We chose 
to use high resolution melting analysis (HRMA) to perform rapid variant scanning of the 
CACNG5 in DNA samples from both patients and controls. The HRMA variant scanning 
principle is based on the dissociation behaviour of DNA under increasing temperature. 
Melting analysis is generated by using a saturating double-stranded DNA-binding dye with 
increasing temperature to denature double-stranded into single-stranded DNA with the loss of 
its fluorescence (Reed and Wittwer 2004). The melting profile gives a specific sequence-
related pattern allowing differentiation between wild-type sequences and homozygote 
heterozygote variants (Graham et al. 2005). Because HRMA is a simple PCR-based method, 
with high accuracy, low cost, and yields rapid results, it is an attractive choice for the 
detection of disease-associated variants. Although the accuracy of HRM is very high, several 
factors have to be taken into consideration when applying this technique into clinical practice, 
such as PCR specificity, length of the amplicon, percentage of GC content, dye, instrument 
and melting analysis software. For example, as melting analysis is performed directly after 
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PCR, different heterozygotes variants may reveal similar melting curves that cannot be 
distinguished from each other, even though they are clearly distinct from homozygous wild-
type variants. Therefore careful design of primers and optimised temperature cycling is 
required to improve the specificity of amplification of the target regions (Er et al. 2012). 
Secondly, studies have suggested that shortening the length of the amplicons can also 
improve melting curve differentiation between mutant and wild-type alleles (Gundry et al. 
2003, Montgomery et al. 2010). As shown in Reed GH and Wittwer CT (2004) study, (Reed 
and Wittwer 2004), when PCR products below or equal to 300 bp, both sensitivity and 
specificity were 100%; when PCR products were between 300 bp and 1000 bp, sensitivity 
and specificity decreased to 96.1% and 99.4% respectively. Third, studies have also 
suggested that there was better sensitivity with GC mismatches, i.e. there were fewer  missed 
variants (false negative) in these circumstances compared to AA and TT mismatches (Reed 
and Wittwer 2004, Krypuy et al. 2006). Finally, the different dye used in HRM, work with 
different efficiencies and also the use of different instruments has an impact on the sensitivity 
and specificity of HRM. In order to overcome these factors, any sample that was detected 
with a suspected variant was directly sequenced to confirm the results from HRMA. The 
frequency of any change then was assessed in healthy subjects compared to our patient 
samples. Genotyping was validated by the Kaspar genotyping method. There was 100% 
concordance between the HRMA and Kaspar genotyping data for the variants described. 
4.2 Results 
4.2.1 CACNG5 gene variants by high resolution melting analysis (HRMA) 
We detected a total of 12 single nucleotide exchange variants within exonic regions and 3 
extra variants were in promoter regions. These results are summarised in the Table 4.1, the 
rare SNPs are named by chromosomal location. For validation of these variants, we 
genotyped all cases and controls samples by the Kaspar as described in the Methods section 
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and the analysed results of each of the variants can be found in Appendix II. The validated 
variants include 8 predicted amino acid substitution variants (non-synonymous SNPs, 
nsSNPs), 4 synonymous SNPs (sSNPs) and 3 single nucleotide exchange polymorphisms in 
promoter regions.  
Table 4-1 Summary of variant screening result 
Name Nucleotide Change Predicted Amino Acid Change 
rs3760263 G>A N/A 
rs181400884 G>T N/A 
rs75486725 C>T N/A 
17_64873468 c.77 G>A Arg6Arg 
rs146874664 c.117 T>C Cys19Cys 
rs71379998 c.141 G>A Ala27Ala 
rs11652480 c.162 G>A Leu34Leu 
17_64875098 c.265 C>T Arg69Trp 
17_64875105 c.272 G>A Arg71His 
rs142916987 c.440 G>A Arg127Gln 
rs149159754 c.443 C>T Thr128Met 
17_64880644 c.496 A>G Val146Met 
17_64880674 c.526 A>T Ile156Phe 
17_64880699 c.551 C>T Thr164Leu 
rs41280112 c.757 C>T His233Tyr 
 
4.2.2 Non-synonymous variants 
HRMA clearly showed an aberrant curve with a base change from cytosine to thymine at 
cDNA position 265 (c.265 C>T) within exon 2 (Figure 4-4 and Figure 4-5 panel A). Direct 
sequencing indicated that the underlying variation corresponded to a novel variant that was 
predicted to cause a non-synonymous p.Arg69Trp (R69W) amino acid change. Further 
genotyping confirmed this change as a rare polymorphism that occurred in only one SCZ 
sample and not in any of the BPD or control samples (Figure 4-4 and Figure 4-5 panel A). A 
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second novel nsSNP with a predicted amino acid change of p.Arg71His (R71H) with a 
guanine to adenine base change at position 272 (c.272 G>A) was only found in one BPD 
sample and not in the SCZ or control samples (Figure 4-4 and Figure  4-5 panel B). Both of 
these nsSNPs were absent from the European samples in the 1K Genome project. However, 
R69W was found in one individual from Africa (NA19175) in the 1K Genome project.
 
Figure 4-4 Detection of SNPs in exon 2 of the CACNG5 gene by HRMA. p.Arg69Trp is 
shown in panel A and p.Arg71His is shown in panel B. The upper panels show the 
detection of the novel changes obtained by comparing melting-curve shapes after signal 
normalisation. Samples that contain heterozygote polymorphisms (red or green) form 
heteroduplexes that are denatured at lower temperatures compared to the wild-type 
samples (blue). The lower panels indicate differences in fluorescence plotted against 
temperature for the sample curves. This leads to clear separation between samples with 
polymorphisms (red or green) and wild-type samples (blue). 
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Figure 4-5 Validation of SNPs found in exon 2 of the CACNG5 gene by HRM analysis. 
The upper panels of A and B show clear genotype groups; wild-type homozygous 
individuals are shown in blue, heterozygous individuals are shown in red, and negative 
samples are shown in grey. The lower panel of A and B shows DNA sequence traces for 
the two samples (the heterozygous polymorphic bases are shown with an arrow. 
HRMA also detected another two nsSNPs within exon 3. A base change from guanine to 
adenine at position 440 (c.440 G>A) was predicted to result in Arg127Gln (R127Q). 
Genotyping results revealed that this SNP occurred in two BPD samples and did not occur in 
the control or SCZ samples. However, this SNP was found in one of the 379 European 
samples from the 1K Genomes project (Table 4-2). Another exon 3 nsSNP was detected 
which was a cytosine to thymine base change at position 443 (c.443 C>T). This SNP was 
predicted to result in p.Thr128Met (T128M) and was found in three BPD samples plus two 
control samples and not in the SCZ samples. A different single nucleotide change that was 
predicted to result in a different amino acid substitution, p.Thr128Lys (T128K) was found in 
only one Asian sample (NA18610) and not in any European sample from the 1K Genome 
project.    
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A Further three nsSNPs were detected by HRMA; the predicted amino acid changes that 
these SNPs caused were p.Val146Met (V146M), p.Ile156Phe (I156F) and p.Thr164Leu 
(T164L). According to our genotyping data, only one BPD patient was identified who carried 
the I156F SNP, whereas two SCZ patients with V146M were identified and only one SCZ 
patient was detected with T164L. None of these SNPs were reported in the 1K Genomes 
project database. A more common nsSNP, rs41280112 was also detected in the UCL samples. 
This SNP was predicted to lead to the His233Tyr (H233Y) amino acid substitution. 
Interestingly, the allele frequencies (AF) for this SNP is higher in both BPD and SCZ 
samples compared to UCL controls and in the European samples from the 1K Genomes 
project; 2.89% in BPD, 3.48% in SCZ, 1.70% in our control, and 1.85% in European samples 
from the 1K Genomes project.  
Furthermore, a nsSNP with the predicted amino acid substitution of Ala182Ser (A182S) was 
observed in a single sample of European origin in the 1K Genomes project. Additional 
genotyping of this variant in the UCL BPD, SCZ and control samples was performed in order 
to identify whether it was a false negative finding from our HRMA. Our results showed that 
A182S did not occur in the UCL samples and also suggests that our HRMA had high 
sensitivity and specificity.  
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Table 4-2 Summary of non-synonymous variants genotype counts together with data from the European samples in the 1K Genomes 
project. The sum of total wild-type homozygous individuals genotyped in each SNP is showed in 0|0 column; the sum of total 
heterozygous individuals genotyped in each SNP is showed in 1|0 column. Percentage of allele frequencies (AF %) was calculated for 
each variant. The numbers in total row represents an aggregation of all non-synonymous variants found in UCL cases. 
0|0 1|0 AF % 0|0 1|0 AF % 0|0 1|0 AF % 0|0 1|0 AF % 0|0 1|0 AF % 0|0 1|0 AF %
R69W 379 0 0 1071 0 0 599 1 0.08 937 0 0 235 0 0 456 0 0
R71H 379 0 0 1067 1 0.05 595 0 0 941 0 0
R127Q 378 1 0.13 1071 2 0.09 596 0 0 916 0 0
T128M 379 0 0 1069 3 0.14 599 0 0 926 2 0.11
V146M 379 0 0 1070 0 0 601 2 0.17 907 0 0 518 0 0 642 1 0.07776
I156F 379 0 0 1072 1 0.05 601 0 0 938 0 0
T164L 379 0 0 1071 0 0 598 1 0.08 940 0 0 496 0 0 635 0 0
H233Y 367 12 1.58 1019 55 2.56 562 38 3.15 910 30 1.59
Total 365 14 1.85 1011 62 2.89 561 42 3.48 909 32 1.7 518 0 0 642 1 0.0778
Aberdeen SCZ n = 643Control n = 9411K EURO n = 379 BP n = 1073 SCZ n = 603 Aberdeen Control n = 518
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Table 4-3 Summary of synonymous variant genotype counts together with data from the European samples in the 1K Genomes project. 
The sum of total wild-type homozygous individuals genotyped in each SNP is showed in 0|0 column; the sum of total heterozygous 
individuals genotyped in each SNP is showed in 1|0 column; the sum of total mutated homozygous individuals genotyped in each SNP is 
showed in 1|1 column. Percentage of allele frequencies (AF %) was calculated for each variant. The numbers in total row represents an 
aggregation of all synonymous variants found in UCL cases. 
0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF %
R6R 0 0 0 0 1071 0 0 0 599 1 0 0.08 940 0 0 0
C19C 374 5 0 0.66 1062 9 0 0.42 591 9 0 0.75 935 5 0 0.27
A27A 367 12 0 1.58 1050 20 0 0.93 583 9 0 0.75 934 8 0 0.42
L34L 314 58 7 9.5 776 139 13 7.7 495 92 9 9.17 778 145 9 8.65
S87S 378 1 0 0.13 0 0 0 0 0 0 0 0 0 0 0 0
Total 296 76 7 11.87 890 168 13 9.06 480 111 9 10.75 775 158 9 9.34
SCZ n = 600 Control n = 9421K EURO n = 379 BP n = 1071
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Table 4-4 Summary of putative promoter variant genotype counts together with data from the European samples in the 1K Genomes 
project. The sum of total wild-type homozygous individuals genotyped in each SNP is showed in 0|0 column; the sum of total 
heterozygous individuals genotyped in each SNP is showed in 1|0 column; the sum of total mutated homozygous individuals genotyped 
in each SNP is showed in 1|1 column. Percentage of allele frequencies (AF %) was calculated for each variant. The numbers in total row 
represents an aggregation of all putative promoter variants found in UCL cases. 
0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF %
rs3760263 345 32 2 4.75 963 91 3 4.59 538 53 4 5.10 866 71 0 3.79
rs181400884 377 2 0 0.26 1046 9 0 0.43 598 0 0 0 928 8 0 0.43
rs75486725 379 0 0 0 1043 8 0 0.38 592 2 0 0.17 923 8 0 0.43
Total 343 34 2 5.01 946 108 3 5.39 539 55 4 5.27 850 87 0 4.64
1K EURO n = 379 BP n = 1057 SCZ n = 598 Control n = 937
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4.2.3 Synonymous variants  
Exon 1 was difficult to screen for novel polymorphisms using only a single set of primer 
pairs because it contains the two common database (DB) SNPs, rs71379998 and rs11652480. 
This is because HRMA detects all polymorphisms in the region that is amplified and this 
makes it difficult to distinguish novel changes amongst a background of common variants. In 
order to resolve this problem several samples from each melting curve cluster were 
sequenced directly from the HRM product. A novel guanine to adenine sSNP at cDNA 
sequence position 77 from the start codon (c.77 G>A; Arg6Arg (R6R)) was only found in 
one SCZ sample and not in control or BPD samples. A 1K Genomes project thymine to 
cytosine sSNP at position 117 (c.117 T>C; Cys19Cys (C19C)) was found in the UCL sample 
with minor AF of 0.42% in BPD, 0.75% in SCZ, and 0.27% in the control sample (Table 4-3). 
The common SNPs rs71379998 (Ala27Ala (A27A)) and rs11652480 (Leu34Leu (L34L)) 
have similar AFs in the BPD, SCZ and control samples to the European samples in the 1K 
Genomes project.  
4.2.4 Putative CACNG5 variant promoter variants  
The putative promoter region of CACNG5 presented 3 aberrant curves in both BPD and SCZ 
samples. SNP rs3760263 was found in the UCL samples and also in the European samples 
from the 1K Genomes project. The AF the UCL SCZ sample was 5.10%, 4.59% in the UCL 
BPD sample, 3.79% in the UCL control sample and 4.75% in the European samples from the 
1K Genomes project (Table 4-4). Furthermore, no homozygous individuals were identified in 
the UCL control sample, while two homozygous individuals were detected in the European 
samples from the 1K Genomes project. Interestingly, SNP rs181400884 was found in UCL 
BPD and control samples and also in two European samples from the 1K Genomes project, 
but was not found in the UCL SCZ samples. Finally SNP rs75486725 was not detected in the 
European samples from the 1K Genomes project but this SNP was detected in the UCL 
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samples albeit at a low AF; 0.17% in the SCZ samples, 0.38% in the BPD samples and 0.43% 
in the control samples.  
4.2.5 UK10K EXOME DATA 
Table 4-5 Summary of non-synonymous variants genotype counts from the UK10K 
exome sequence data. Percentage of allele frequencies (AF %) was calculated for each 
variant. The sum of total wild-type homozygous individuals genotyped in each SNP is 
showed in 0|0 column; the sum of total heterozygous individuals genotyped in each SNP 
is showed in 1|0 column; the sum of total mutated homozygous individuals genotyped in 
each SNP is showed in 1|1 column. The numbers in total row represents an aggregation 
of all non-synonymous variants found in UCL cases. 
0|0 1|0 AF % 0|0 1|0 1|1 AF %
R69W 982 0 0.00 1391 1 0 0.04
R71H 982 0 0.00 1390 2 0 0.07
R127Q 982 0 0.00 1391 1 0 0.04
T128M 980 2 0.10 1392 0 0 0.00
V146M 982 0 0.00 1392 0 0 0.00
I156F 981 1 0.05 1391 1 0 0.04
T164L 982 0 0.00 1392 0 0 0.00
H233Y 952 30 1.53 1346 44 1 1.65
Total 949 33 1.68 1342 49 1 1.83
UK10K Control n = 982 UK10K SCZ n = 1392
 
The UK10K study examined 982 UK sample with chronic obesity which we used on controls 
for our study and 1,392 SCZ patients. Five out of our total eight rare nsSNPs were found in 
UK10K exome data. These were R69W, R71H, R127Q, T128M, and I156F. R69W and 
R71H were found one and two SCZ cases, respectively and were absent in the controls. 
Conversely, T128M was found one control subject but was absent in the cases. Interestingly, 
variant I156F was found once in control and case, where was not found in both 1K Genomes 
project data and UCL control subjects. Thus, the minor AF of this variant was almost equal in 
both control and case samples of UK10K exome sequence data. The common variant H233Y 
was also found in both control and case subject with increased minor AF in cases, but this 
was dramatically decreased compared with UCL BPD and SCZ subjects (from AF = 2.56% 
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and 3.15%, respectively, to 1.65% in UK10K cases). The additional UK10K exome sequence 
data did not strengthen the findings for the frequencies of all nsSNP variants combined in 
case verse control subject comparison.  Possible reasons could be the two rare variants were 
absent in the UK10K data and also the common variant appears to be occurring more 
frequently.  
Table 4-6 Summary of synonymous variants genotype counts from the UK10K exome 
sequence data. Percentage of allele frequencies (AF %) was calculated for each variant. 
The sum of total wild-type homozygous individuals genotyped in each SNP is showed in 
0|0 column; the sum of total heterozygous individuals genotyped in each SNP is showed 
in 1|0 column; the sum of total mutated homozygous individuals genotyped in each SNP 
is showed in 1|1 column. The numbers in total row represents an aggregation of all 
synonymous variants found in UCL cases. 
0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF %
R6R 982 0 0 0 1391 1 0 0.04
C19C 963 19 0 0.97 1374 18 0 0.65
A27A 966 16 0 0.81 1360 31 1 1.19
L34L 827 151 4 8.10 1160 221 11 8.73
Total 792 186 4 9.88 1109 271 12 10.60
UK10K Control n = 982 UK10K SCZ n = 1392
 
Nevertheless, all sSNP variants found in the UCL sample were also found in UK10K exome 
data with similar minor AF. Interestingly, the R6R variant was found in one case not in any 
of the controls. This is similar to the findings in the UCL samples and 1K Genome project 
data. C19C and A27A variants were detected at different AFs the controls and cases. A27A 
was more common in the SCZ samples compared to controls but the difference was not 
significant. L34L common variant showed modest evidence for association in UK10K cases 
(p = 0.042). Burden analysis of combined sSNP variants showed significantly associated (p = 
0.0195) as shown in Table 4-6.  
  
217 
 
4.2.6 Swedish exome data analysis 
Table 4-7 Summary of non-synonymous variants genotype counts from the Swedish 
exome sequence data. Percentage of allele frequencies (AF %) was calculated for each 
variant. The sum of total wild-type homozygous individuals genotyped in each SNP is 
showed in 0|0 column; the sum of total heterozygous individuals genotyped in each SNP 
is showed in 1|0 column. The numbers in total row represents an aggregation of all non-
synonymous variants found in UCL cases. 
0|0 1|0 AF % 0|0 1|0 1|1 AF %
R69W 2545 0 0.00 2545 0 0 0.00
R71H 2545 0 0.00 2545 0 0 0.00
R127Q 2538 7 0.14 2538 7 0 0.14
T128M 2543 2 0.04 2543 2 0 0.04
V146M 2545 0 0.00 2545 0 0 0.00
I156F 2544 1 0.02 2545 0 0 0.00
T164L 2545 0 0.00 2545 0 0 0.00
H233Y 2484 60 1.18 2484 58 2 1.22
Total 2475 70 1.38 2476 67 2 1.39
Swedish Control n = 2545 Swedish SCZ n = 2545
 
Swedish SCZ exome sequencing data for 2,500 SCZ and 2,500 controls was downloaded 
from dbGAP. Only four out of eight UCL genotyping nsSNP variants were detected and 
these included R127Q, T128M, I156F, and H233Y. Interestingly, the minor AF of R127Q 
was increased in both control and case samples (AF = 0.14%) of Swedish exome data. This 
SNP variant was not found in control samples from the UK10K exome sequencing data and 
UCL control subjects (Table 4-7). Conversely, the minor AF of T128M was decreased in 
controls and increased in case. Moreover, I156F was only found one in control subject and 
was absent in the cases. This was an opposite result to the previous sample.  The minor AF of 
H233Y was quite similar between control and case samples, 2 individual subjects with SCZ 
were found to be homozygous for H233Y. Overall, the burden analysis of the variants 
showed almost equal minor AF in cases and controls. One reason for this is that only half the 
variants were found in Swedish data, and these were more common in controls compared to 
cases.  
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Table 4-8 Summary of synonymous variants genotype counts from the Swedish exome 
sequence data. Percentage of allele frequencies (AF %) was calculated for each variant. 
The sum of total wild-type homozygous individuals genotyped in each SNP is showed in 
0|0 column; the sum of total heterozygous individuals genotyped in each SNP is showed 
in 1|0 column; the sum of total mutated homozygous individuals genotyped in each SNP 
is showed in 1|1 column. The numbers in total row represents an aggregation of all 
synonymous variants found in UCL cases. 
0|0 1|0 1|1 AF % 0|0 1|0 1|1 AF %
R6R 2545 0 0 0.00 2545 0 0 0.00
C19C 2499 46 0 0.90 2483 62 0 1.22
A27A 2472 73 0 1.43 2481 63 1 1.28
L34L 2162 366 17 7.86 2186 343 16 7.37
Total 2043 485 17 10.20 2060 468 17 9.86
Swedish Control n = 2545 Swedish SCZ n = 2545
 
Three out of four UCL sSNP variants were found in the Swedish data (Table 4-8). 
Interestingly, the rare variant R6R was not found in the Swedish exome sequencing data, and 
C19C variant showed an increase in minor AF in cases compared to controls. However, both 
A27A and L34L variants showed higher minor AF in controls than in cases, but this was not 
significant. Burden analysis of combined total allele counts of three variants showed a slight 
significant associated in controls (p = 0.0434).  
4.2.7 Association analysis of CACNG5 variants 
Burden analysis was performed using data for the combined allele counts of the 8 nsSNVs 
detected in CACNG5. The case versus control comparison study using the UCL control 
samples, were significant for SCZ (p = 0.0016) and BPD (p = 0.0127), and for the two 
diseases combined (p = 0.0022) (Table 4-9 Upper). These findings were supported by the use 
of the data from the European samples in the 1K Genomes project as controls. In these 
analyses there was evidence for association with SCZ (p = 0.0213), but was not significant in 
BPD (p = 0.0814) and also for both diseases combined (p = 0.0389) (data not shown). The 
evidence for association with both diseases seems to be decreased by BPD, and also UCL 
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controls seems to give better results than 1 K. A good explanation is because the UCL study 
includes healthy supercontrols. Using a combined set of control data that comprised 
genotypes from the UCL control samples and the data from the European samples in the 1K 
Genomes project compared with the BPD and SCZ sample data showed increased evidence 
for association with SCZ (p = 5.89 x 10
-4
) and with BPD (p = 5.91 x 10
-3
), and for both 
diseases combined (p = 5.69 x 10
-4
). Hence, increasing the sample size for controls (and cases) 
appeared to increase the evidence for association (Table 4-9 Lower). Furthermore, using the 
combined set of control data that comprised genotypes from the UCL control samples, the 
data from the 1K Genomes projects, and the data from the UK10K control exome sequencing 
compared with the BPD and SCZ samples data showed increased evidence for association 
with SCZ (p = 1.14 x 10
-5
) and with BPD (p = 1.71 x 10
-4
), and for both diseases combined (p 
= 2.17 x 10
-
). However, when both diseases were combined with additional UK10K SCZ data 
and this was compared with the combined set of control data there was decreased evidence 
for association (p = 3.44 x 10
-3
). Similar significant findings were observed when the 
combined set of control data comprised additional genotypes from the Swedish control 
exome sequencing, when compared with the BPD and SCZ samples data showed increased 
evidence for association with SCZ (p = 9.45 x 10
-7
) and with BPD (p = 1.51 x 10
-5
), for both 
diseases combined (p = 2.04 x 10
-8
), for both diseases and UK10K SCZ combined (p = 9.98 x 
10
-6
), and for both diseases combined with UK10K SCZ and Swedish SCZ (p = 5.12 x 10
-3
). 
The results showed that the additional data from UK10K and Swedish exome sequencing 
data did not strengthen the evidence for association. Perhaps, some individual variants such 
as R69W, R71H, V146M, and T164L were still interesting to be further investigated with 
functional test. This is particularly the case for V146M and T164L which were not found in 
both UK10K and Swedish controls and cases data, and R69W and R71H were only not found 
in both sets of control data. According to the previous GWAS by the International 
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Schizophrenia Consortium (PSC) and CNV study, there was no evidence of major population 
stratification within our samples {Purcell, 2009 #917} {Consortium, 2008 #918}. As the 
UCL case-control samples were only recruited if both parents were English, Scottish or 
Welsh, and with at least three grandparents having the same origin. Furthermore, the data was 
only included if the fourth grandparent was of another white European origin, but if one 
grandparent was of Jewish or non-European Union (EU) then the subject was excluded. In 
the Aberdeen samples, all participants self-identified as born in the British Isles and 95% 
were in Scotland {Purcell, 2009 #919}. Therefore, despite the finding that both V146M and 
T164L were absent in the UK10K, it is unlikely not the presence of these variants in the 
cohorts studies here represents the effect of population stratification. Similar analyses of data 
for the five sSNPs revealed no evidence for association with either disorder. The results of 
the nsSNP and sSNP analyses are summarised in Table 4-9 and Table 4-10 
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Table 4-9 Summary of combined total 8 non-synonymous variants genotypic count and significant association p-values from the 1K 
Genome Project data, UCL samples, UK10K exome sequence data and Swedish exome data. The upper table represents genotype counts 
of rare non-synonymous variants found in CACNG5 from each cohort. The lower table represents CACNG5 a pooled burden analysis of 
rare non-synonymous variants in each of the cohorts and in a combined analysis of the cohorts . 1K = 1K genome project data; UCL 
CONT = UCL control subjects; UCL BP = UCL bipolar disorder subjects; UCL_SCZ = UCL schizophrenia subjects; UK10K = UK10K 
exome data control and schizophrenia subjects; Swedish exome data = Swedish exome data control and schizophrenia; 1K + UCL 
CONT = combined set of 1K and UCL CONT. 0|0 column represents the sum of total wild-type homozygous individuals genotyped in 
each data set; 1|0 column represents the total of heterozygous individuals genotype; 1|1 column represents the total mutated 
homozygous individuals genotyped. 
0|0 1|0 1|1 0|0 1|0 1|1 0|0 1|0 1|1 0|0 1|0 1|1
UCL 909 32 0 1011 62 0 561 42 0 1572 104 0
UCL + 1K 1274 45 0 1011 62 0 561 42 0 1572 104 0
UK10K 949 33 0 0 0 0 1342 49 1 1342 49 1
UCL + 1K + UK10K 2223 78 0 1011 62 0 1903 91 1 2914 153 1
Swedish 2475 70 0 0 0 0 2476 67 2 2476 67 2
UCL + 1K + UK10K + Swedish 4698 148 0 1011 62 0 4379 158 3 5390 220 3
Genotypic Count
CasesControl BPD SCZ
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UCL 1.27E-02 1.58E-03 2.21E-03 1.18E-01 3.79E-02 7.85E-01 2.97E-01 7.52E-01 3.66E-01
UCL + 1K 5.91E-03 5.89E-04 5.69E-04 8.11E-02 1.82E-02 7.71E-01 2.38E-01 7.32E-01 3.05E-01
UCL + UK10K 4.37E-02 5.63E-03
UCL + Swedish 1.31E-01 4.55E-03
UCL + 1K + UK10K 1.71E-04 1.13503E-05 2.17E-06 3.53E-02 3.44E-03 2.34E-01 4.04E-02
All Controls 1.52464E-05 9.92111E-07 1.11E-08 1.16E-03 7.86E-06 1.35E-01 8.15E-03
Cases
C
o
n
tr
o
ls
All Cases
Association analysis (p-
value)
UCL BPD UCL SCZ UCL Cases
UCL + 
UK10K SCZ
UCL + 
UK10K 
Cases
All SCZ
UCL + 
Swedish 
SCZ
UCL + 
Swedish 
Cases
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Table 4-10  Summary of genotype counts and significant association p-values  for combined analysis of the 5 synonymous variants from 
the 1K Genome Project data, the UCL samples, the UK10K exome sequence data and the Swedish exome data. The upper table 
represents genotype counts of synonymous variants found in CACNG5 from each cohort. The lower table represents CACNG5 pooled 
burden analysis association test result for the synonymous variants in each cohort or combined analysis of these cohorts. 1K = 1K 
genome project data; UCL CONT = UCL control subjects; UCL BP = UCL bipolar disorder subjects; UCL_SCZ = UCL schizophrenia 
subjects; UK10K = UK10K exome data control and schizophrenia subjects; Swedish exome data = Swedish exome data control and 
schizophrenia; 1K + UCL CONT = combined set of 1K and UCL CONT. 0|0 column represents the sum of total wild-type homozygous 
individuals genotyped in each data set; 1|0 column represents the total of heterozygous individuals genotype; 1|1 column represents the 
total mutated homozygous individuals genotyped. 
0|0 1|0 1|1 0|0 1|0 1|1 0|0 1|0 1|1 0|0 1|0 1|1
UCL 775 158 9 890 168 13 480 111 9 1370 279 22
UCL + 1K 1071 234 16 890 168 13 480 111 9 1370 279 22
UK10K 792 186 4 0 0 0 1109 271 12 1109 271 12
UCL + 1K + UK10K 1863 420 20 890 168 13 1589 382 21 3430 747 39
Swedish 2043 485 17 0 0 0 2060 468 17 2060 468 17
UCL + 1K + UK10K + Swedish 3906 905 37 890 168 13 3649 850 38 5490 1215 56
SCZ Cases
Genotypic Count
Control BPD
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UCL 7.55E-01 2.02E-01 7.03E-01
UCL + 1K 2.38E-01 5.19E-01 6.03E-01
UCL + UK10K 1.32E-01 4.42E-01
UCL + 1K + UK10K 3.19E-01 8.63E-01
UCL + Swedish 8.99E-01 7.07E-01
UCL + 1K + Swedish 8.13E-01 4.35E-01
All Controls 8.07E-01 7.90E-01
C
o
n
tr
o
ls
Association analysis 
(p-value)
UCL 
BPD
UCL SCZ
UCL 
Cases
UCL + Swedish 
SCZ
UCL + Swedish 
Cases
All SCZ All Cases
Cases
UCL + 
UK10K SCZ
UCL + UK10K 
Cases
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The allelic association of the three promoter region SNPs between patients and healthy controls 
are summarised in Table 4-11. As shown in the table, there was no evidence for association with 
SCZ, BPD, or in a combined analysis. Only SNP 17_64873175 showed a significant association 
with UCL controls (p = 0.0236) and with a combined set of controls (p = 0.0327) when 
compared with UCL SCZ samples, no carrier found.  
Table 4-11 Summary of putative promoter variants genotype counts and allelic association 
analysis 
0|0 1|0 1|1 UCL_BP UCL_SCZ UCL BP+SCZ
1K EURO 345 32 2 0.857 0.709 0.970
UCL CONT 866 71 0 0.210 0.076 0.095
1K + UCL CONT 1211 103 2 0.377 0.139 0.184
UCL BPD 963 91 3
UCL SCZ 538 53 4
UCL BPD + SCZ 1501 144 7
0|0 1|0 1|1 UCL_BP UCL_SCZ UCL BP+SCZ
1K EURO 377 2 0 0.534 0.076 0.968
UCL CONT 928 8 0 0.997 0.024 0.349
1K + UCL CONT 1305 10 0 0.802 0.033 0.464
UCL BPD 1046 9 0
UCL SCZ 598 0 0
UCL BPD + SCZ 1644 9 0
0|0 1|0 1|1 UCL_BP UCL_SCZ UCL BP+SCZ
1K EURO 379 0 0 0.089 0.258 0.129
UCL CONT 923 8 0 0.808 0.218 0.463
1K + UCL CONT 1302 8 0 0.658 0.444 0.992
UCL BPD 1043 8 0
UCL SCZ 592 2 0
UCL BPD + SCZ 1635 10 0
rs75486725
Genotype Counts p-value
rs3760263
Genotype Counts p-value
17_64873175
Genotype Counts p-value
 
4.2.8 Bioinformatics analysis – prediction of the effects of variant on protein function 
To assess the possibility that the CACNG5 nsSNPs variants have functional effects on the protein, 
we performed bioinformatic analysis of the variants with the widely used programmes SIFT, 
PolyPhen2, and Mutation Taster. These programmes predict the functional effects of variants on 
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a protein. The results of these analyses are summarised in Table 4-12. The variant that was 
predicted to have the strongest effect on protein function variant was p.Val146Met and this 
variant had the highest scores in all tests with the prediction of the protein as probably 
functionally affected. Variants p.Arg69Trp and p.His233Tyr were predicted to be possibly 
damaging; H233Y is a relatively common SNP and is widely reported in the genome databases, 
whilst R69W was found in a single individual of African origin in the 1K Genomes project data. 
Three variants, p.Thr128Met, p.Ile156Phe, and p.Thr164Ile were predicted to be probably 
damaging by PolyPhen2; conversely they were predicted to be tolerated by SIFT. Two further 
variants p.Arg127Gln and p.Ala182Ser, which were detected in the European sample from the 
1K genome databases and were predicted to be benign.  
Table 4-12 Summary of bioinformatic analysis of nsSNPs 
PolyPhen2 SIFT Mutation Taster
R69W Possibly damaging Affect protein function Protein affected
R71H Probably damaging Tolerated Disease causing
R127Q Benign Tolerated Protein affected
T128M Probably damaging Tolerated Disease causing
V146M Probably damaging Affect protein function Protein affected
I156F Probably damaging Tolerated Protein affected
T164L Probably damaging Tolerated Protein affected
A182S Benign Tolerated Disease causing
H233Y Possibly damaging Affect protein function Disease causing
Amino acid 
change
Predicted effect on protein
 
PolyPhen2: http://genetics.bwh.harvard.edu/pph2/index.shtml 
SIFT: http://sift.jcvi.org/ 
Mutation Taster: http://www.mutationtaster.org/ 
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4.3 Discussion 
The aim of our study was to identify functional risk variants for psychiatric disorders in the 
calcium channel subunit gene CACNG5. We chose HRMA as a fast and cost effective technique 
to analyse the complete coding and putative promoter regions of the CACNG5 gene. Amplicons 
that were likely to contain variants were then selected for Sanger sequencing. All variants 
successfully validated by Sanger sequencing were then genotyped in all available BPD, SCZ and 
controls samples. Our results do not unequivocally implicate the rare variants of the CACNG5 
gene in the aetiology of BPD and SCZ. They also do not provide a clear answer to the question 
of whether certain variants are involved in distinct or overlapping susceptibility. They may 
however, go some way to explaining some of the association finding reported by Curtis et al., 
2011 (Curtis et al. 2011). 
One of the most promising variants detected was p.Val146Met in exon 4 of CACNG5. 
This variant was first identified in a UCL SCZ patient but was absent in the UCL BPD and 
control samples and in the European samples from the 1K Genomes project. Additionally, this 
variant was also detected in one SCZ patient from a replication case (n = 643) control (n = 518) 
cohort from Aberdeen (Table 4.2.2). Furthermore, it was also not found in both UK10K and 
Swedish exome sequencing data. Therefore p.Val146Met could be considered to be a rare SCZ 
relevant polymorphic variant. Bioinformatic analysis and localisation of the variant have also 
suggested that it is highly likely to have a functional effect on the protein. Interestingly, a recent 
functional study reported a de novo variant p.Val143Leu in CACNG2 (also known as stargazin), 
which is another calcium channel   subunit gene, was found in a patient with intellectual 
disability. This variant significantly decreased stargazin’s ability to bind to GluR1 or GluR2 
AMPAR subunits in HEK293 cells (Hamdan et al. 2011). It also showed a decrease in GluR1 
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cell surface expression and excitatory postsynaptic current in transfected hippocampal neurons. 
Amino acid alignments with the other TARP subunits show that the V146 and V143 residues are 
conserved within TARP subgroups (Figure 4-6). 
 
Figure 4-6 Evolutionary conservation of the V146 region of CACNG5. A. Protein sequence 
alignments of all human calcium channel  subunits surrounding the mutations. B. Cross 
species Amino acid conservation of CACNG5 residues affected by the variant (Hamdan et 
al. 2011). 
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Figure 4-7 Analysis of variants in the extracellular loop of CACNG5. A. Schematic 
diagrams showing predicted membrane topology and putative functional sites on TARP 
subunits and claudins. B. Protein sequence alignments of the first large extracellular loop 
of all human TARP subunits (Chen et al. 2007). 
The molecular dissection of TARP function has begun to elucidate the domains that 
mediate differential regulation of AMPA receptor trafficking and function (Tomita et al. 2005a). 
Structural and functional studies suggest that the long extracellular loop is essential for the 
modulation of the channel properties and also a binding site for AMPAR ligand binding domain 
(Tomita et al. 2005a, Turetsky et al. 2005). However, the protein alignments of TARPs show 
important differences between subgroups. Previous studies showed that the substitution of this 
domain of stargzin ( with that from 4 increased glutamate affinity and reduced the kinetics of 
deactivation and desensitisation (Cho et al. 2007, Milstein et al. 2007).  Thus, the sequence 
differences in this domain may confer altered receptor pharmacology and channel gating. In 
addition, this domain has a close sequence alignment with Claudin proteins particularly at N-
glycosylation sites and at two cysteine residues. Interestingly, two of our variants R69W and 
R71H, are located in the first extracellular between the two cysteine residues (Figure 4-7). 
Bioinformatic prediction revealed that R69W possibly effects protein function, while R71H was 
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only predicted to be probably damaging by one analysis. This is likely to be a reflection of 
difference in the conservation of the two residues. Maher et al (Maher et al. 2011) showed that 
residue of R69W has similar amino acids present in >50% of sequences in other calcium channel 
 subunits. Whereas, Chu et al (Chu et al. 2001) showed that this residue was only common to 2 
through 8, excluding 6. Conversely, R71H polymorphism is not a conserved residue, but the 
alternative codon histidine is identical to the equivalent 4 residue. Even though there is not 
strong support for this finding, there is still the possibility that the physical properties of this 
substitution could have an effect on the functioning of neighbouring amino acid(s) that in turn 
alter protein affinity. 
 
Figure 4-8 Evolutionary conservation of the R127 and T128 region of CACNG5. A. Protein 
sequence alignments of all human  subunits surrounding the R127Q and T128M variant 
sites. B. Cross species amino acid conservation of CACNG5 residues affected by the 
variants. 
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 Bioinformatic analysis of the R127Q amino acid substitution revealed that this change is 
likely to have a benign effect on protein function. Similar analysis of T128M with Polyphen 2, 
SIFT produced a prediction of probably damaging (albeit with a damaging score of 0.997; the 
most damaging score being 1) with Polyphen 2 whilst SIFT predicted that this amino acid 
change would be tolerated.  According to their amino acid position, R127Q and T128M are 
likely to be located in the intracellular loop of the protein, close to the third transmembrane 
domain. Cross species amino acid conservation analysis showed that both R127Q and T128M 
SNPs are highly conserved within the species analysed (Figure 4-8 pane B). However, the amino 
acid alignment of all human  subunits revealed a low conservation in T128M, while R127Q has 
approximately 50% identical residue to other -subunits (Figure 4-8 pane A). Hence, these two 
amino acid substitutions might be predicted to have a low possibility of effecting protein 
function. 
 Two novel nsSNPs that were predicted to lead to I156F and T164I amino acid 
substitutions were predicted to be probably damaging in PolyPhen2 analysis but were predicted 
to be tolerated in SIFT. Both residues are located in the second extracellular loop, which does not 
appear to be involved in AMPA receptor binding or trafficking. However, amino acid 
substitutions could cause alterations in the secondary structure of the protein. Hence, there is still 
a possibility that these SNPs could still have an effect on protein function.  
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Figure 4-9 Schematic diagrams showing predicted membrane topology and PDZ binding 
site motif on both types of TARPs (Kato et al. 2010). 
 Bioinformatic analysis of the H233Y substitution caused by the more common nsSNP 
rs41280112 was also been predicted to affect protein function. Type I TARPs contain a typical 
PDZ domain binding motif (-TTPV) at their C-terminus (Figure 4-9). This binding motif has 
showed to regulate the synaptic localisation of AMPARs. In contrast, Type II TARPs contain an 
atypical PDZ-binding motif (-S/TTPC) at their C-terminus. H233Y is located in the C-terminus 
and close to the atypical PDZ-binding motif (Figure 4-9). Hence, the amino acid substitution, 
which changes the physical properties of the residue, could affect the binding affinity of the 
domain.  
In summary, screening of CACNG5 for variants by HRMA enabled identification of rare 
variants of that may have a role in susceptibilities to SCZ and/or BPD. However, bioinformatic 
analysis only provides a prediction of the effect of these substitutions without giving evidence 
for how these changes may affect the normal functioning of the protein. To find mechanistic 
evidence for the impact of the candidate variants on CACNG5 function, further functional studies 
must be conducted. Thus, the full characterisation of molecular aetiology of variants in the 
CACNG5 gene may facilitate possible therapeutic intervention. 
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5 Rare mutations identified in CACNG5 from bipolar disorder and 
schizophrenia individuals exhibit impaired expression of intracellular and 
cell surface AMPA receptors 
5.1 Background 
Bipolar disorder and schizophrenia are important causes of disability as well as financial and 
emotional burden worldwide. Over the past decade, the glutamatergic system has been 
implicated in the pathophysiology and possible treatment of major depressive disorder, bipolar 
disorder, and schizophrenia; however, the molecular changes that underlie this pathology still 
remain poorly understood (Auer et al. 2000, Hashimoto et al. 2007, Mauri et al. 1998, Mitani et 
al. 2006). Accordingly, ionotropic glutamate receptors (iGluRs) which mediate fast excitatory 
neuro-transmission at synapses within the central nervous system are promising therapeutic 
targets for the treatment of neuropsychiatric disorders. Previous studies have suggested that the 
iGluR N-methyl-D-aspartate (NMDA) receptor may be involved in the pathophysiology of mood 
disorders (Javitt 2004, Petrie et al. 2000, Skolnick et al. 2009). NMDA receptor antagonists such 
as phencyclidine (PCP) and ketamine induce schizophrenia-like symptoms in normal subjects 
and that there are even worse in schizophrenia patients (Allen and Young 1978, Barbon et al. 
2007, Coyle 1996, Coyle et al. 2003, Ellison 1995, Lahti et al. 1995, Meador-Woodruff and 
Healy 2000). Recently, a review of ketamine suggests that a low-dose ketamine effects on the 
glutamatergic system and abnormalities in this neurotransmitter system are present in depression 
(Naughton et al. 2014). One mechanism that may explain the abnormal regulation of NMDA is 
that this may be due to abnormal expression and localisation of AMPA glutamate receptors. 
There is evidence that alteration of AMPA receptor activity at the postsynaptic density either by 
their dysregulation of receptor expression or cell surface trafficking could decrease activity of 
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NMDA receptors (NMDAR), resulting in the appearance of psychotic symptoms (Coyle et al. 
2003, Meador-Woodruff and Healy 2000). Some studies have also found increased AMPA 
receptor (AMPAR) binding in the cortex of schizophrenia patients (Noga et al. 2001) 
(Zavitsanou et al. 2002). These findings suggest that the dysregulation of AMPA receptors 
(AMPARs) may lead to psychotic illness.  
A potential mechanism underlying AMPAR disturbances in neuropsychiatric conditions is 
abnormal expression of AMPAR auxiliary proteins that regulate AMPAR function, localisation, 
and trafficking (Beneyto and Meador-Woodruff 2006, Dracheva et al. 2005, Hammond et al. 
2010, Malinow and Malenka 2002, Mirnics et al. 2000, Song and Huganir 2002, Toyooka et al. 
2002, Whiteheart and Matveeva 2004). Transmembrane AMPAR regulatory protein gamma () 
subunit 2 (TARP-2/stargazin), was the first such protein found to interact with AMPARs (Chen 
et al. 2000, Diaz 2010, Nakagawa and Sheng 2000, Tomita 2010, Vandenberghe et al. 2005b). 2 
was initially identified from the natural occurring mutation that is found in the so called stargazer 
mice, result in absence epilepsy, cerebellar ataxia, and a characteristic abnormal motor syndrome 
(Khan et al. 2004). The stargazin mutation is associated with selective loss of AMPARs function 
in cerebellar granule cells (Chen et al. 2000, Hashimoto et al. 1999). The gene encoding 2 is 
known as voltage-dependent calcium channel gamma subunit 2 (CACNG2) due to its sequence 
homology to the skeletal muscle tetraspanning calcium channel 1 subunit (Jay et al. 1990). 
Currently, eight TARPs have been identified, each subunit seems to have a variety of roles in 
AMPAR cell surface trafficking and its biophysical properties (Chen et al. 2003, Chen et al. 
2007, Coombs and Cull-Candy 2009, Diaz 2010, Jackson and Nicoll 2011a, Kato et al. 2007, 
Klugbauer et al. 2000, Tomita et al. 2003). For instance, 4 shows an effect on the slow gating of 
AMPARs (Cho et al. 2007, Korber et al. 2007, Kott et al. 2007, Milstein et al. 2007); whereas 7 
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greatly enhance glutamate-evoked currents from GluR1 (Kato et al. 2007). Specifically, 5 has 
been widely used as a negative control in experiments for identifying TARPs (Tomita et al. 
2005a, Tomita et al. 2004, Turetsky et al. 2005), because it does not restore functional AMPARs 
on stargazer cerebellar granule cells (Kato et al. 2007). Recently, 5 was found to selectively 
regulate the functional properties of a splice variant of the AMPAR GluR2 subunit and the 
homomeric AMPAR of GluR1 receptor (Soto et al. 2009). In addition to trafficking of AMPAR, 
5 significantly decreased the cell surface expression of homomeric GluR2(Q) and long form 
GluR2(Q) protein; in contrast, it led to a slight increase in the cell surface expression of 
homomeric GluR2(R) protein (Soto et al. 2009).    
Although several studies have reported the regulation of AMPAR by TARPs, little is known 
about the expression of TARP-5. Several recent studies on inflammatory bowel disease (Rivas 
et al. 2011), multiple sclerosis (Zhuang et al. 2015), type 2 diabetes (Bonnefond et al. 2012), 
schizophrenia (Gulsuner et al. 2013, Kenny et al. 2014) have demonstrated that susceptibility to 
common disease may mediated by rare variants. With this disease mechanism in mind, we 
characterised eight non-synonymous SNPs (R69W; R71H; rs142916987, R127Q; rs149159754, 
T128M; V146M; I156F; T174L; rs41280112, H233Y) in human CACNG5,  using a combination 
of in vitro co-transfection and flow cytometry (fluorescence activated cell sorting; FACS). 
Functional characterisation of such variants may prove useful for the translation of genetic 
findings to disease prediction, pharmacogenetic applications and novel drug development.   
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5.2 Aims and Objective 
The previous genotyping analysis found evidence that nsSNP CACNG5 variants were associated 
with psychiatric illness. Bioinformatic analysis of the potential consequence that the variant may 
have a damaging effect on protein structure/function. It is therefore possible that the nsSNPs may 
have an effect upon the regulation of protein expression and/or AMPAR surface expression, 
which in turn may be associated with psychosis illness. Additionally, in vitro mutated CACNG5 
constructs should provide opportunities to understand how TARP-5 function is affected.  
To determine the effects of these variants, the previous genotyping results were used to design 
mutated CACNG5 expression constructs that were subsequently co-transfected into HEK293 
cells alone with GluR1 or GluR2 homotetramer subunits. The subsequent effect of the CACNG5 
variants on GluR1 or GluR2 homotetramer subunit expression was monitored by the presence of 
a pH-sensitive green fluorescent protein (GFP) fusion protein on the cell membrane. This pH-
sensitivity GFP tag protein is a mutated GFP with pH sensor, known as super-ecliptic pHluorin 
(SEP), which was tagged on AMPAR subunits and acts as a marker for surface-expressed 
receptors (Ashby et al. 2004, Miesenbock et al. 1998, Sankaranarayanan et al. 2000).  The 
construct is a chimera of SEP fused to the N-terminus of the AMPAR subunit (i.e. SEP-GluR2). 
When the N-terminal domain of receptor tagged with SEP migrates to the pH neutral outside of 
the cell from the relatively acidic internal vesicle compartments there is a dramatic (100 fold) 
increase in fluorescence (Figure 5-1) (Ashby et al. 2004). The green fluorescent intensity signal 
from each cells were captured by FACS. This cell sorting technique allowed discrimination of 
cells by the intensity of their green fluorescent signal. The actual numbers of cells with different 
levels of fluorescence determined automatically by the software. FACS has been widely used for 
237 
 
a number of studies including those that have studied the identity and fluorescent intensity from 
large numbers of cells.  
 
Figure 5-1 The migration of SEP-GluR2 through the compartments of the secretory 
pathway. ER: endoplasmic reticulum (Ashby et al. 2004). 
Since the disease-associated rare variants found in our previous study were predicted to have a 
possible effect on protein structure or binding affinity, it is a highly interesting investigation on 
their effect. To test this, SEP-GluR1 or SEP-GluR2 alone with wild-type TARP-5 or mutated 
TARP-5 were co-transfected in HEK293 cells. 24 hours after transfection, the cells were 
collected and sorted using FACS (BD FACSAriaII) to quantify the number of cells and the 
intensity of green fluorescence in each cell. Discrimination the location of AMPAR subunits 
expressed between intracellular and surface was set by the given green fluorescent intensity from 
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the membrane AMPAR proteins, where it showed a 100-fold brighter green fluorescent signal. 
Data were analysed using Kaluza software and presented as the mean ± SEM. The statistical 
analysis was performed using a two-tailed unpaired Student’s t-test in Excel. The differences 
were considered significant with a P-value < 0.05. 
5.3 Results 
To quantify the number of GluR2 expressing cells, a control experiment was run from with and 
without fluorescent tag proteins. The data from these experiments were used to determine 
baseline parameters for the Kaluza analysis software. Each sample of cells was sorted at a rate of 
7500 – 8500 events ensuring that necrotic cells and cellular debris were not captured as 
legitimate events. Co-transfection of non-tagged AMPAR and TARP-5 in HEK293 cells 
revealed zero green fluorescent intensity as shown in region C of figure 5-2 A; this represented 
the distribution of unstained cells. In contrast, SEP tagged AMPAR co-expressed with TARP-5 
showed a 10-fold increase in green fluorescent intensity and this represented the intracellular 
expression of the AMPAR fusion protein in the cells (Figure 5-2 B; area D and Y). As mentioned 
previously SEP tagged GluR2 constructs expressed a super-ecliptic pHluorin protein, which is 
known as an enhanced version of pHluorin. The trafficking of the AMPAR to the cell surface 
would be expected to show a 100-fold brighter green light from cells. Cells with these high 
levels of fluorescence would represent cells expressing cell surface trafficked AMAPR (Figure 
5-2 B; area Y).  
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Figure 5-2 Typical histogram plots of GFP intensity from transfected cells generated by Kaluza 
software. The figure illustrates how regions were set to discriminate between the regions of 
SEP-AMPAR expression in the data. Areas E+D+Y represent all AMPAR expressing cells; 
areas C or E represent non-green fluorescent protein expression cells; area D represents 
intracellular AMPAR expressing cells; area Y represents membrane AMPAR expressing 
cells. 
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5.3.1 TARP-5 increased cells expressing GluR2 
 
Figure 5-3 Percentage of cells expressing GluR2 was compared with cotransfected wild-
type TARP-5 and control vector. Unstained represents cells co-expressing non-fluorescent 
control constructs; GluR2 represents as cells co-expressing SEP-GluR2 and a control 
vector; TARP-5 represents cells co-expressing SEP-GluR2 and the wild-type TARP-5 
construct. 
The discrimination parameter utilised by the Kaluza software showed that the percentage of cells 
expressing GluR2 was increased when the cells were co-transfected with wild-type TARP-
5from 58.06% to 67.05% of cells (Figure 5-3). Only two replicates of these experiments were 
performed and it was not possible to statistically analyse these data. However, the findings were 
in agreement with the previous literature (Tomita et al. 2005a, Tomita et al. 2004, Turetsky et al. 
2005). If wild-type TARP-5 enhanced GluR2 expression in the cells, does TARP-5also 
regulate the trafficking of GluR2 to the cell surface?  
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5.3.2 TARP-5 increases GluR2 trafficking to the cell surface 
 
Figure 5-4 The percentage of cells expressing GluR2 on their surface was compared with 
co-expressed wild-type TARP-5 and control vector. Unstained represents cells co-
expressing non-fluorescent constructs; GluR2 represents cells co-expressing SEP-GluR2 
and control vector constructs; TARP-5 represents cells co-expressing SEP-GluR2 and the 
wild-type TARP-5 construct. 
To identify whether TARP-5 regulates the trafficking of GluR2 in the cells, the surface and 
intracellular expression of GluR2 were discriminated via the intensity of the green fluorescence 
(Figure 5-2 B; area Y). The results from these experiments revealed that wild-type TARP-5 co-
transfection led to increased surface trafficking of GluR2, from 0.21% to 0.78% (Figure 5-4). A 
similar result has been published which showed that the co-expression of wild-type TARP-5 
increased surface trafficking of edited GluR2, known as Ca
2+
 impermeable subunit (Soto et al. 
2009). Taken together, the results suggested that wild-type TARP-5 regulates specific Ca2+ 
impermeable GluR2 subunit expression and surface trafficking in the cells.  
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5.3.3 TARP-5 variants significantly increase GluR2 cell surface expression 
  
Figure 5-5 Percentage of cells expressing GluR2 was compared after co-transfection with 
wild-type mutated TARP-5. WT represents cells-co-expressing wild-type TARP-5 
constructs; SNP represents cells co-expressing mutated TARP-5 constructs. Data were 
presented as mean ± SEM (n = 3 or 4). 
To characterise the rare variants (nsSNPs) found in our schizophrenia and bipolar disorder 
patients (Table 4-2), each variant was introduced into the CACNG5 gene, and then co-transfected 
with GluR2 in HEK293 cells. The cells expressing GluR2 were not significantly affected by the 
co-transfection of mutated CACNG5 (Figure 5-5).  
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Figure 5-6 Percentage of cells expressing surface GluR2 was compared after co-
transfection with wild-type and mutated TARP-5. WT represents cells-co-expressing wild-
type TARP-5 constructs; SNP represents cells co-expressing mutated TARP-5 constructs. 
Data are presented as mean ± SEM (n = 3 or 4), * = p<0.05; ** = p<0.005; *** = p<0.001. 
By contrast cell surface GluR2 expression was significantly affected by co-transfection with 
specific TARP-5 variants (Figure 5-6). The most promising result is that the cells co-transfected 
with an amino acid substitution at p.Val146Met of TARP-5 gene significantly increased cells 
expressing surface GluR2, from 0.78% ± 0.40 cells to 18.89% ± 1.22 cells, p = 3.12 x 10
-5
 
(Figure 5-6 B). Based on the observed changes in cell surface GluR2 expression, it may be 
assumed that this rare allele may have a role in psychiatric conditions such as schizophrenia 
(characterised by excess of GluR2 trafficking). Another functional study of the de novo variant 
p.Val143Leu in TARP-5 found in an individual with intellectual disabilities showed 
significantly decreased binding affinity to GluR2 in HEK293 cells (Hamdan et al. 2011). These 
results suggest that rare variants in Ca
2+
 channel  subunit genes have the potential to affect 
regulation of GluR2.  
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Another variant, p.Ile156Phe also located in second extracellular loop of TARP-5 protein 
showed a significant increase in the percentage of cells expressing surface GluR2 from 0.78% ± 
0.40 cells to 10.15% ± 3.23 cells (p = 0.019; Figure 5-6 B).  
The variant p.His233Tyr located at the C-terminus and close to the atypical PDZ-binding motif 
of TARP-5, also showed a significantly increase in the percentage of cells expressing GluR2 on 
their surface (from 0.78% ± 0.40 cells to 11.38% ± 2.20 cells, p = 0.0026; Figure 5-6 B). The 
atypical PDZ domain binding motif (-TTPV) of type I TARPs at their C-terminus has been 
shown to regulate the synaptic localisation of AMPARs (Itakura et al. 2014). Our results indicate 
that the C-terminus of TARP-5 may play a role in regulating cell surface trafficking of Ca2+ 
impermeable GluR2 subunits. 
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5.3.4 The effect of TARP-5 on the proportion of cells expressing GluR1 
 
Figure 5-7 The percentage of cells expressing GluR1 was compared after co-transfection 
with wild-type TARP-5 and a control vector. Unstained represents cells co-expressing 
unstained constructs; GluR1 represents cells co-expressing SEP-GluR1 and control vector 
constructs; TARP-5 represents cells co-expressing SEP-GluR1 and the wild-type TARP-5 
construct. Data are presented as mean ± SEM (n = 4) 
Several of the Ca
2+
 channel  subunit gene family members interact with GluR1 subunits of 
AMPAR. Therefore, TARP-5 could conceivably facilitate the elevation of intracellular or cell 
surface GluR1 expression and trafficking. Our result showed that there was a modest trend for an 
increase in the percentage of cells expressing GluR1 following by co-transfection with wild-type 
TARP-5 (from 55.91% ± 3.41 cells to 61.43% ± 4.77 cells, p = 0.14; Figure 5-7).  
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Figure 5-8 The percentage of cells expressing surface GluR1 was compared after co-
transfection with wild-type TARP-5 and a control vector. Unstained represents cells co-
expressing unstained constructs; GluR1 represents cells co-expressing SEP-GluR1 and 
control vector constructs; TARP-5 represents cells co-expressing SEP-GluR1 and the 
wild-type TARP-5 construct. Data are presented as mean ± SEM (n = 4). 
There was also a non-significant trend for an increase in the percentage of cells expressing 
GluR1 on their cell surface after co-transfection with wild-type TARP-5 (Figure 5-8). One 
explanation for the lack of significance was that the number of cells expressing intracellular and 
cell surface GluR1 were variable. Although we did not produce strong evidence of TARP-5 
regulating the percentage of cells expressing GluR1, it is still interesting to understand the 
regulation of GluR1 by TARP-5 in the cells.    
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5.3.5 Mutated TARP-5 decreases the percentage of cells expressing intracellular and cell 
surface GluR1 
 
Figure 5-9 The percentage of cells expressing GluR1 was compared after co-transfection 
with wild-type and mutated TARP-5. WT represents cells-co-expressing wild-type TARP-
5 constructs; SNP represents cells co-expressing mutated TARP-5 constructs. Data are 
presented as mean ± SEM (n = 4), * = p<0.05; ** = p<0.005. 
To identify whether each rare variant in TARP-5 affects regulation of the percentage of 
GluR1expressing cells, co-transfection of GluR1 and mutated TARP-5 cells were compared 
with co-transfection with wild-type TARP-5 . Both p.Arg69Trp and p.Arg71His located in the 
long extracellular loop of the TARP-5 protein showed a significant reduction in the percentage 
of cells expressing GluR1 (Figure 5-9). Structural and functional studies have suggested that the 
long extracellular loop of TARP-5 plays an important role in the modulation of AMPAR 
channel properties. This loop also harbours the AMPAR ligand binding domain (Tomita et al. 
2005a, Turetsky et al. 2005). The substitution of this domain of TARP-2 with the domain from 
TARP-4 increases glutamate affinity (Cho et al. 2007, Milstein et al. 2007). Therefore, the 
reduction in the percentage of cells expressing GluR1 that resulted from the presence of these 
two variants may also affect channel properties and binding affinity.  
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The most significant changes in GluR1 expression were with the p.Thr128Met and p.Thr164Leu 
variants. Both showed a decrease in cells expressing GluR1 (p = 0.0029 and p = 0.0041, 
respectively; Figure 5-9). p.Thr164Leu is also located in the extracellular loop of the TARP-5 
protein, which is known to mediate the binding affinity of AMPAR (Turetsky et al. 2005); 
whereas p.Thr128Met is located in the intracellular loop, close to the third transmembrane 
domain. To date, there is no evidence to suggest a functional role for the intracellular loop of the 
TARP- 5protein.  
 
Figure 5-10 The percentage of cells expressing GluR1 on their surface was compared after 
co-transfection with wild-type and mutated TARP-5. WT represents cells co-expressing 
wild-type TARP-5 constructs; SNP represents cells co-expressing mutated TARP-5 
constructs. Data are presented as mean ± SEM (n = 3 or 4), * = p<0.05. 
The four CACNG5 variants that were found to reduce the percentage of cells expressing GluR1 
also showed significant decreases in the percentage of cells expressing GluR1 on their surface 
(Figure 5-10). This significant reduction also included p.Arg127Gln one of the variants that was 
also located in the intracellular loop of the TARP-5 protein. These results suggest that TARP-5 
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variants may have a potential effect on the expression of both GluR1 and GluR2 subunits and 
particularly on their trafficking to the cell surface.  
5.4 Discussion 
TARPs are important regulatory proteins that indirectly mediate glutamatergic synapses. Several 
variants in this family of proteins have been shown to be associated with different 
neuropsychiatric disorders, such as schizophrenia, epilepsy, and intellectual disability, 
(Drummond et al. 2013, Hamdan et al. 2011, Letts et al. 1998). However, gaps remain in the in 
depth understanding of functional characterisation of all TARPs. From our previous genetic 
study, the rare variants found in TARP-5 gene, known as CACNG5, showed an association in 
bipolar disorder and schizophrenia. Such rare variants may contribute to the aetiology of these 
complex disorders and therefore the functional characterisation of their effects is important 
(Bamshad et al. 2011, Gibson 2011). 
Quantitative and functional analysis of eight variants in the CACNG5 gene in comparison to the 
wild-type have provided insights into which of them may affect functionally important amino 
acids. Of the eight CACNG5 variants analysed, p.Val146Met and p.Ile156Phe which are located 
in the second extracellular loop region of TARP-5, significantly increased cell surface 
expression of GluR2 (Figure 5-6 B). Conversely, these two variants led to non-significant 
decreases in the percentage of cells expressing GluR1 on their surface (Figure 5-7).  The analysis 
presented here suggests that this TARP-5 domain may differentially interact with specific 
AMPAR subunits.  
The p.Thr164Leu variant is also located in the second extracellular loop region of TARP-5, and 
showed a significant decrease in the percentage of cells expressing GluR1 on their surface 
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(Figure 5-8). There was also a non-significant reduction in cells expressing surface GluR2 was 
also reduced when co-transfected with this in CACNG5 variant (Figure 5-6 A). These results 
suggest that this variant may reduce the expression and trafficking of AMPAR subunits.  
Four rare variants, p.Arg69Trp, p.Arg71His, p.Arg127Gln, and p.Thr128Met are located in the 
first extracellular loop and intracellular loop regions of TARP-5 and led to significant decreases 
in the percentage of cells expressing GluR1 on their surface (Figure 5-9). These variants also led 
to non-significant decreases in the percentage of cells expressing surface GluR2 on their surface 
(Figure 5-6 A). Functional and structural studies have suggested that the first extracellular loop 
of TARP-5 controls AMPAR channel properties and its binding affinity (Tomita et al. 2005a, 
Turetsky et al. 2005). Our results are in agreement with the previous findings and suggest that 
p.Arg69Trp and p.Arg71His variants reverse the normal regulation of AMPAR subunits in these 
cells. By contrast, there is an unexpected considering that p.Arg127Gln, and p.Thr128Met 
variants fall in the region involved in trafficking of AMPAR subunits. To date this intracellular 
loop region of TARPs has not been functionally characterised. Therefore, our results are the first 
evidence that variants embedded in this intracellular loop region of TARP-5 affect expression 
and trafficking of AMPAR subunits.  
Functional analysis of the p.His233Tyr variant showed an increase in the percentage of cells 
expressing GluR2 on their surface, but a decrease in the percentage of cells expressing GluR1 on 
their surface. Both TARP-5 and its close relative TARP-7 have unusually short cytosolic tails 
(C-tails), and consequently lack two, of the ten, phosphorylation sites present in the C-tails of 
other TARP members. This shorter PDZ binding domain differs from those of other members 
suggesting that they may interact with distinct protein partners, such as Ca
2+
 impermeable GluR2 
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subunits (Bats et al. 2007). Moreover, as these sites are thought to be involved in regulation of 
AMPAR trafficking (Choi et al. 2002, Tomita et al. 2005b), it seems likely these differences 
between TARPs could enable differential receptor regulation. 
Since the regulation role of TARP-5 may be functionally different from other TARPs, the 
functional analysis of each amino acid substitution revealed that the specific functional domains 
of TARP-5 appear to differentially regulate specific AMPAR subunits. For instance, the 
variants embedded in the second extracellular loop and C-terminus region showed an increase in 
cells expressing GluR2 on their surface, but a decrease in cells expressing GluR1 on their 
surface. As a result, TARP-5 appears to act as a unique functional regulator of AMPARs 
compared to other members of calcium channel  subunit gene family.  
Variants in the extracellular loop and C-terminus of TARP-5 (p.Arg69Trp, p.Arg71His, 
p.Val146Met, p.Ile156Phe, p.Thr164Leu and p.His233Tyr) appear to be involved in GluR1 
and/or GluR2 trafficking. These variants appear to affect the binding of TARP-5 to AMPARs 
leading to altered trafficking rate. These variants provide a substrate that could be used to 
develop and understanding of the functional relationship between TARP-5 and this important 
neurotransmitter receptor which is also a high affinity antipsychotic target. 
From the genetic perspective the burden analysis suggested that in aggregate all of the variants 
studied here were associated (Chapter 4.0); however, the analysis presented here did not 
functionally implicate all of the variants. For the variants that do appear to alter AMPAR 
trafficking to the cell surface, these may begin to explain some of the complexity in the clinical 
features, etiology, family history and treatment response of bipolar disorder and schizophrenia. 
Psychostimulants that mimic altered AMPAR subunit trafficking in the manner that appear to be 
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caused by some of the  CACNG5 variants described here, may be of therapeutic value for bipolar 
disorder, schizophrenia, and similar neuropsychiatric disorders.  
Continued functional investigation of genetic variants could hold promise for improved 
understanding of the underlying mechanisms that lead to disease and also in the development of 
new therapeutics.  For example, a recent review on this topic highlighted of a rare homozygous 
mutation in the PCSK9 gene that reduces cholesterol levels and the potential for the translation 
of this finding into a blockbuster drug (Hall 2013). Our results based on rare amino acid 
substitution variants and their possible functional analysis provide a further level of evidence that 
some rare variants (V146M, I156F, and T164L) may disrupt cellular or molecular mechanisms 
and that these may lead to complex neuropsychiatric conditions.  
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6 Replicated study of rare mutations identified in CACNG5 from bipolar 
disorder and schizophrenia individuals exhibit impaired cell surface 
trafficking of AMPA receptors subunit 2  
6.1 Background 
The pathophysiology of major depressive disorder, bipolar disorder, and schizophrenia are 
thought to associate with the abnormal regulation of glutamate receptor signalling; however, the 
molecular changes that underpin this genetic susceptibility remain unclear (Auer et al. 2000, 
Hashimoto et al. 2007, Mauri et al. 1998, Mitani et al. 2006). The principle glutamate receptors 
are classified as ionotropic and metabotropic receptors. The ionotropic receptor family comprises 
NMDA, AMPA, and kainate receptors. The AMPA receptor (AMPAR) subfamily is particularly 
important in diverse sensory, behavioural and cognitive processes involving fast synaptic 
transmission, including learning and memory. By contrast, excessive AMPAR activity at the 
postsynaptic density mediated  by dysregulation of receptor expression or cell surface trafficking, 
could cause central nervous system disorders ranging from stroke to epilepsy (Addae et al. 2007). 
The development of AMPAR antagonists has been suggested as a way to improve abnormal 
glutamate neurotransmission, and would possibly to provide treatments for neuropsychiatric 
disorders such as schizophrenia, depression, and bipolar disorder.  
In the past decade, transmembrane AMPAR regulatory proteins (TARPs) were identified as 
AMPAR auxiliary subunits. They are thought to control receptor trafficking, gating, and 
pharmacology (Chen et al. 2000, Hashimoto et al. 1999, Vandenberghe et al. 2005a). Stargazin 
increases AMPAR glutamate affinity, enhances single-channel conductance, slows deactivation 
and desensitisation, and reduces the extent of desensitisation (Bedoukian et al. 2006, Priel et al. 
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2005, Tomita et al. 2005a, Turetsky et al. 2005). Mutations of TARP-2 (CACNG2; known as 
stargazing) cause absence epilepsy and cerebellar ataxia, and are thought to be associated with 
selective loss of AMPAR function (Chen et al. 2000, Hashimoto et al. 1999). Later, a family of 
related TARPs were identified, including 3, 4, 5, 7, and 8, and these regulate AMPARs in 
distinct cell types throughout the brain (Tomita et al. 2003). Molecular analyses have found that 
abnormal expression of TARPs is also associated with neurological illness. Post-mortem studies 
using brains from people suffering from schizophrenia and major depressive disorder showed 
increased and decreased stargazin mRNA expression, respectively (Beneyto and Meador-
Woodruff 2006). Additionally, the allelic polymorphisms found in the gene that encodes 
stargazin, CACNG2 are associated with increased response to lithium, the classical treatment for 
bipolar disorder (Silberberg et al. 2008). CACNG2 deletion copy number variants have also been 
found in patients with bipolar disorder and schizophrenia (Wilson et al. 2006). Taken together, 
there is good evidence to suggest that dysregulation of TARPs may associate with these 
neuropsychiatric illnesses. The results of our FACS analysis presented in chapter 5 suggested 
that transient co-expression of GluR2 and TARP-5 showed a modest increase of GluR2 
expression in HEK293 cells and that this may have been on the cell surface. Moreover, a 
statistically significant increase in GluR2 expression was shown when the cells were co-
transfected with GluR2 and certain TARP-5 variants, such as V146M, I156F, and H233Y; 
whereas the other variants led to decreased GluR2 expression. In addition experiments using the 
GluR1 subunit gave similar results but there were not statistically significant. These results 
suggested that TARP-5 may regulate the expression of GluR2, and that some of the rare 
variants detected in our studies may have specific effects on GluR2 expression and trafficking. 
TARP-5 may therefore be an effective tool for modulating the plasticity of excitatory synapses.  
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Although the increased green fluorescence intensity of GluR2 indicated that co-transfection with 
TARP-5 was having an effect in the cells, the actual mechanism by which these proteins 
interact are still unclear. For instance, the green fluorescence intensity of the SEP fusion protein 
in the cells could be altered by its environment pH level, and this could provide spurious results. 
Also, the intensity of green fluorescence was not a quantitative measure of the amount of GluR2 
protein expressed in the cells or trafficked to the cell surface. In addition to TARP-5 expression, 
the possible effect of the TARP-5 variants on TARP-5 expression or localisation was not 
measured in the previous experiments.  Therefore, in order to determine whether TARP-5 
variants alter the trafficking or expression of GluR2 in the cells, cell surface biotinylation assays 
with an additional red fluorescent tag protein on TARP-5, RFP-5 wild type or variant 
constructs were applied (see Methods section).  
Cell surface biotinylation is a method to quantify the total amount of protein on the surface of a 
cell (Fairfax et al. 2004). This is an useful method for comparing treated versus untreated groups 
of cells, and also can be used to determine the proportion of the total receptor pool that resides at 
the cell surface (Fairfax et al. 2004). Cell surface biotinylation has been used to investigate the 
relative increase in the proportion of GluR1 receptor subunits that reside at the neuronal surface 
with increasing maturity in spinal cord neurons (Mammen et al. 1997). It is therefore a suitable 
method for identifying small differences in the amount of glutamate receptor trafficked to the 
cell surface between TARP-5 wild type and its variants, which might not have been apparent 
with FACS analysis. Additionally, this method can also be used to demonstrate that whether 
TARP-5 is trafficked to the cell surface with GluR2, or is retained intracellularly.  
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The aim of this chapter was to quantify the total amount of GluR2 and TARP-5 at the cell 
surface and confirms the changes in its trafficking by the co-transfection of TARP-5 variants. 
To quantify the amount of GluR2 and TARP-5 at the cell surface, SEP-GluR2 and wild type 
RFP -TARP or mutated RFP-TARP were co-expressed in HEK293 cells. 24 hours after 
transfection, the cells were separated into two aliquots. The first was directly lysed and this was 
used to measure the total cellular amount of GluR2 and TARP-5. The second aliquot of 
transfected cells were used to measure the amount of GluR2 and TARP-5 on the cell surface. 
The cells were subjected to biotinylation prior to lysis which meant that proteins on the surface 
of the cell could then by purified away from cytoplasmic proteins using streptavidin. The 
quantification of fluorescent intensity from each protein expression band in each experiment and 
in the biological replicates was variable. Thus, the data was analysed using a linear mixed model 
to account for systematic variation. This model helps avoid potentially misleading results due to 
very different expression of proteins in different experiment or different biological replicates. 
Our findings may help to implicate the pathogenic importance TARP/AMPA interaction and 
pave the way for further investigations into the disruption of the excitatory synaptic transmission 
at the post-synapse in BPD and/or SCZ. 
6.2 Results 
6.2.1 TARP-5 increased trafficking of GluR2 to the cell surface 
To determine whether TARP-5 regulates cell surface trafficking of GluR2, cell surface 
biotinylation assays with a red fluorescent protein (RFP)-CACNG5 and pH sensitivity GFP 
fluorescent (SEP)-GluR2 constructs was performed (See Methods section). After biotin cleavage 
and western blotting, antibodies recognising RFP and SEP were able to target in GluR2 and 
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TARP-5. This method allowed quantification of both total and cell-surface expression of both 
GluR2 and TARP-5 proteins. Cells were co-transfected with either SEP-GluR2 and control 
vector or SEP-GluR2 and RFP-TARP-5. Co-transfected SEP-GluR2 and control vector cells 
showed a faint green fluoresce signal on both live cell image and western blot gel analysis 
(Figure 6-1 A); whereas co-transfected SEP-GluR2 and RFP-TARP-5 cells showed both a 
yellow signal which was as combination of both green and red fluorescent signals (Figure 6-1 B). 
When GluR2 was co-expressed with TARP-5 protein, there was a 3 fold increase expression 
(from 260.02 ± 90.65 to 962.5 ± 128.2; (n = 3, p = 0.0029) as shown in Table 6-1. However, this 
increase was not significant for the cell surface of GluR2 expression (from 335 ± 861.5 to 2788.3 
± 1218.3; (n = 3, p = 0.084). A similar result was reported by Soto et al. (Soto et al. 2009). In this 
study, the surface expression of GluR2(R) was increased by the presence of TARP-5 in 
HEK293 cells but this change was not statistically significant. Our result suggests that TARP-5 
may regulate the expression of GluR2 in the HEK293 cells, and may also have a role in 
influencing cell surface trafficking of GluR2.  
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Figure 6-1 Quantification of GluR2 in HEK293 when co-transfected with TARP-5 or a 
control plasmid (n = 3). Panel A is live cell imaging of HEK293 cells co-transfected with 
SEP-GluR2 and control vector, where only green fluorescence appears this demonstrates 
expression of GluR2 in the cell.  Panel B is live cell imaging of HEK293 cells co-transfected 
with SEP-GluR2 and RFP-TARP-5, two cells are shown with red fluorescence that 
represents TARP-5 expression. The cell with the yellow signal represents overlapping 
expression of TARP-5 and GluR2. Lower panel: western blot of cell surface GluR2 
isolated after cell surface biotinylation and of total GluR2. Panel C: box plot of western 
blot results from total cell’s GluR2 expression with and without TARP-5 expression (n = 
3). . Panel D: cell surface biotinylation result of surface GluR2 expression with and with 
TARP-5 expression analysed by linear model regression (n = 3). * P < 0.05; ** P < 0.005. 
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Table 6-1 Statistical results for GluR2 expression from western blot and biotinylation assay. 
Total represents total GluR2 in the cells; surface represents biotinylated GluR2 as surface 
GluR2. Medium represents the mean fluorescent intensity of expression; SEM = standard 
error of medium; R-square = linear regression of GluR2 expression; p-value is a 
probability under the condition that the null hypothesis is false, where the null hypothesis 
is “TARP-5 has no effect on GluR2 expression. 
Medium SEM Medium SEM
R2 260.02 90.65 335 861.5
R2 + 5 962.5 128.2 2788.3 1218.3
R-squared
p-value
Co-transfected
Total Surface
0.9137
0.002878
0.567
0.08398  
The expression of GluR2 and its trafficking in the cells appeared to be regulated by the presence 
of TARP-5; however, the underlying mechanism was still unclear. For instance, the question of 
whether TARP-5 traffics together with GluR2 or only assists it intracellularly was still 
unanswered. To address this question the expression of TARP-5 in the cells and on the cell 
surface was quantified via western blot with the combination of cell surface biotinylation assays 
(Figure 6-2). The result showed that more than half of TARP-5 in the cells was trafficked to the 
cell surface (see Table 6-2). This finding suggests that approximately half of the TARP-5 is 
trafficked to the cell surface along with GluR2, but that some is also retained intracellularly.  
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Figure 6-2 Quantification of TARP-5 in HEK293 cells when co-transfected with GluR2 (n 
= 3). Panel A: Total TARP-5 in HEK293 cells was quantified via fluorescence intensity 
(R2 + g5 represents co-transfected GluR2 and TARP-5; surface represents only surface 
proteins in the cells; whereas total represents as total proteins in the cells). Panel B: 
western blot of cell surface TARP-5 isolated by biotinylation and of total TARP-5. 
Table 6-2 Statistical results for TARP-5 expression in the cells with or without cell surface 
biotinylation assay (Total represents all cellular proteins; surface represents cell surface 
proteins detected using the cell surface biotinylation assay). Medium represents as mean 
fluorescent intensity of expression; SEM = standard error of medium; R2 = linear 
regression of TARP-5 expression; p-value is a probability under the condition that the null 
hypothesis is false, where the null hypothesis is “GluR2 has no effect on trafficking TARP-
5 to cell surface. 
Medium SEM
Total 1174.4 414.4
Surface 688.7 293
R-squared
p-value
Co-transfected
0.2556
R2 + 5
0.3063  
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6.2.2 Rare TARP-5 variant R69W showed no significant effect on GluR2 expression 
 
Figure 6-3 Quantification of GluR2 in HEK293 cells when co-transfected with wild-type 
TARP-5 or mutated TARP-5 (n = 3). Panel A is live cell imaging of co-transfected 
HEK293 cells with GluR2 and p.Arg69Trp mutated TARP-5 (R69W), the red – orange 
fluorescent signal indicates that there is little  GluR2 was expression on the cell surface.  
Panel B is live cell imaging of co-transfected HEK293 cells with GluR2 and wild type 
TARP-5. The cells expressed both red fluorescent signal and yellow signal, which indicates 
that the cells express both GluR2 and TARP-5 proteins on their surface.  Panel C: western 
blot of cell surface GluR2 isolated by biotinylation and of total GluR2. Panel D: box plot 
from western blot and cell surface biotinylation assays for GluR2 expression (n = 3). 
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Table 6-3 Statistical results for GluR2 expression from western blot and cell surface 
biotinylation assay. Total represents total GluR2 in the cells; surface represents cell surface 
biotinylated GluR2. Medium represents as mean fluorescent intensity of expression; SEM 
= standard error of medium;R2 = linear regression of GluR2 expression, p-value is a 
probability under the condition that the null hypothesis is false, where the null hypothesis 
is “R69W variant has no effect GluR2 expression in the total or surface cells. 
Medium SEM Medium SEM
Wild-type 1003 486.2 3123.4 899.3
R69W 1525.7 687.5 1516.7 1271.8
Adjusted R2
p-value
TotalCo-transfected Surface
AMPA-R2 Expression
0.126
0.49
0.2852
0.2751   
The Arg69Trp (R69W) variant was identified in one SCZ patient (Table 4-2). It is located in the 
first extracellular loop of the TARP-5 protein. To investigate whether this variant affects 
surface trafficking or expression of GluR2, the variant was introduced into a wild-type TARP-5 
and then co-transfected with GluR2 in HEK293 cells. The western blot studies showed that 
R69W was no significant effect on the expression of GluR2 in the cells; however, a slightly 
decrease in the cell surface expression of GluR2 was observed (Figure 6-3 D). Live cell imaging 
also demonstrated reduced GFP signal in the R69W transfected compared to the wild-type 
transfected cells (Figure 6-3 A and B). This result could implicate the first extracellular loop of 
TARP-5 as a possible regulatory domain for GluR2 trafficking to the cell surface. 
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Figure 6-4 Comparison of wild type TARP-5 and its carried R69W variant on the their 
expression in HEK293 cells (n = 3). Panel A: Total wild type TARP-5 and its carried 
R69W variant in HEK293 cells were quantified via fluorescence intensity (SNP69 
represents co-transfected GluR2 and TARP-5 carried R69W variant; wild-type represents 
as wild-type TARP-5; surface represents only surface TARP-5 in the cells; total 
represents as total proteins in the cells). Panel B: western blot of cell surface TARP-5 
isolated by biotinylation and of total TARP-5 in either co-transfected with GluR2 and 
wild-type TARP-5 or TARP-5 with R69W variant. 
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Table 6-4 Statistical results for TARP-5 expression in the cells with or without cell surface 
biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium;R2 = linear regression of TARP-5 
expression; p-value is a probability under the condition that the null hypothesis is false, 
where the null hypothesis “R69W variant has no effect total or surface expression of 
TARP-5. 
Medium SEM Medium SEM
Wild-type 1308.7 512.8 836.3 256.5
R69W 1174.4 725.3 984 362.7
Adjusted R2
p-value
Co-transfected Total
0.008504
0.8621
0.03978
0.7048
Surface
TARP-5 Expression
 
Furthermore, both TARP-5 surface and total expression showed no effect in the present of 
R69W variant (Figure 6-4). Hence, R69W variant does not affect expression of TARP-5 in the 
cells, but slightly reduced the trafficking of GluR2 to the cell surface (Figure 6-4).  
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6.2.3 Rare variant R71H in TARP-5 showed no significant effect on GluR2 expression 
 
Figure 6-5 Quantification of GluR2 in HEK293 cells when co-transfected with wild-type 
TARP-5 or mutated TARP-5 (n = 3). Panel A is live cell imaging of co-transfected 
HEK293 cells with GluR2 and wild type TARP-5, green fluorescent represents GluR2 
protein, red fluorescent represents TARP-5, and yellow represents overlapping these two 
proteins. Panel B is live cell imaging of co-transfected HEK293 cells with GluR2 and 
p.Arg71His mutated TARP-5 (R71H). Panel C: western blot of cell surface GluR2 isolated 
by biotinylation and of total GluR2.Panel D: pooled data from western blot and 
biotinylation assay for GluR2 expression (n = 3). 
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Table 6-5 Statistical results for GluR2 expression in the cells with or without cell surface 
biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of GluR2 expression; 
p-value is a probability under the condition that the null hypothesis is false, where the null 
hypothesis is “R71H has no effect on the total or surface expression of GluR2. 
Medium SEM Medium SEM
Wild-type 869.7 287.1 1940 908.4
R71H 735.7 203 756.7 1284.6
Adjusted R2
p-value
TotalCo-transfected
0.05164
0.665
Surface
AMPA-R2 Expression
0.175
0.4091  
p.Arg71His (R71H) was identified in one bipolar disorder patient (Table 4-2). Our functional 
studies result showed that there was no significantly decrease in total or cell surface of GluR2 
expression (Figure 6-5). Both R69W and R71H variants are located at the first long extracellular 
loop of TARP-5 protein. Structural and functional studies of TARP-2/stargazin suggest that 
this long extracellular loop is an essential functional domain for the channel properties 
modulation and also the binding site for AMPAR ligand binding domain (Tomita et al. 2005a) 
(Turetsky et al. 2005). The substitution of this domain of stargzin/2 with that from TARP-4 
increased glutamate affinity and reduced kinetics of deactivation and desensitisation (Cho et al. 
2007, Milstein et al. 2007). Although these variants had no effect on the trafficking or expression 
of GluR2 in the cells, it could possibly effect on the kinetics of receptor and binding affinity of 
glutamate.  
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Figure 6-6 Comparison of wild type TARP-5 and its carried R71H variant on their 
expression in HEK293 cells (n = 3). Panel A: Total wild type TARP-5 and the R71H 
variant in HEK293 cells were quantified via fluorescence intensity (SNP71 represents cells 
co-transfected GluR2 and TARP-5 with the R71H variant; wild-type represents wild-type 
TARP-5; surface represents cell surface TARP-5; total represents as total proteins in the 
cells). Panel B: western blot of cell surface TARP-5 isolated by biotinylation and of total 
TARP-5 in either co-transfected with GluR2 and wild-type TARP-5 or TARP-5 with 
R71H variant. 
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Table 6-6 Statistical results for TARP-5 expression in the cells with or without cell surface 
biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of TARP-5 
expression; p-value is a probability under the condition that the null hypothesis is false, 
where the null hypothesis is “R71H variant has no effect on the total or surface expression 
of TARP-5. 
Medium SEM Medium SEM
Wild-type 1174.3 535.2 511.3 818.8
R71H 1500 378.4 688.7 579
Adjusted R2
p-value
Co-transfected
0.08474
0.5757
Total Surface
0.08883
0.5662
TARP-5 Expression
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6.2.4 Rare variant R127Q in TARP-5 showed no significant effect on GluR2 expression 
 
Figure 6-7 Quantification of GluR2 in HEK293 cells when co-transfected with wild-type 
TARP-5 or mutated TARP-5 (n = 3). Panel A is live cell imaging of HEK293 cells with co-
transfected GluR2 and wild type TARP-5, green fluorescent represents GluR2 protein, 
red fluorescent represents TARP-5, and yellow represents overlap between these two 
proteins. Panel B is live cell imaging of co-transfected HEK293 cells with GluR2 and 
TARP-5 p.Arg127Gln mutated (R7127Q). Panel C: western blot of cell surface GluR2 
isolated by biotinylation and of total GluR2.Panel D: pooled data from western blot and 
cell surface biotinylation assay for GluR2 expression (n = 3). 
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Table 6-7 Statistical analysis of GluR2 expression in HEK293 cells with or without cell 
surface biotinylation before assay (Total represents as without surface biotinylation assay; 
surface represents as with biotinylation assay). Medium represents as mean fluorescent 
intensity of expression; SEM = standard error of medium;; R2 = linear regression of 
GluR2 expression; p-value is a probability under the condition that the null hypothesis is 
false, where the null hypothesis is “R127H variant has no effect the total or surface 
expression of GluR2. 
Medium SEM Medium SEM
Wild-type 916.7 163.898 2045.3 1230.6
R127H 1002 115.893 1078 870.2
Adjusted R2
p-value
TotalCo-transfected
AMPA-R2 Expression
Surface
2.585 x 10-5
0.9924
0.4085
0.1718  
The p.Arg127Gln (R127Q) variant was found in two bipolar disorder patients and in one person 
from European 1000 Genome project control (1K Genome project) (Table 4-2). According to our 
previous bioinformatic analysis, R127Q was predicted to have a benign effect on protein 
function. The green fluorescent intensity from our FACS analysis showed a reduction of both 
surface and total percentage of cells expressed GluR2 (Figure 5-3 and 5-4).  A similar result also 
revealed from our biotinylation and western blot assay, where the GluR2 expression in the cells 
was showed no effect, but the surface GluR2 expression showed reduced in the present of 
R127Q variant (Figure 6-7 D). From the live cell image, the visible green fluorescent signal from 
the R127Q variant co-transfected cells was lower than the wild-type co-transfected cells (Figure 
6-7 A and B). Although the statistical analysis showed that the R127Q variant has effect, it is 
still possible that it may have an effect on the trafficking of GluR2. Further experiments may 
reveal the specific effect on this variant.  
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Figure 6-8 Comparison of wild type TARP-5 and its carried R127Q variant on the their 
expression in HEK293 cells (n = 3). Panel A: Total wild type TARP-5 and its carried 
R127Q variant in HEK293 cells were quantified via fluorescence intensity (SNP127 
represents co-transfected GluR2 and TARP-5 carried R127Q variant; wild-type 
represents as wild-type TARP-5; surface represents only surface TARP-5 in the cells; 
total represents as total proteins in the cells). Panel B: western blot of cell surface TARP-5 
isolated by biotinylation and of total TARP-5 in either co-transfected with GluR2 and 
wild-type TARP-5 or TARP-5 with R127Q variant. 
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Table 6-8 Statistical results for TARP-5 expression in the cells with or without cell surface 
biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of TARP-5 
expression; p-value is a probability under the condition that the null hypothesis is false, 
where the null hypothesis is “R127 has no effect on the total or surface TARP-5 
expression”. 
Medium SEM Medium SEM
Wild-type 1174.3 285.2 688 356.4
R127H 898 208.7 594.7 252
Adjusted R2
p-value
Co-transfected Total
0.1797
0.4022
Surface
0.0171
0.805
TARP-5 Expression
 
The R127Q variant only appeared to have a slight effect on GluR2 cell surface expression and 
therefore it was of interest to know whether to this variant could have an effect on its own 
expression or trafficking. Our result revealed that this variant did not have significant effect on 
its own protein expression, or variant located in one of the loops of TARp-5 only have a modest 
effect on GluR2 trafficking to the cell surface (Table 6-8). Thus, this intracellular variant only 
has a possibility effect on GluR2 trafficking.   
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6.2.5 Rare variant R128M in TARP-5 slightly reduced GluR2 expression 
 
Figure 6-9 Quantification of GluR2 in HEK293 cells when co-transfected with wild-type 
TARP-5 or mutated TARP-5 (n = 3). Panel A is live cell imaging of co-transfected 
HEK293 cells with GluR2 and wild type TARP-5, green fluorescent represents GluR2 
protein, red fluorescent represents TARP-5, and yellow represents overlapping these two 
proteins. Panel B is live cell imaging of co-transfected HEK293 cells with GluR2 and 
p.Thr128Met mutated TARP-5 (R128M). Panel C: western blot of cell surface GluR2 
isolated by biotinylation and of total GluR2.Panel D: pooled data from western blot and 
biotinylation assay for GluR2 expression (n = 3). 
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Table 6-9 Statistical results for GluR2 expression in the cells with or without cell surface 
biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of GluR2 expression; 
p-value is a probability under the condition that the null hypothesis is false, where the null 
hypothesis is “T128M has no effect on the total or surface expression of GluR2”. 
Medium SEM Medium SEM
Wild-type 1003.7 200.6 2215.3 1213.9
T128M 512 141.9 908 858.4
Adjusted R2
p-value
TotalCo-transfected
AMPA-R2 Expression
0.6002
0.074
Surface
0.4543
0.1421  
We then investigated whether the p.Thr128Met variant, which lies adjacent to the R127Q variant 
in the first intracellular loop of TARP-5 affects GluR2 trafficking and its expression in co-
transfected HEK293 cells. This variant was found in three bipolar disorder patients and two in 
UCL control samples (Table 4-2). Previous Polyphen2 bioinformatic analysis predicted it was 
probably damaging to protein function; whereas the SIFT analysis revealed this variant to be 
tolerated. The percentage of cells expressing surface GluR2 in co-transfected variant cells was 
reduced compared to wild-type TARP-5 expressed cells, and so does the total GluR2 expressed 
in the cells, but without statistical significant (Figure 5-3 and 5-4). In addition, the western blot 
and cell surface analysis showed decreased total GluR2 expression in the cells and on the cell 
surface when co-transfected with R128M variant. These results were not statistically significant, 
but the result with total GluR2 expression was so close to p < 0.05 (Table 6-9).  
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Figure 6-10 Comparison of wild type TARP-5 and its carried R128M variant on the their 
expression in HEK293 cells (n = 3). Panel A: Total wild type TARP-5 and its carried 
R128M variant in HEK293 cells were quantified via fluorescence intensity (SNP128 
represents co-transfected GluR2 and TARP-5 carried R128M variant; wild-type 
represents as wild-type TARP-5; surface represents only surface TARP-5 in the cells; 
total represents as total proteins in the cells). Panel B: western blot of cell surface TARP-5 
isolated by biotinylation and of total TARP-5 in either co-transfected with GluR2 and 
wild-type TARP-5 or TARP-5 with R128M variant. 
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Table 6-10 Statistical results for TARP-5 expression in the cells with or without cell 
surface biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of TARP-5 
expression; p-value is a probability under the condition that the null hypothesis is false, 
where the null hypothesis is “T128M has no effect on the total or surface expression of 
TARP-5” 
Medium SEM Medium SEM
Wild-type 1174.3 244.1 688.6 356.6
T128M 633 172.6 390.3 252.1
Adjusted R2
p-value
Co-transfected
0.5515
TARP-5
0.0982
Total Surface
0.1489
0.4498  
The presence of the T128M variant in the co-transfected cells appeared decrease to lead to a 
modest in the expression and cell surface trafficking of GluR2 in the cells. It was therefore 
important to know whether this variant affects its own expression and cell surface trafficking. 
Interestingly, the biotinylation assays showed that the presence of this variant actually also affect 
on its own expression, and the statistical result was much closed to the p < 0.05. By contrast, the 
trafficking of TARP-5 was not significantly much affected by this variant. One of the possible 
explanation of reducing expression and trafficking of GluR2 in the cells is due to the reduction of 
TARP-5 expression in the cells. The reduction of TARP-5 expression decreased the expression 
of GluR2; it suggests that TARP-5 may have a regulation role in intracellular GluR2 assembly.  
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6.2.6 Rare variant I156F in TARP-5 significantly reduced GluR2 expression 
 
Figure 6-11 Quantification of GluR2 in HEK293 cells when co-transfected with wild-type 
TARP-5 or mutated TARP-5 (n = 3). Panel A is live cell imaging of co-transfected 
HEK293 cells with GluR2 and wild type TARP-5, green fluorescent represents GluR2 
protein, red fluorescent represents TARP-5, and yellow represents overlapping these two 
proteins. Panel B is live cell imaging of co-transfected HEK293 cells with GluR2 and 
p.Ile156Phe mutated TARP-5 (I156F). Panel C: western blot of cell surface GluR2 isolated 
by biotinylation and of total GluR2.Panel D: pooled data from western blot and 
biotinylation assay for GluR2 expression (n = 3). * P < 0.05. 
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Table 6-11 Statistical results for GluR2 expression in the cells with or without cell surface 
biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium;; R2 = linear regression of GluR2 expression; 
p-value is a probability under the condition that the null hypothesis is false, where the null 
hypothesis is “I156F variant has no effect on the cell total or surface expression of GluR2”. 
Medium SEM Medium SEM
Wild-type 1003.7 176.2 3123.7 1211.9
I156F 501 124.6 375 856.9
Adjusted R2
p-value
0.6704
Co-transfected
AMPA-R2 Expression
0.04627
Total Surface
0.5625
0.08593  
Variant p.Ile156Phe (I156F) is one of the more interesting variants. This variant that was 
discovered found in one bipolar disorder patient. The I156F variant showed significantly 
increased surface expression of GluR2 compared to the wild type in our FACS analysis (Figure 
5-6). However, the biotinylation assay revealed an opposite effect, where the expression and 
trafficking of GluR2 were decreased by the presence of this variant (Figure 6-11); specifically, 
the expression of GluR2 in cells was decreased in the presence of the I156F variant (from 1003.7 
± 176.2 to 501 ± 124.6, n = 3, p = 0.046) (Table 6-11). Both live cell image and western blot 
analysis showed a lower signal of GluR2 compared to the wild type. Although the different 
assays were not in argument, it still showed a statistical significant effect on the expression of 
GluR2 by the presence of I156F variant. Therefore, a single amino acid substitution in second 
extracellular loop of TARP-5 may affect its functional domain and the binding affinity to 
GluR2 protein; however, further experiments are required to explain this mechanism.   
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Figure 6-12 Comparison of wild type TARP-5 and the I156F variant on expression in 
HEK293 cells (n = 3). Panel A: Total wild type TARP-5 and the TARP-5 I156F variant in 
HEK293 cells were quantified via fluorescence intensity (SNP156 represents co-transfected 
GluR2 and TARP-5 carried I156F variant; wild-type represents as wild-type TARP-5; 
surface represents surface TARP-5 expression; total represents total TARP-5 in the cells). 
Panel B: western blot of cell surface TARP-5 isolated by biotinylation and of total TARP-
5 in either co-transfected with GluR2 and wild-type TARP-5 or TARP-5 with the I156F 
variant. 
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Table 6-12 Statistical results for TARP-5 expression in the cells with or without cell 
surface biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of TARP-5 
expression; p-value is a probability under the condition that the null hypothesis is false, 
where the null hypothesis is “I156F has no effect on the total or surface expression of 
TARP-5”. 
Medium SEM Medium SEM
Wild-type 1174 301.2 688.7 365.3
I156F 475.3 213 271 258.3
Adjusted R2
p-value
Co-transfected
0.5739
0.08105
Total Surface
0.2463
0.3167
TARP-5 Expression
 
The result of biotinylation assay on TARP-5 expression showed that in the presence of the 
I156F variant, the expression and trafficking of TARP-5 may also have been reduced. However 
this effect was not statistically significant.  This reduction of TARP-5 expression and trafficking 
could actually affect on the rate of GluR2 assembly in the cells, and also their cell surface 
trafficking.  
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6.2.7 Rare variant T164L in TARP-5 significantly reduced GluR2 expression 
 
Figure 6-13 Quantification of GluR2 in HEK293 cells when co-transfected with wild-type 
TARP-5 or mutated TARP-5 (n = 3). Panel A is live cell imaging of co-transfected 
HEK293 cells with GluR2 and wild type TARP-5, green fluorescent represents GluR2 
protein, red fluorescent represents TARP-5, and yellow represents overlapping these two 
proteins. Panel B is live cell imaging of co-transfected HEK293 cells with GluR2 and 
p.Thr164Leu mutated TARP-5 (T164L). Panel C: western blot of cell surface GluR2 
isolated by biotinylation and of total GluR2.Panel D: pooled data from western blot and 
biotinylation assay for GluR2 expression (n = 3). * P < 0.05. 
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Table 6-13 Statistical results for GluR2 expression in the cells with or without cell surface 
biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of GluR2 expression; 
p-value is a probability under the condition that the null hypothesis is false, where the null 
hypothesis is “T164L has no effect on the total or surface expression of GluR2”. 
Medium SEM Medium SEM
Wild-type 1003.67 132.14 2638.7 1210.2
T164L 285 93.44 484.7 855.7
 R-squared
p-value
TotalCo-transfected
AMPA-R2 Expression
0.8809
0.005548
Surface
0.5431
0.0947  
TARP-5 variant p.Thr164Leu was found in one schizophrenia patient (Table 4-2). According to 
our FACS analysis, the presence of this variant in the TARP-5 protein led to a non-significant 
reduction in GluR2 expression in the cells. A further study with western blot analysis combined 
with cell surface biotinylation assays also showed a decreased expression of GluR2 in the cells 
from 1003.67 ± 132.14 to 285 ± 93.44 (n = 3, p = 0.0055) (Table 6-13). There was also a trend 
for decreased GluR2 trafficking to the cell surface was also showed when the cells were co-
transfected with this variant (Table 6-13). This variant was the most interesting finding from our 
experiments, and it showed a reduction of GluR2 expression and trafficking with two different 
experimental approaches. Additionally, the live cell image also showed red signal in most of the 
co-transfected cells (Figure 6-13 B).  
283 
 
 
Figure 6-14 Comparison of wild type TARP-5 and its carried T164L variant on the their 
expression in HEK293 cells (n = 3). Panel A: Total wild type TARP-5 and its carried 
T164L variant in HEK293 cells were quantified via fluorescence intensity (SNP164 
represents co-transfected GluR2 and TARP-5 carried T164L variant; wild-type represents 
as wild-type TARP-5; surface represents only surface TARP-5 in the cells; total 
represents as total proteins in the cells). Panel B: western blot of cell surface TARP-5 
isolated by biotinylation and of total TARP-5 in either co-transfected with GluR2 and 
wild-type TARP-5 or TARP-5 with T164L variant. 
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Table 6-14 Statistical results for TARP-5 expression in the cells with or without cell 
surface biotinylation assay (Total represents as without surface biotinylation assay; surface 
represents as with biotinylation assay). Medium represents as mean fluorescent intensity of 
expression; SEM = standard error of medium; R2 = linear regression of TARP-5 
expression; p-value is a probability under the condition that the null hypothesis is false, 
where the null hypothesis is “T164L has no effect on the total or surface expression of 
TARP-5”. 
Medium SEM Medium SEM
Wild-type 1174.3 293.5 688.7 350.2
T164L 663.3 207.5 435 247.6
 R-squared
p-value
Co-transfected Total
0.4312
0.1566
Surface
0.116
0.5089
TARP-5 Expression
 
Although the expression of GluR2 in the cells were significantly reduced in the co-transfected 
T164L variant of TARP-5, the expression of TARP-5 was not significantly influenced by the 
presence of this variant. In particular, the surface expression of TARP-5 in the presence of this 
variant led to approximated equal expression to the wild-type (Table 6-14). Hence, 
approximately 1.5 fold reduction on the surface expression of GluR2 was not changed by altered 
TARP-5 in the cells. This result suggests that an amino acid substitution at the second 
extracellular loop of TARP-5 would possibly affect the binding affinity of GluR2, where 
leading to the reduction of their trafficking.  
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6.3 Discussion 
Table 6-15 Summary of TARP-5 and its variant effect results on GluR2 and TARP-5 
expression. – represents as no effect;  represents modest  increased expression;  
represents modest decreased expression;  represents significantly decreased expression, 
p < 0.05;  represents significantly decreased expression, p < 0.005. 
Total Surface Total Surface
TARP-5  
R69W - - - -
R71H - - - -
R127Q -  - -
T128M    -
I156F    -
T164L   - -
GluR2 TARP-5
 
The data presented here provide evidence that TARP-5 mediates AMPAR2 trafficking and its 
expression. This confirms and extends results from one recent study reporting that TARP-5 
decreases both cell surface trafficking of unedited GluR2 short and long isoform, and increased 
the trafficking of edited GluR2 receptor, known as Ca
2+
 impermeable receptors (Soto et al. 2009). 
Although the statistical significant alteration was not revealed in the trafficking of edited GluR2 
receptor, the similar result trend has also been showed in our preliminary experiment (Figure 5-
3). One of the explanations is that the three biological replications and each expression were 
variable.  
  R69W and R71H are variants that located at the first extracellular loop of TARP-5, and were 
found in one schizophrenia and one bipolar disorder patient, respectively (Table 4-2). Molecular 
dissection of stargazin/2 identified that the first extracellular loop controls channel properties 
and glutamate affinity (Cho et al. 2007, Milstein et al. 2007, Osler et al. 2005, Tomita et al. 
2005a). In addition, our biotinylation assay showed no effect on both expression and trafficking 
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of GluR2 when cells were co-expressed with R69W and R71H individually. Furthermore, the 
green fluorescent intensity from surface sensitivity tag protein revealed a decreased level, but 
without statistical significant. This result suggests that the first extracellular loop domain does 
mediate GluR2 trafficking; hence, further electrophysiological experiments are required to 
investigate of this variant.  
R127H and T128M were found only in bipolar disorder patients, and also in control subjects 
(Table 4-2). These two variants are located at the short intracellular loop and close to 
transmembrane domain III. Bioinformatic analysis of these two variants has revealed a benign 
effect on protein function; the green fluorescent intensity from surface GluR2 showed a trend for 
decreased trend. Here, our biotinylation assay showed that both expression and surface GluR2 
were decreased when co-expressed with these two variants individually, but also without any 
statistical significant. Although the explanation could be variable on each expression level, the 
expression of TARP-5 was reduced when co-expressed with T128M variant. Therefore, one 
possible reduction reason could be due to TARP-5 expression reduced in the cells. Furthermore, 
literature has suggested any function of this region to mediate AMPAR channel properties or 
trafficking. Hence, these two variants are also confirmed to have no effect on protein function.  
Another two rare variants I156F and T164L are found in one bipolar disorder and one 
schizophrenia, respectively. Both residues are located in the second extracellular loop, which is 
thought to mediate changes in AMPAR channel properties and its binding affinity (Tomita et al. 
2005a). Our FACS data has showed that co-expression I156F variant in the HEK293 cells, 
surface GluR2 expression was significantly enhanced; conversely, the biotinylated surface 
GluR2 expression showed a decreased trend, while the TARP-5 expression in the cells was also 
reduced. These results suggest that the expression level in the cells and on the cell surface is 
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regulated by the amount of TARP-5 expressed in the cells. The most promising characteristic 
variant is T164L, which has not occurred in any other cohort. Previously green fluorescent 
intensity result revealed a reduction of surface GluR2 expression when cells were co-expressed 
with T164L variant. Here, both total GluR2 and biotinylated GluR2 were decreased when cells 
were co-transfected with T164L variant, particular significantly reduced in the total GluR2 
expression (Table 6-15). This reduction from the present of T164L was not affected by the 
expression levels of TARP-5.  
Analysis of mutants as a single amino acid substitution variants shows that alters the total 
expression of AMPAR2 and also its surface expression. Co-expressed wild-type TARP-5 
increased the expression of AMPAR2; whereas, the specific amino acid substitution, T164L 
decreased AMPAR2 expression. This evidence suggests that a single rare variants found in 
TARP-5 have an effect on AMPAR2 assembly or trafficking in the cells. In term this 
dysregulation of AMPAR2 function may increase susceptibility to a variant of neuropsychiatric 
conditions.  
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7 Conclusion 
According to the Kraepelinian dichotomy bipolar disorder (BPD) and schizophrenia (SCZ) are 
traditionally regarded as two separate disorders. However, there is increasing evidence to support 
the notion that they share common neurobiological abnormalities (Domjan et al. 2012). Clinical 
genetic studies imply a familiar aggregation and considerable heritability of BPD shared with 
SCZ (Lichtenstein et al. 2009). As such, it would be natural to hypothesize that multiple risk 
variants may be involved in the aetiology of both diseases. Despite advancing study design and 
technology, the underlying genetic and pathophysiological components of the disorders remain 
unclear. Intensive research in the field of shared variants in BPD and SCZ, including numerous 
family linkage studies, locus specific association studies, and GWAS, has demonstrated 
susceptibility loci and candidate genes that may confer risk to both BPD and SCZ.  
In this study, the CACNG5 gene was screened for all variants that may be associated with BPD 
and/or SCZ in the UCL BPD and/or SCZ patient and control sample. This was followed by 
genotyping the identified CACNG5 variants to confirm allele frequencies from the gene scanning 
method. These variants were then tested for association with BPD and/or SCZ. The genetic study 
revealed four novel rare non-synonymous (SNPs) (nsSNPs), three rare nsSNPs, and one more 
common nsSNP. It provided evidence for the efficiency of the gene scanning method and 
demonstrated that HRMA has a high sensitivity and specificity.  
Burden analysis of all nsSNPs in UCL BPD versus UCL controls found evidence for weak 
association (p = 0.0127); whereas UCL SCZ versus UCL controls found moderately associated 
(p = 0.00158). Combined both UCL cases versus UCL controls did not strengthen the association 
signal (p = 0.0022). Combined analysis including the European samples from the 1000 Genomes 
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project strengthened the association signal (p = 0.00057). The larger combined analysis that 
included the UK10K data reduced the association signal to (p = 0.0034); moreover combined 
analysis that included the Swedish exome sequence data also did not strengthen the association 
signal (p = 0.0051). Analysis of data from all controls versus all cases found a weakened 
association signal (p = 0.0082). These results have revealed that the association signal was 
stronger in UCL samples, perhaps due to the healthy super-normal controls that were included. 
In fact, our genetic study showed a different result compared to the original case-case study 
{Curtis, 2011 #810}, where the association result implicated that the rs17645023 SNP is a 
disorder specific variant, but our current result showed multiple coding variants moderately 
associated with SCZ and even less in BPD. It is possible to speculate that CACNG5 may be more 
involved in susceptibility to SCZ gene and that CACNG4 may be more involved in susceptibility 
to  BPD and that this may be the explanation for the finding with  SNP rs17645023, that was 
found to be associated in case versus case analysis, which is located between these two genes. 
Because of this possible implication, one of our colleagues has been working on sequencing and 
genotyping of CACNG4 gene to identify it is a possible explanation. Furthermore, as our 
association signal was modest, this study is probably underpowered to detect significant 
association between individual CACNG5 variants and SCZ. Thus, much larger samples than 
available in the current study are needed to obtain statistical power to address the role of 
CACNG5 mutations in SCZ and/or BPD, or other complex phenotypes. Moreover, a further 
family study may strength the genetic association analysis and to understand whether these rare 
variants are affected in specific family 
The most promising rare variant detected in this thesis was p.Val146Met in exon 4 of CACNG5, 
which was identified in a UCL SCZ patient but was absent in other UCL cohorts. The variant 
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was also detected in one SCZ patient in a replication cohort from Aberdeen. The limitations of 
genetic analysis mean that it was not possible to unequivocally implicate the rare CACNG5 gene 
variants in the aetiology of SCZ and/or BPD. We were also unable to obtain clear evidence that 
individual variants were involved in distinct or overlapping susceptibility. One way to obtain 
further evidence to support the genetic association finding is to sequence this gene in further 
large cohorts or family samples in order to further ascertain their involvement in mental health 
illness.  
Missense variants that are associated with Mendelian disorders typically interfere with protein 
stability, folding solubility or cellular processing {Kleppe, 2001 #920}. Although SIFT and 
Polyphen can predict whether individual variants are likely to have a benign or deleterious effect 
on a protein, these results are often discrepant between the different analyses. This is probably 
due to the overall limitations of analysis and the limitations encountered, for instance, due to lack 
of structural or functional data for many proteins. Functional studies of likely susceptibility 
variants may produce evidence that supports their likely pathogenic role in BPD and SCZ. This 
type of evidence may also highlight the importance of the glutamatergic pathways in these 
disorders. Recent sequencing of candidate glutamatergic genes in nonsyndromic intellectual 
disability and SCZ also reported an excess of de novo deleterious mutations in these diseases 
(Hamdan et al. 2011). These observations further support the notion that BPD and SCZ or other 
psychiatric disorders may share a common causal synaptic component.  
The most promising findings from our functional studies is the characterisation of both V146M 
and T164L variants in CACNG5; overexpressed V146M significantly increased the percentage of 
cells surface expressed GluR2 AMPA receptor (AMPAR) subunits, and overexpressed T164L 
decreased cell surface expression of GluR2. Indeed, TARP-5 has been shown to regulate 
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AMPAR trafficking and also the permeability to calcium in the synapse. These significant 
alterations in the presence of the variants may implicate dysfunctional trafficking of AMPAR to 
the synapse resulting in unbalanced intracellular ion concentrations. Abnormal AMPAR 
trafficking and/or activity has been linked to several neuropathologies, as outlined in section 1.4. 
This suggests a possible pathogenic mechanism for these variants. For instance, mutations in 
GRIA3, which encodes an AMPAR subunit and in several genes known to affect AMPAR 
trafficking (such as CACNG2) have been previously shown to cause forms of neurophathology 
(Wu et al. 2007) (Hamdan et al. 2011). Thus, our results suggest a potential causative role for 
rare CACNG5 variants in SCZ and/or BPD, and emphasise that CACNG5 gene mutations may 
contribute to dysregulation of AMPAR leading to a variety of neuropsychiatric disorders. 
Although our functional study has shown that two of the rare variants identified from SCZ 
samples altered the trafficking of AMPA receptors to the cell surface, how the localisation of 
individual variants affect to the trafficking of AMPAR receptors was not characterised. A further 
protein binding affinity study could be applied to each individual variant to detect whether each 
variant led to a loss of protein binding affinity; thus reducing the surface trafficking of AMPA 
receptors. Furthermore 3 dimensional protein structural analyses may also explain whether each 
individual variant has an effect on protein structure including altering protein folding or stability. 
Phosphorylation of TARP-5 is also an essential mechanism which regulates AMPAR trafficking, 
raising the possibility that deleterious mutations at critical sites may reduce protein binding 
affinity. Additional work is needed to investigate whether this is the case for these variants. 
Finally, further functional studies of disease-associated variants may identify new drug targets 
and therapeutic pathways. 
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9 Appendix I 
9.1 Transient transfection efficiency of CACNG5 & GIRA2 
9.1.1 Introduction 
The most essential step for studying mutated gene function and regulation and further protein 
function is to delivery genetic materials into cell cultures to produce genetically modified cells 
(Nikcevic et al. 2003, Ohama et al. 2005). Over the past decades, scientists have been 
desperately finding suitable gene delivery methods to overcome the understanding of human 
genetic disorders.  The principle of gene delivery methods is classified into viral and non-viral 
ways. Viral techniques are most commonly used in clinical research also known as transduction 
(Pfeifer and Verma 2001) (Figure 9-1). Transductions normally use several classes of viruses as 
a tool for gene delivery such as retrovirus, adenovirus, adeno-associated virus, and herpes 
simplex virus. Viral vector are generally most effective and easy to achieve transgene expression 
in vivo, but they present harmful side-effects such as immunogenicity and cytotoxicity (Hacein-
Bey-Abina et al. 2002, Roesler et al. 2002, Woods et al. 2003). Thus, much effect has been made 
to develop non-viral transfection and become the most prevalent methods in contemporary 
research (Glover 2012, Hart 2010). 
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Figure 9-1 Transduction of mammalian cells using an adenoviral vector 
(http://ibidi.com/applications/transfection-transduction-and-proteofection/transduction/) 
In contrast, non-viral vectors are generally less effective in gene delivery and expression, when 
compared with viral vectors especially in vivo application (Piskin 2005). However, scientists 
have developed new non-viral vectors to overcome these limitations , such as increasing genetic 
material carrying capacity and producing easily in large quantities (Luo and Saltzman 2000, 
Schmidt-Wolf and Schmidt-Wolf 2003). Non-viral vectors are classified into physical or 
chemical based transfections. The physical methods include direct micro injection, biolistic 
particle delivery, electroporation, and laser-based transfection (Mehier-Humbert and Guy 2005). 
Those methods either require expensive instruments, or often cause cell death and physically 
damage to the samples (Kim and Eberwine 2010). Conversely, the chemical methods are much 
cheaper and easier to handle, such as cationic polymer transfection, calcium phosphate 
precipitation, and cationic lipid based transfection (Holmen et al. 1995, Schenborn and Goiffon 
2000, Washbourne and McAllister 2002). Their principle methods are similar; positively charged 
chemicals combine nucleic acid to form chemical complexes. Thus, the positively charged 
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complexes bind to the negatively charged cell membrane through ionic interaction and enter into 
cells by endocytosis, without significant cytotoxicity (Dincer et al. 2005) (Figure 9-2).  
 
Figure 9-2 Transfection of eukaryotic cells with plasmid 
Although many commercial non-viral vectors hold promises to achieve high transfection 
efficiencies, there are still several factors need to be considered such as nucleic acid/chemical 
ratio, medium conditions, cell types and cell density on the time of transfection (Nikcevic et al. 
2003). Thus, the optimised transfection conditions should be required before the studies are 
implemented. The aim of this study was optimising and improving selected non-viral gene 
transfection commercially available into HEK293 (human embryonic kidney) cells. We tested 
the hypothesis that, under the manufacture recommended optimised conditions, these 
transfection are capable of yielding high-transfection efficiencies for gene function and 
expression studies.  We chose two of the most prevalence commercial reagents; FuGENE6, a 
lipid with other component, and Lipofectamine2000, a cationic lipid. For these studies, two 
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different plasmid DNAs encoding green and red fluorescent tag fusion proteins were determined 
by flow cytometric analysis of the resulting shift in fluorescence patterns on dot plots.  
9.1.2 Results of FuGene6-HD transfection efficiency 
To optimise the best FuGENE6-HD mediated gene delivery into HEK293 cells, the ratios of 
plasmid DNA/ FuGENE6-HD were prepared as 1:0.75, 1:1.5, 1:2, 1:3, 1:4, and 1:6, and then 
added to 10
5
 or 20
5
 cells in 6 well plates. The best transfection rate was conferred up to 55% by 
using 9 µl of FuGENE6-HD (1:1.5 ratios) with 20
5
 cells in each well (Fig 9-3B). Moreover, 
more than 70% of HEK293 cells were viable when FuGENE6-HD reagent was increased up to 
36 µl (6:1 ratio). However, when FuGENE6-HD ratio was increased to 3:1 and further, the rate 
of gene delivery was decreased dramatically (Figure 9-3).  
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Figure 9-3 The best result for transfection was achieved in presence of 9 µl FuGENE6-HD. 
Increasing the volume of FuGENE6-HD did not cause any cell toxicity, but the transfection 
efficiency was decreased. A: 1 x 105 HEK293 cells were plated 24 hours before transfection 
time; B: 2 x 105 HEK293 cells were plated. 
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9.1.3 Lipofectamine2000 transfection efficiency 
Although the rate of transfection into HEK293 cells in presence of Lipofectamine
TM
2000 
investigated in different condition such as amount of Lipofectamine
TM
2000. The best 
transfection rate was conferred up to 73% by using 8 ul of Lipofectamine
TM
2000 (2:1 ratio) with 
2 x 10
5
 HEK293 cells in each well (Fig 9-4B). HEK293 cells were transfected at the average of 
75% by increased amount of Lipofectamine
TM
2000 with 1 x 10
5
 of HEK293 cells per well (Fig 
9-4A). However, increased amount of Lipofectamine
TM
2000 decreased the cell viability because 
of exacerbating cell toxicity. 
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Figure 9-4 The best result for transfection was achieved in presence of 8 ul 
Lipofectamine
TM
2000. Increasing the volume of LipofectamineTM2000 increased the 
transfection efficiency rate, but the cell toxicity was also increased. A: 1 x 105 HEK293 cells 
were plated 24 hours before transfection time; B: 2 x 105 HEK293 cells were plated. 
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9.1.4 Discussion 
Having an acceptable gene delivery level into eukaryotic cells is important to determine gene 
expression and function, protein production for recombinant genes and mutated gene studies 
(Nikcevic et al. 2003). Significant differences in amounts of transfected cells were measured 
depending on the transfection reagent, the regaent/DNA ratio, and amount of plasmid per well. 
Currently, there are few data that have been published on Lipofectamine
TM
2000 based on 
transient expression in human cell line such as HEK293 cells. In fact, Lipofectamine
TM
2000 is 
not common as much as FuGENE6-HD. FuGene6-HD, the most effective transfection reagent 
across literature, however was not transfected very well in our studies. It only allowed 
transfected up to 40%, whereas Lipofectamine2000 can transfected up to 73%. No remarkable 
differences were found between the obtained transfection results with increased FuGene6-HD. 
Another similar result from Wiesenhofer and Humpel has shown only 16.3% and 5.1% 
transfection efficiency with the optimised FuGENE-HD in C6 glioma cells and in primary glial 
cells, respectively (Wiesenhofer and Humpel 2000).  
According to our findings, cationic lipid gene delivery based on using Lipofactamine
TM
2000 is 
an appropriate procedure to mediate DNA transfer into HEK293T cells because of their high 
transfection in comparison with FuGENE6-HD, although it also had a higher cytotoxicity. Taken 
together, the significant factors that can influence gene transfection including cell conditions 
such as cell number and amount of transfection reagents and the type of cell lines should be 
considered for gene delivery experiments, as reported before and shown here (Felgner et al. 1987, 
Nikcevic et al. 2003, Wiesenhofer and Humpel 2000).  
Furthermore, our finding pointed that to achieve the highest gene delivery into HEK293 cell line; 
one cannot rely on the transfection reagents suggested by manufacturers. As a matter of fact, 
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reagents such as FuGENE6-HD despite being highly recommended by manufacturers for gene 
transfer, they were not efficient as much as the reagent Lipofectamine
TM
2000 for HEK293 cell 
line. Finally, it can be suggested that Lipofectamine
TM
2000 is an appropriate reagent to transfer 
HEK293 cells. 
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10 Appendix II 
10.1 Genotyping plots are shown for 15 variants found in CACNG5 gene for the UCL cases 
and control samples using Karspar analysis 
 
Figure 10-1Genotyping plots of promoter variants in CACNG5 including rs3760263, 
rs181400884, and rs75486725 are shown. The SNP genotypes have been assigned based on 
cluster formation in scatter plots of normalised allele intensities X and Y. Each circle 
represents one individual’s genotype. Blue and purple colours indicate homozygote 
genotypes for the SNP (AA/aa), red colour indicates heterozygote (Aa) and green colour 
indicates negative sample such as water. Four distinct, tight clusters exhibited by all three 
representative SNPs indicate good discrimination of the three genotypes.  
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Figure 10. 2 Genotyping plots of synonymous variants, R6R, C19C, A27A, and L34L found 
in CACNG5 are shown. The SNP genotypes have been assigned based on cluster formation 
in scatter plots of normalised allele intensities X and Y. Each circle represents one 
individual’s genotype. Blue and purple colours indicate homozygote genotypes for the SNP 
(AA/aa), red colour indicates heterozygote (Aa) and green colour indicates negative sample 
such as water. Four distinct, tight clusters exhibited by all three representative SNPs 
indicate good discrimination of the three genotypes. 
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Figure 10. 3 Genotyping plots of non-synonymous variants, R69W, R71H, R127Q, T128M 
found in CACNG5 are shown. The SNP genotypes have been assigned based on cluster 
formation in scatter plots of normalised allele intensities X and Y. Each circle represents 
one individual’s genotype. Blue colour indicates homozygote genotype for the SNP (AA), 
red colour indicates heterozygote (Aa) and green colour indicates negative sample such as 
water. Three distinct, tight clusters exhibited by all three representative SNPs indicate 
good discrimination of the three genotypes. 
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Figure 10. 4 Genotyping plots of non-synonymous variants, V146M, I156F, T164L, H233Y 
found in CACNG5 are shown. The SNP genotypes have been assigned based on cluster 
formation in scatter plots of normalised allele intensities X and Y. Each circle represents 
one individual’s genotype. Blue colour indicates homozygote genotype for the SNP (AA), 
red colour indicates heterozygote (Aa) and green colour indicates negative sample such as 
water. Three distinct, tight clusters exhibited by all three representative SNPs indicate 
good discrimination of the three genotypes. 
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11 Appendix III 
11.1 Raw data of protein expression levels 
AMPA  TARP5 AMPA TARP5
GluR2 33.1            0 694               0
TARP5 911             1,650            1,640             174              
SNP 69 764             410              1,120             0
SNP 71 704             2,300            2,830             695              
SNP 127 795             1,200            1,150             407              
SNP 128 359             642              741               167              
SNP 156 232             201              307               34                
SNP 164 266             727              510               239              
GluR2 244             5                  151               0
TARP5 1,220           1,020            2,220             1,320            
SNP 69 2,880           2,650            2,330             2,570            
SNP 71 1,390           1,550            1,520             1,110            
SNP 127 991             875              614               562              
SNP 128 328             673              783               428              
SNP 156 576             810              194               530              
SNP 164 165             912              280               510              
GluR2 231             33                160               0
TARP5 880             853              5,510             572              
SNP 69 933             866              1,100             1,030            
SNP 71 515             650              1,470             704              
SNP 127 1,220           619              1,470             815              
SNP 128 849             584              1,200             576              
SNP 156 695             415              624               249              
SNP 164 424             351              664               556              
Replication 1
Samples
Total Expression Level Surface Expression Level
Replication 2
Replication 3 
 
Table 11- 2 Raw data of protein expression levels 
